?2356215 Summary - Canadian Patents Database (2024)

CA 02356215 2006-12-29
61009-491
1
HUMAN MONOCLONAL ANTIBODIES TO CTLA-4
BACKGROUND rWTHF INVENTION
2. Summar!, of the Invention
In accordance with the present invention, there are provided fully human
monoclonal antibodies against human cytotoxic T-Iymphocyte antigen 4
(CTLA-4). Nucleotide sequences encoding and amino acid sequences
comprising heavy and light chain immunoglobulin molecules, particularly
contiguous heavy and light chain sequences spanning the complementarity
determining regions (CDRs), specifically from within FR1 and/or CDR1
through CDR3 and/or within FR.4, are provided. Further provided are
antibodies having similar binding properties and antibodies (or other
antagonists) having similar functionality as antibodies disclosed herein.
3. Background of the rechnolopv
Regulation of immune response in patients would provide a desirable
treatment of many human diseases that could lead to a specificity of action
that
is rarely found through the use of conventional drugs. Both up-regulation and
= down-regulation of responses of the immune system would be possible.
The =
roles of T cells and B cells have been extensively studied and characterized
in
connection with the regulation of immune response. From these studies, the
role
of T cells appear, in many cases, to be particularly important in disease
prevention and treatment.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
2
T cells possess very complex systems for controlling their interactions.
Interactions between T cells utilize numerous receptors and soluble factors
for
the process. Thus, what effect any particular signal may have on the immune
response generally varies and depends on the particular factors, receptors and
counter-receptors that are involved in the pathway. The pathways for down-
regulating responses are as important as those required for activation. Thymic

education leading to T-cell tolerance is one mechanism for preventing an
immune response to a particular antigen. Other mechanisms, such as secretion
of suppressive cytokines, are also known.
Activation of T cells requires not only stimulation through the antigen
receptor (T cell receptor (TCR)), but additional signaling through co-
stimulatory surface molecules such as CD28. The ligands for CD28 are the B7-
1 (CD80) and B7-2 (CD86) proteins, which are expressed on antigen-presenting
cells such as dendritic cells, activated B-cells or monocytes that interact
with T-
cell CD28 or CTLA-4 to deliver a costimulatory signal. The role of
costimulatory signaling was studied in experimental allergic encephalomyelitis

(EAE) by Perrin et al. Immunol Res 14:189-99 (1995). EAE is an autoimmune
disorder, induced by Thl cells directed against myelin antigens that provides
an
in vivo model for studying the role of B7-mediated costimulation in the
induction of a pathological immune response. Using a soluble fusion protein
ligand for the B7 receptors, as well as monoclonal antibodies specific for
either
CD80 or CD86, Perrin et al. demonstrated that B7 costimulation plays a
prominent role in determining clinical disease outcome in EAE.
The interaction between B7 and CD28 is one of several co-stimulatory
signaling pathways that appear to be sufficient to trigger the maturation and
proliferation of antigen specific T-cells. Lack of co-stimulation, and the
concomitant inadequacy of IL-2 production, prevent subsequent proliferation of

the T cell and induce a state of non-reactivity termed "anergy". A variety of
viruses and tumors may block T cell activation and proliferation, leading to
insufficient activity or non-reactivity of the host's immune system to the
infected or transformed cells. Among a number of possible T-cell disturbances,

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
3
anergy may be at least partly responsible for the failure of the host to clear
the
pathogenic or tumorgenic cells.
The use of the B7 protein to mediate anti-tumor immunity has been
described in Chen et al. Cell 71:1093-1102 (1992) and Townsend and Allison
Science 259:368 (1993). Schwartz Cell 71:1065 (1992) reviews the role of
CD28, CTLA-4, and B7 in IL-2 production and immunotherapy. Harding et al.
Nature 356:607-609 (1994) demonstrates that CD28 mediated signaling co-
stimulates murine T cells and prevents the induction of anergy in T cell
clones.
See also U.S. Patent Nos. 5,434,131, 5,770,197, and 5,773,253, and
International Patent Application Nos. WO 93/00431, WO 95/01994, WO
95/03408, WO 95/24217, and WO 95/33770.
From the foregoing, it was clear that T-cells required two types of
signals from the antigen presenting cell (APC) for activation and subsequent
differentiation to effector function. First, there is an antigen specific
signal
generated by interactions between the TCR on the T-cell and MHC molecules
presenting peptides on the APC. Second, there is an antigen-independent signal

that is mediated by the interaction of CD28 with members of the B7 family (B7-
1 (CD80) or B7-2 (CD86)). Exactly where CTLA-4 fit into the milieu of
immune responsiveness was initially evasive. Murine CTLA-4 was first
identified and cloned by Brunet et al. Nature 328:267-270 (1987), as part of a
quest for molecules that are preferentially expressed on cytotoxic T
lymphocytes. Human CTLA-4 was identified and cloned shortly thereafter by
Dariavach et al. Eur. J. Immunol. 18:1901-1905 (1988). The murine and human
CTLA-4 molecules possess approximately 76% overall sequence hom*ology and
approach complete sequence identity in their cytoplasmic domains (Dariavach
et al. Eur. J. Immunol. 18:1901-1905 (1988)). CTLA-4 is a member of the
immunoglobulin (Ig) superfamily of proteins. The Ig superfamily is a group of
proteins that share key structural features of either a variable (V) or
constant (C)
domain of Ig molecules. Members of the Ig superfamily include, but are not
limited to, the immunoglobulins themselves, major histocompatibility complex
(MHC) class molecules (i.e., MHC class I and II), and TCR molecules.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
4
In 1991, Linsley et al. J. Exp. Med. 174:561-569 (1991), proposed that
CTLA-4 was a second receptor for B7. Similarly, Harper et al. J Immunol
147:1037-44 (1991) demonstrated that the CTLA-4 and CD28 molecules are
closely related in both mouse and human as to sequence, message expression,
gene structure, and chromosomal location. See also Balzano et al. Int J Cancer
Suppl 7:28-32 (1992). Further evidence of this role arose through functional
studies. For example, Lenschow et al. Science 257:789-792 (1992)
demonstrated that CTLA-4-Ig induced long term survival of pancreatic islet
grafts. Freeman et al. Science 262:907-909 (1993) examined the role of CTLA-
to 4 in B7 deficient mice. Examination of the ligands for CTLA-4 are
described
in Lenschow et al. P.N.A.S. 90:11054-11058 (1993). Linsley et al. Science
257:792-795 (1992) describes inununosuppression in vivo by a soluble form of
CTLA-4. Linsley et al. J Exp Med 176:1595-604 (1992) prepared antibodies
that bound CTLA-4 and that were not cross-reactive with CD28 and concluded
that CTLA-4 is coexpressed with CD28 on activated T lymphocytes and
cooperatively regulates T cell adhesion and activation by B7. Kuchroo et al.
Cell 80:707-18 (1995) demonstrated that the B7-1 and B7-2 costimulatory
molecules differentially activated the Th1/Th2 developmental pathways. Yi-
qun et al. Int Immunol 8:37-44 (1996) demonstrated that there are differential
requirements for co-stimulatory signals from B7 family members by resting
versus recently activated memory T cells towards soluble recall antigens. See
also de Boer et al. Eur J Immunol 23:3120-5 (1993).
Several groups proposed alternative or distinct receptor/figand
interactions for CTLA-4 as compared to CD28 and even proposed a third B-7
complex that was recognized by a BB1 antibody. See, for example, Hathco*ck et
al. Science 262:905-7 (1993), Freeman et al. Science 262:907-9 (1993),
Freeman et al. J Exp Med 178:2185-92 (1993), Lenschow et al. Proc Nat! Acad
Sci U S A 90:11054-8 (1993), Razi-Wolf et al. Proc Natl Acad Sci U S A
90:11182-6 (1993), and Boussiotis et al. Proc Nat! Acad Sci USA 90:11059-63
(1993). But, see, Freeman et al. J Immunol 161:2708-15 (1998) who discuss
fmding that BB1 antibody binds a molecule that is identical to the cell
surface
form of CD74 and, therefore, the BB 1 mAb binds to a protein distinct from B7-

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
1, and this epitope is also present on the B7-1 protein. Thus, this
observation
required the field to reconsider studies using BB1 mAb in the analysis of CD80

expression and function.
Beginning in 1993 and culminating in 1995, investigators began to
5 further delineate the role of CTLA-4 in T-cell stimulation. First,
through the
use of monoclonal antibodies against CTLA-4, Walunas et al. Immunity 1:405-
13 (1994) provided evidence that CTLA-4 can function as a negative regulator
of T cell activation. Thereafter, Waterhouse et al. Science 270:985-988 (1995)

demonstrated that mice deficient for CTLA-4 accumulated T cell blasts with up-
regulated activation markers in their lymph nodes and spleens. The blast cells
also infiltrated liver, heart, lung, and pancreas tissue, and amounts of serum

immunoglobulin were elevated and their T cells proliferated spontaneously and
strongly when stimulated through the T cell receptor, however, they were
sensitive to cell death induced by cross-linking of the Fas receptor and by
gamma irradiation. Waterhouse et al. concluded that CTLA-4 acts as a negative
regulator of T cell activation and is vital for the control of lymphocyte
homeostasis. In a comment in the same issue, Allison and Krummel Science
270:932-933 (1995), discussed the work of Waterhouse et al. as demonstrative
that CTLA-4 acts to down regulate T-cell responsiveness or has an inhibitory
signaling role in T-cell activation and development. Tivol et al. Immunity
3:541-
7 (1995) also generated CTLA-4-deficient mice and demonstrated that such
mice rapidly develop lymphoproliferative disease with multiorgan lymphocytic
infiltration and tissue destruction, with particularly severe myocarditis and
pancreatitis. They concluded that CTLA-4 plays a key role in down-regulating
T cell activation and maintaining immunologic homeostasis. Also, Krummel
and Allison J Exp Med 182:459-65 (1995) further clarified that CD28 and
CTLA-4 have opposing effects on the response of T cells to stimulation. They
generated an antibody to CTLA-4 and investigated the effects of its binding to

CTLA-4 in a system using highly purified T cells. In their report, they showed
that the presence of low levels of B7-2 on freshly explanted T cells can
partially
inhibit T cell proliferation, and this inhibition was mediated by interactions
with
CTLA-4. Cross-linking of CTLA-4 together with the TCR and CD28 strongly

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
6
inhibits proliferation and IL-2 secretion by T cells. Finally, the results
showed
that CD28 and CTLA-4 deliver opposing signals that appear to be integrated by
the T cell in determining the response to antigen. Thus, they concluded that
the
outcome of T cell antigen receptor stimulation is regulated by CD28
costimulatory signals, as well as inhibitory signals derived from CTLA-4. See
also Krummel et al. Int Immunol 8:519-23 (1996) and U.S. Patent No.
5,811,097 and International Patent Application No. WO 97/20574.
A variety of additional experiments have been conducted further
elucidating the above function of CTLA-4. For example, Walunas et al. J Exp
Med 183:2541-50 (1996), through the use of anti-CTLA-4 antibodies, suggested
that CTLA-4 signaling does not regulate cell survival or responsiveness to IL-
2,
but does inhibit CD28-dependent IL-2 production. Also, Perrin et al. J Immunol

157:1333-6 (1996), demonstrated that anti-CTLA-4 antibodies in experimental
allergic encephalomyelitis (EAE), exacerbated the disease and enhanced
mortality. Disease exacerbation was associated with enhanced production of the
encephalitogenic cytoldnes TNF-alpha, IFN-gamma and IL-2. Thus, they
concluded that CTLA-4 regulates the intensity of the autoimmune response in
EAE, attenuating inflammatory cytokine production and clinical disease
manifestations. See also Hurwitz et al. J Neuroimmunol 73:57-62 (1997) and
Cepero et al. J Exp Med 188:199-204 (1998) (an anti-CTLA-4 hairpin ribozyme
that specifically abrogates CTLA-4 expression after gene transfer into a
murine
T-cell model).
In addition, Blair et al. J Immunol 160:12-5 (1998) assessed the
functional effects of a panel of CTLA-4 monoclonal antibodies (mAbs) on
resting human CD4+ T cells. Their results demonstrated that some CTLA-4
mAbs could inhibit proliferative responses of resting CD4+ cells and cell
cycle
transition from GO to Gl. The inhibitory effects of CTLA-4 were evident within

4 h, at a time when cell surface CTLA-4 expression remained undetectable.
Other CTLA-4 mAbs, however, had no detectable inhibitory effects, indicating
that binding of mAbs to CTLA-4 alone was not sufficient to mediate down-
regulation of T cell responses. Interestingly, while IL-2 production was shut
off,
inhibitory anti-CTLA-4 mAbs permitted induction and expression of the cell

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
7
survival gene bc1-X(L). Consistent with this observation, cells remained
viable
and apoptosis was not detected after CTLA-4 ligation.
In connection with anergy, Perez et al. Immunity 6:411-7 (1997)
demonstrated that the induction of T cell anergy was prevented by blocking
CTLA-4 and concluded that the outcome of antigen recognition by T cells is
determined by the interaction of CD28 or CTLA-4 on the T cells with B7
molecules. Also, Van Parijs et al. J Exp Med 186:1119-28 (1997) examined the
role of interleukin 12 and costimulators in T cell anergy in vivo and found
that
through inhibiting CTLA-4 engagement during anergy induction, T cell
proliferation was blocked, and full Thl differentiation was not promoted.
However, T cells exposed to tolerogenic antigen in the presence of both IL-12
and anti-CTLA-4 antibody were not anergized, and behaved identically to T
cells which have encountered immunogenic antigen. These results suggested
that two processes contribute to the induction of anergy in vivo: CTLA-4
engagement, which leads to a block in the ability of T cells to proliferate,
and
the absence of a prototypic inflammatory cytokine, IL-12, which prevents the
differentiation of T cells into Thl effector cells. The combination of IL-12
and
anti-CTLA-4 antibody was sufficient to convert a normally tolerogenic stimulus

to an immunogenic one.
In connection with infections, McCoy et al. J Exp Med 186:183-7 (1997)
demonstrated that anti-CTLA-4 antibodies greatly enhanced and accelerated the
T cell immune response to Nippostrongylus brasiliensis, resulting in a
profound
reduction in adult worm numbers and early termination of parasite egg
production. See also Murphy et al. J. Immunol. 161:4153-4160 (1998)
(Leishmania donovani).
In connection with cancer, Kwon et al. PNAS USA 94:8099-103 (1997)
established a syngeneic murine prostate cancer model and examined two
distinct manipulations intended to elicit an antiprostate cancer response
through
enhanced T cell costimulation: (i) provision of direct costimulation by
prostate
cancer cells transduced to express the B7.1 ligand and (ii) in vivo antibody-
mediated blockade of T cell CTLA-4, which prevents T cell down-regulation. It
was demonstrated that in vivo antibody-mediated blockade of CTLA-4

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
8
enhanced antiprostate cancer immune responses. Also, Yang et al. Cancer Res
57:4036-41 (1997) investigated whether the blockade of the CTLA-4 function
leads to enhancement of antitumor T cell responses at various stages of tumor
growth. Based on in vitro and in vivo results they found that CTLA-4 blockade
in tumor-bearing individuals enhanced the capacity to generate antitumor T-
cell
responses, but the expression of such an enhancing effect was restricted to
early
stages of tumor growth in their model. Further, Hurwitz et al. Proc Nat! Acad
Sci US A 95:10067-71 (1998) investigated the generation of a T cell-mediated
antitumor response depends on T cell receptor engagement by major
to histocompatibility complex/antigen as well as CD28 ligation by B7.
Certain
tumors, such as the SM1 mammary carcinoma, were refractory to anti-CTLA-4
irnmunotherapy. Thus, through use of a combination of CTLA-4 blockade and
a vaccine consisting of granulocyte-macrophage colony-stimulating factor-
expressing SM1 cells, regression of parental SM1 tumors was observed, despite
the ineffectiveness of either treatment alone. This combination therapy
resulted
in long-lasting immunity to SM1 and depended on both CD4(+) and CD8(+) T
cells. The findings suggested that CTLA-4 blockade acts at the level of a host-

derived antigen-presenting cell.
In connection with diabetes, Luhder et al. J Exp Med 187:427-32 (1998)
injected an anti-CTLA-4 mAb into a TCR transgenic mouse model of diabetes
at different stages of disease. They found that engagement of CTLA-4 at the
time when potentially diabetogenic T cells are first activated is a pivotal
event;
if engagement is permitted, invasion of the islets occurs, but remains quite
innocuous for months. If not, insulitis is much more aggressive, and diabetes
quickly ensues.
In connection with vaccine immunization, Horspool et al. .1 Immunol
160:2706-14 (1998) found that intact anti-CTLA-4 mAb but not Fab fragments
suppressed the primary humoral response to pCIA/beta gal without affecting
recall responses, indicating CTLA-4 activation inhibited Ab production but not
T cell priming. Blockade of the ligands for CD28 and CTLA-4, CD80 (B7-1)
and CD86 (B7-2), revealed distinct and nonoverlapping function. Blockade of
CD80 at initial immunization completely abrogated primary and secondary Ab

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
9
responses, whereas blockade of CD86 suppressed primary but not secondary
responses. Simultaneous blockade of CD80 + CD86 was less effective at
suppressing Ab responses than either alone. Enhancement of costimulation via
coinjection of B7-expressing plasmids augmented CTL responses but not Ab
responses, and without evidence of Thl to Th2 skewing. These findings suggest
complex and distinct roles for CD28, CTLA-4, CD80, and CD86 in T cell
costimulation following nucleic acid vaccination.
In connection with allograft rejection, Markees et al. J Clin Invest
101:2446-55 (1998) found in a mouse model of skin allograft rejection that
to acceptance initially depended on the presence of IFN-gamma, CTLA-4, and
CD4(+) T cells. Addition of anti-CTLA-4 or anti-IFN-gamma mAb to the
protocol was associated with prompt graft rejection, whereas anti-IL-4 mAb had

no effect.
In connection with the role of CTLA-4 in relation to CD28, Fallarino et
al. J Exp Med 188:205-10 (1998) generated TCR transgenic/recombinase
activating gene 2-deficient/CD28-wild-type or CD28-deficient mice which were
immunized with an antigen-expressing tumor. Primed T cells from both types
of mice produced cytokines and proliferated in response to stimulator cells
lacking B7 expression. However, whereas the response of CD28+/+ T cells was
augmented by costimulation with B7-1, the response of the CD28-/- T cells was
strongly inhibited. This inhibition was reversed by monoclonal antibody
against
B7-1 or CTLA-4. Thus, CTLA-4 can potently inhibit T cell activation in the
absence of CD28, indicating that antagonism of a TCR-mediated signal is
sufficient to explain the inhibitory effect of CTLA-4. Also, Lin et al. J Exp
Med
188:199-204 (1998) studied rejection of heart allografts in CD28-deficient
mice.
H-2(q) hearts were transplanted into allogeneic wild-type or CD28-deficient
mice (H-2(b)). Graft rejection was delayed in CD28-deficient compared with
wild-type mice. Treatment of wild-type recipients with CTLA-4-
immunoglobulin (Ig), or with anti-B7-1 plus anti-B7-2 mAbs significantly
prolonged allograft survival. In contrast, treatment of CD28-deficient mice
with
CTLA-4-Ig, anti-B7-1 plus anti-B7-2 mAbs, or a blocking anti-C'TLA-4 mAb
induced acceleration of allograft rejection. This increased rate of graft
rejection

CA 02356215 2008-02-01
6100 9-4 91
was associated with more severe mononucicar cell infiltration and enhanced
levels of IFN-gamma and IL-6 transcripts in donor hearts of untreated wild-
type
and CTLA-4-1g- or anti-CTLA-4 mAb-treated CD28-deficient mice. Thus, the
negative regulatory role of CTLA-4 extends beyond its potential ability to
prevent CD28 activation through ligand competition. Even in the absence of
CD28, CTLA-4 plays an inhibitory role in the regulation of allograft
rejection.
Also, further characterization of the expression of CTLA-4 has been
investigated. For example, Alegre et al. .1 Immunol 157:4762-70 (1996)
proposed that surface CTLA-4 is rapidly internalized, which may explain the
low levels of expression generally detected on the cell surface. They
concluded
that both CD28 and IL-2 play important roles in the up-regulation of CTLA-4
expression. In addition, the cell surface accumulation of CTLA-4 appeared to
be
primarily regulated by its rapid endocytosis. Also, Castan et al. Immunology
90:265-71 (1997) based on in situ immunohistological analyses of the
expression of CTLA-4, suggested that germinal center T cells, which were
CTLA-4 positive, could be important to immune regulation.
Accordingly, in view of the broad and pivotal role that CTLA-4 appears
to possess in immune responsiveness, it would be desirable to generate
antibodies to CTLA-4 that can be utilized effectively in immunotherapy.
Moreover, it would be desirable to generate antibodies against CTLA-4 that can
be utilized in chronic diseases in which repeat administrations of the
antibodies
are required.
BRIEF DESCRIPTION OF THE DRAWING FIGURES
Figure 1 provides a series of nucleotide and an amino acid sequences of
heavy chain and kappa light chain immunoglobulin molecules in accordance
with the invention: 4.1.1 (Figure 1A), 4.8.1 (Figure 1B), 4.14.3 (Figure 1C),
6.1.1 (Figure ID), 3.1.1 (Figure 1E), 4.10.2 (Figure 1F), 2.1.3 (Figure 1G),
4.13.1 (Figure 1H), 11.2.1 (Figure II), 11.6.1 (Figure IJ), 11.7.1 (Figure
1K),
12.3.1.1 (Figure IL), and 12.9.1.1 (Figure 1M),

CA 02356215 2008-02-01
61009-491
11
Figure 2 provides a sequence alignment between the
predicted heavy chain amino acid sequences from the clones
4.1.1 (SEQ ID NO: 74), 4.8.1 (SEQ ID NO: 75),
4.14.3 (SEQ ID NO: 78), 6.1.1 (SEQ ID NO: 79),
3.1.1 (SEQ ID NO: 73)1 4.10.2 (SEQ ID NO: 76),
4.13.1 (SEQ ID NO: 77), 11.2.1 (SEQ ID NO: 80),
11.6.1 (SEQ ID NO: 81), 11.7.1 (SEQ ID NO: 82),
12.3.1.1 (SEQ ID NO: 83), and 12.9.1.1 (SEQ ID NO: 84) and
the germline DP-50 (3-33) amino acid sequence
(SEQ ID NO: 72). Differences between the DP-50 germline
sequence and that of the sequence in the clones are
indicated in bold. The Figure also shows the positions of
the CDR1, CDR2, and CDR3 sequences of the antibodies as
shaded.
Figure 3 provides a sequence alignment between the
predicted heavy chain amino acid sequence of the clone
2.1.3 (SEQ ID NO: 86) and the germline DP-65 (4-31) amino
acid sequence (SEQ ID NO: 85). Differences between the
DP-65 germline sequence and that of the sequence in the
clone are indicated in bold. The Figure also shows the
positions of the CDR1, CDR2, and CDR3 sequences of the
antibody as underlined.
Figure 4 provides a sequence alignment between the
predicted kappa light chain amino acid sequence of the
clones 4.1.1 (SEQ ID NO: 88), 4.8.1 (SEQ ID NO: 89),
4.14.3 (SEQ ID NO: 90), 6.1.1 (SEQ ID NO: 91),
4.10.2 (SEQ ID NO: 92), and 4.13.1 (SEQ ID NO: 93) and the
germline A27 amino acid sequence (SEQ ID NO: 87).
Differences between the A27 germline sequence and that of
- 30 the sequence in the clone are indicated in bold. The Figure
also shows the positions of the CDR1, CDR2, and CDR3
sequences of the antibody as underlined. Apparent deletions

CA 02356215 2008-02-01
61009-491
llb
clone are indicated in bold. The Figure also shows the
positions of the CDR1, CDR2, and CDR3 sequences of the
antibody as underlined.

CA 02356215 2008-02-01
61009-491
11a
in the CDR1s of clones 4.8.1, 4.14.3, and 6.1.1 are
indicated with "Os".
Figure 5 provides a sequence alignment between the
predicted kappa light chain amino acid sequence of the
clones 3.1.1 (SEQ ID NO: 95), 11.2.1 (SEQ ID NO: 96),
11.6.1 (SEQ ID NO: 97), and 11.7.1 (SEQ ID NO: 98) and the
germline 012 amino acid sequence (SEQ ID NO: 94).
Differences between the 012 germline sequence and that of
the sequence in the clone are indicated in bold. The Figure
also shows the positions of the CDR1, CDR2, and CDR3
sequences of the antibody as underlined.
Figure 6 provides a sequence alignment between the
predicted kappa light chain amino acid sequence of the clone
2.1.3 (SEQ ID NO: 112) and the germline A10/A26 amino acid
sequence (SEQ ID NO: 99). Differences between the
A10/A26 germline sequence and that of the sequence in the
clone are indicated in bold. The Figure also shows the
positions of the CDR1, CDR2, and CDR3 sequences of the
antibody as underlined.
Figure 7 provides a sequence alignment between the
predicted kappa light chain amino acid sequence of the clone
12.3.1 (SEQ ID NO: 114) and the germline A17 amino acid
sequence (SEQ ID NO: 113). Differences between the
A17 germline sequence and that of the sequence in the clone
are indicated in bold. The Figure also shows the positions
of the CDR1, CDR2, and CDR3 sequences of the antibody as
underlined.
Figure 8 provides a sequence alignment between the
predicted kappa light chain amino acid sequence of the clone
12.9.1 (SEQ ID NO: 116) and the germline A3/A19 amino acid
sequence (SEQ ID NO: 115). Differences between the
A3/A19 germline sequence and that of the sequence in the

CA 02356215 2008-02-01
61009-491
1-)
Figure 9 provides a summary of N-terminal amino acid sequences
generated through direct protein sequencing of the heavy and light chains of
the
antibodies.
Figure 10 provides certain additional characterizing information about
, certain of the antibodies in accordance with the invention. In Figure
10A, data
related to clones 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.14_3, and 6.1.1 is
summarized.
Data related to concentration, isoelectric focusing (IEF), SDS-PAGE, size
exclusion chromatography, liquid chromatography/mass spectroscopy (LCMS),
mass spectroscopy (MALDI), light chain N-terminal sequences is provided.
Additional detailed information related to LEF is provided in Figure 10B;
related
to SDS-PAGE is provided in 10C; and SEC of the 4.1.1 antibody in 10D.
Figure 11 shows the expression of B7-1 and B7-2 on Raji cells using
anti-CD8O-PE and anti-CD86-PE mAbs.
Figure 12 shows the concentration dependent enhancement of 11-2
production in the T cell blast/Raji assay induced by anti-CTLA-4 blocking
antibodies (BN13, 4.1.1,4.8.1, and 6.1.1).
Figure 13 shows the concentration dependent enhancement of IFN-y
production in the T cell blast/Raji assay induced by anti-CTLA-4 blocking
antibodies (BNI3, 4.1.1, 4.8.1, and 6.1.1)(same donor T cells).
TP
Figure 14 shows the mean enhancement of 11-2 production in T cells
from 6 donors induced by anti-CTLA-4 blocking antibodies in the T cell
blast/Raji assay.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
13
Figure 15 shows the mean enhancement of IFN-y production in T cells
from 6 donors induced by anti-CTLA-4 blocking antibodies in the T cell
blast/Raji assay.
Figure 16 shows the enhancement of IL-2 production in hPBMC from 5
donors induced by anti-CTLA-4 blocking mAbs as measured at 72 hours after
stimulation with SEA.
Figure 17 shows the enhancement of IL-2 production in whole blood
from 3 donors induced by anti-CTLA-4 blocking mAbs as measured at 72 and
96 hours after stimulation with SEA.
Figure 18 shows the inhibition of tumor growth with an anti-murine
CTLA-4 antibody in a murine fibrosarcoma tumor model.
Figure 19 shows enhancement of IL-2 production induced by anti-
CTLA4 antibodies (4.1.1 and 11.2.1) of the invention in a 72 hour T blastfRaji

and Superantigen (whole blood and peripheral blood mononuclear cells from 6
donors) assays.
Figure 20 shows dose dependent enhancement of IL-2 production
induced by anti-CTLA4 antibodies (4.1.1 and 11.2.1) of the invention in a 72
hour T blast/Raji assay.
Figure 21 shows dose dependent enhancement of IL-2 production
induced by anti-CTLA4 antibodies (4.1.1 and 11.2.1) of the invention in a 72
hour Superantigen whole blood assay stimulated with 100 ng/ml superantigen.
Figure 22 provides a series of additional nucleotide and amino acid
sequences of the following anti-CTLA-4 antibody chains: full length 4.1.1
heavy chain (cDNA 22(a), genomic 22(b), and amino acid 22(c)), full length
aglycosylated 4.1.1 heavy chain (cDNA 22(d) and amino acid 22(e)), 4.1.1 light
chain (cDNA 22(f) and amino acid 22(g)), full length 4.8.1 heavy chain (cDNA
22(h) and amino acid 22(i)), 4.8.1 light chain (cDNA 22(j) and amino acid
22(k)), full length 6.1.1 heavy chain (cDNA 22(1) and amino acid 22(m)), 6.1.1

light chain (cDNA 22(n) and amino acid 22(o)), full length 11.2.1 heavy chain
(cDNA 22(p) and amino acid 22(q)), and 11.2.1 light chain (cDNA 22 (r) and
amino acid 22(s)).

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
14
SUMMARY OF THE INVENTION
In accordance with a first aspect of the present invention, there is
provided an antibody that is capable of binding CTLA-4, comprising a heavy
chain variable region amino acid sequence that comprises a contiguous amino
acid sequence from within an FR1 sequence through an FR3 sequence that is
encoded by a human VH3-33 family gene and that comprises at least one of the
amino acid substitutions in the CDR1 sequences, CDR2 sequences, or
framework sequences shown in Figure 2. In a preferred embodiment, the amino
acid sequence comprises a sequence selected from the group consisting of SEQ
ID NO:!, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID
NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:!!, SEQ ID
NO:12, SEQ ID NO:13, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ
ID NO:68, and SEQ ID NO:70. In another preferred embodiment, the antibody
further comprises a light chain variable region amino acid sequence comprising
a sequence selected from the group consisting of a sequence comprising SEQ
ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ NO:17, SEQ ID NO:18,
SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID
NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:65, SEQ
ID NO:67, SEQ ID NO:69, and SEQ ID NO:71.
In accordance with a second aspect of the present invention, there is
provided an antibody comprising a heavy chain amino acid sequence
comprising SEQ ID NO:1 and a light chain variable amino acid sequence
comprising SEQ ID NO:14.
In accordance with a third aspect of the present invention, there is
provided an antibody comprising a heavy chain amino acid sequence
comprising SEQ ID NO:2 and a light chain variable amino acid sequence
comprising SEQ NO:15.
In accordance with a fourth aspect of the present invention, there is
provided an antibody comprising a heavy chain amino acid sequence
comprising SEQ ID NO:4 and a light chain variable amino acid sequence
comprising SEQ ID NO:17.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
In accordance with a fifth aspect of the present invention, there is
provided an isolated human monoclonal antibody that is capable of binding to
CTLA-4. In a preferred embodiment, antibody is capable of competing for
binding with CTLA-4 with an antibody selected from the group consisting of
5 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1,
11.7.1, 12.3.1.1,
and 12.9.1.1. In another preferred embodiment, the antibody possesses a
substantially similar binding specificity to CTLA-4 as an antibody selected
from
the group consisting of 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1,
11.2.1,
11.6.1, 11.7.1, 12.3.1.1, and 12.9.1.1. In another preferred embodiment, the
10 antibody is selected from the group consisting of 3.1.1, 4.1.1, 4.8.1,
4.10.2,
4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, and 12.9.1.1. In
another
preferred embodiment, the antibody is not cross reactive with CTLA-4 from
lower mammalian species, preferably the lower mammalian species comprises
mouse, rat, and rabbit and more preferably mouse and rat. In another preferred
15 embodiment, the antibody is cross reactive with CTLA-4 from primates,
preferably the primates comprise cynomolgous and rhesus monkeys. In another
preferred embodiment, the antibody possesses a selectivity for CTLA-4 over
CD28, B7-2, CD44, and hIgG1 of greater than about 100:1 and preferably about
500:1 or greater. In another preferred embodiment, the binding affinity of the
antibody is about 10-9 M or greater and preferably about 10-1 M or greater.
In
another preferred embodiment, the antibody inhibits binding between CTLA-4
and B7-2 with an IC50 of lower than about 100 nM and preferably lower than
about 0.38 nM. In another preferred embodiment, the antibody inhibits binding
between CTLA-4 and B7-1 with an IC50 of lower than about 100 nM or greater
and preferably lower than about 0.50 nM. In another preferred embodiment, the
antibody enhances IL-2 production in a T cell blast/Raji assay by about 500
pg/ml or greater and preferably by about 3846 pg/ml or greater. In another
preferred embodiment, the antibody enhances IFNI production in a T cell
blast/Raji assay by about 500 pg/ml or greater and preferably by about 1233
pg/ml or greater. In another preferred embodiment, the antibody enhances IL-2
production in a hPBMC or whole blood superantigen assay by about 500 pg/ml
or greater. In another preferred embodiment, the antibody enhances IL-2

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
16
production in a hPBMC or whole blood superantigen assay by about 500 pg/ml
or preferably 1500 pg/ml or greater or by greater than about 30% or preferably

50% relative to control.
In accordance with a sixth aspect of the present invention, there is
provided a humanized antibody that possesses a substantially similar binding
specificity to CTLA-4 as an antibody selected from the group consisting of
3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1,
12.3.1.1,
and 12.9.1.1. In a preferred embodiment, the antibody is not cross reactive
with
CTLA-4 from lower mammalian species, preferably the lower mammalian
species comprises mouse, rat, and rabbit and preferably mouse and rat. In
another preferred embodiment, the antibody is cross reactive with CTLA-4 from
primates, preferably the primates comprise cynomolgous and rhesus monkeys.
In another preferred embodiment, the antibody possesses a selectivity for
CTLA-4 over CD28, B7-2, CD44, and hIgG1 of greater than about 100:1 and
preferably about 500:1 or greater. In another preferred embodiment, the
binding affinity of the antibody is about 10-9 M or greater and preferably
about
1040 M or greater. In another preferred embodiment, the antibody inhibits
binding between CTLA-4 and B7-2 with an IC50 of lower than about 100 nM
and preferably lower than about 0.38 nM. In another preferred embodiment, the
antibody inhibits binding between CTLA-4 and B7-1 with an Icso of lower than
about 100 nM or greater and preferably lower than about 0.50 nM. In another
preferred embodiment, the antibody enhances IL-2 production in a T cell
blast/Raji assay by about 500 pg/ml or greater and preferably by about 3846
pg/ml or greater. In another preferred embodiment, the antibody enhances IFN-
y production in a T cell blast/Raji assay by about 500 pg/ml or greater and
preferably by about 1233 pg/ml or greater. In another preferred embodiment,
the antibody induces IL-2 production in a hPBMC or whole blood superantigen
assay by about 500 pg/ml or greater. In another preferred embodiment, the
antibody enhances IL-2 production in a hPBMC or whole blood superantigen
assay by about 500 pg/ml or preferably 1500 pg/ml or greater or by greater
than
about 30% or preferably 50% relative to control.

CA 02356215 2001-06-21
WO 00137504
PCT/US99/30895
17
In accordance with a seventh aspect of the present invention, there is
provided an antibody that binds to CTLA-4, comprising a heavy chain amino
acid sequence comprising human FR1, FR2, and FR3 sequences encoded by a
human VH 3-33 gene family operably linked in frame with a CDR1, a CDR2,
and a CDR3 sequence, the CDR1, CDR2, and CDR3 sequences being
independently selected from the CDR1, CDR2, and CDR3 sequences illustrated
in Figure 2. In a preferred embodiment, the antibody of Claim 32, further
comprising any of the somatic mutations to the FR1, FR2, and FR3 sequences
as illustrated in Figure 2.
In accordance with an eighth aspect of the present invention, there is
provided an antibody that binds to CTLA-4, comprising a heavy chain amino
acid sequence comprising human FR1, FR2, and FR3 sequences encoded by a
human VH 3-33 gene family operably linked in frame with a CDR1, a CDR2,
and a CDR3 sequence, which antibody has the following properties: a binding
affinity for CTLA-4 of about 10-9 or greater; inhibits binding between CTLA-4
and B7-1 with an IC50 of about 100 nM or lower; inhibits binding between
CTLA-4 and B7-2 with an IC50 of about 100 nM or lower; and enhances
cytokine production in an assay of human T cells by 500 pg/ml or greater.
In accordance with a ninth aspect of the present invention, there is
provided an antibody that binds to CTLA-4, comprising a heavy chain amino
acid sequence comprising FR1, FR2, and FR3 sequences operably linked in
frame with a CDR1, a CDR2, and a CDR3 sequence independently selected
from the CDR1, CDR2, and CDR3 sequences illustrated in Figures 2 and 3,
which antibody has the following properties: a binding affinity for CTLA-4 of
about 10-9 or greater; inhibits binding between CTLA-4 and B7-1 with an IC50
of about 100 nM or lower; inhibits binding between CTLA-4 and B7-2 with an
IC50 of about 100 nM or lower; and enhances cytokine production in an assay of

human T cells by 500 pg/ml or greater.
In accordance with a tenth aspect of the present invention, there is
provided a cell culture system for assaying T cell stimulation, comprising a
culture of human T cell blasts co-cultured with a Raji cell line. In a
preferred
embodiment, the T cell blasts are washed prior to culture with the Raji cell
line.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
18
In accordance with an eleventh aspect of the present invention, there is
provided an assay for measuring T cell stimulation, comprising: providing a
culture of human T cell blasts and a Raji cell line; contacting the culture
with an
agent; and measuring cytokine production by the culture.
In accordance with an twelfth aspect of the present invention, there is
provided a functional assay for screening a moiety for T cell stimulatory
function, comprising: providing a culture of human T cell blasts and a Raji
cell
line; contacting the culture with the moiety; and assessing cytokine
production
by the culture.
In accordance with a thirteenth aspect of the present invention, there is
provided a T cell stimulatory assay for CTLA-4 inhibitory function, comprising

contacting a culture comprising human T cell blasts and a Raji cell line with
an
agent and assessing cytokine production by the culture.
In accordance with a fourteenth aspect of the present invention, there is
provided a method for screening an agent for T cell stimulatory activity,
comprising: contacting the agent with a cell culture comprising human T cell
blasts and a Raji cell line; and assessing cytokine production by the culture.

In each of the tenth through the fourteenth aspects of the present
invention, in a preferred embodiment, the T cell blasts are washed prior to
culture with the Raji cell line. In another preferred embodiment, the cytokine
is
IL-2 or IFN-y. In a preferred embodiment, cytokine production is measured in
supernatant isolated from the culture. In a preferred embodiment, the agent is

an antibody and preferably binds to CTLA-4.
In accordance with a fifteenth aspect of the present invention, there is
provided an assay for measuring T cell stimulation, comprising: providing a
population of human peripheral blood mononuclear cells or human whole blood
stimulated with staphylococcus enterotoxin A; contacting the culture with an
agent; and measuring cytokine production by the cell population.
In accordance with a sixteenth aspect of the present invention, there is
provided a functional assay for screening a moiety for T cell stimulatory
function, comprising: providing a population of human peripheral blood
mononuclear cells or human whole blood stimulated with staphylococcus

CA 02356215 2014-12-17
54405-2
19
enterotoxin A; contacting the culture with the moiety; and assessing cytokine
production by the cell population.
In accordance with a seventeenth aspect of the present invention, there
is provided a T cell stimulatory assay for CTLA-4 inhibitory function,
comprising
contacting a population of human peripheral blood mononuclear cells or human
whole blood stimulated with staphylococcus enterotoxin A with an agent and
assessing cytokine production by the cell population.
In accordance with an eighteenth aspect of the present invention, there
is provided a method for screening an agent for T cell stimulatory activity,
comprising:
contacting the agent with a population of human peripheral blood mononuclear
cells
or human whole blood stimulated with staphylococcus enterotoxin A; and
assessing
cytokine production by the cell population.
In each of the fifteenth through the eighteenth aspects of the present
invention, in a preferred embodiment, the cytokine is IL-2. In another
preferred
embodiment, cytokine production is measured in supernatant isolated from the
culture. In a preferred embodiment, the agent is an antibody and preferably
binds
to CTLA-4.
Accordingly, the invention as claimed relates to:
- a monoclonal antibody or an antigen-binding portion thereof that
specifically binds to cytotoxic T lymphocyte antigen 4 (CTLA-4), wherein said
antibody or portion comprises heavy chain CDR1, CDR2, and CDR3 amino acid
sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences selected
from the group consisting of: (a) the heavy chain CDR1, CDR2, and CDR3 amino
acid sequences in SEQ ID NO: 73 and the light chain CDR1, CDR2, and CDR3
amino acid sequences in SEQ ID NO: 95, respectively; (b) the heavy chain CDR1,

CDR2, and CDR3 amino acid sequences in SEQ ID NO: 74 and the light chain
CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID NO: 88, respectively;
(c) the heavy chain CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID

CA 02356215 2014-12-17
54405-2
19a
NO: 75 and the light chain CDR1, CDR2, and CDR3 amino acid sequences in
SEQ ID NO: 89, respectively; (d) the heavy chain CDR1, CDR2, and CDR3 amino
acid sequences in SEQ ID NO: 76 and the light chain CDR1, CDR2, and CDR3
amino acid sequences in SEQ ID NO: 92, respectively; (e) the heavy chain CDR1,
CDR2, and CDR3 amino acid sequences in SEQ ID NO: 77 and the light chain
CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID NO: 93, respectively;
(f) the heavy chain CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID
NO: 78 and the light chain CDR1, CDR2, and CDR3 amino acid sequences in SEQ
ID NO: 90, respectively; (g) the heavy chain CDR1, CDR2, and CDR3 amino acid
sequences in SEQ ID NO: 79 and the light chain CDR1, CDR2, and CDR3 amino
acid sequences in SEQ ID NO: 91, respectively; (h) the heavy chain CDR1, CDR2,
and CDR3 amino acid sequences in SEQ ID NO: 80 and the light chain CDR1,
CDR2, and CDR3 amino acid sequences in SEQ ID NO: 96, respectively; (i) the
heavy chain CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID NO: 81 and
the light chain CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID NO: 97,
respectively; (j) the heavy chain CDR1, CDR2, and CDR3 amino acid sequences in

SEQ ID NO: 82 and the light chain CDR1, CDR2, and CDR3 amino acid sequences
in SEQ ID NO: 98, respectively; (k) the heavy chain CDR1, CDR2, and CDR3 amino

acid sequences in SEQ ID NO: 83 and the light chain CDR1, CDR2, and CDR3
amino acid sequences in SEQ ID NO: 114, respectively; and (I) the heavy chain
CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID NO: 84 and the light
chain CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID NO: 116,
respectively;
- a monoclonal antibody or an antigen-binding portion thereof that
specifically binds to CTLA-4, wherein said antibody comprises: (a) the CDR1,
CDR2,
and CDR3 amino acid sequences shown in SEQ ID NO: 63 and the CDR1, CDR2,
and CDR3 amino acid sequences shown in SEQ ID NO: 65; (b) the CDR1, CDR2,
and CDR3 amino acid sequences shown in SEQ ID NO: 66 and the CDR1, CDR2,
and CDR3 amino acid sequences shown in SEQ ID NO: 67; (c) the CDR1, CDR2,
and CDR3 amino acid sequences shown in SEQ ID NO: 68 and the CDR1, CDR2,

CA 02356215 2014-12-17
54405-2
19b
and CDR3 amino acid sequences shown in SEQ ID NO: 69; or (d) the CDR1, CDR2,
and CDR3 amino acid sequences shown in SEQ ID NO: 70 and the CDR1, CDR2,
and CDR3 amino acid sequences shown in SEQ ID NO: 71;
- a human monoclonal antibody that binds to CTLA-4, wherein the
heavy chain of said antibody comprises the amino acid sequence of SEQ ID NO:
70
and the light chain of said antibody comprises the amino acid sequence of SEQ
ID
NO: 71;
- a monoclonal antibody or an antigen-binding portion thereof that
specifically binds to CTLA-4, wherein said antibody comprises a heavy chain
comprising amino acid residues 17 to 26, 41 to 55 and 90 to 105 of SEQ ID NO:
80;
and wherein said antibody further comprises a light chain comprising amino
acid
residues 17 to 27, 43 to 49 and 82 to 90 of SEQ ID NO: 96;
- a monoclonal antibody that specifically binds to CTLA-4, comprising a
heavy chain amino acid sequence comprising SEQ ID NO: 70 and a light chain
amino
acid sequence comprising SEQ ID NO: 71;
- a mammalian host cell line comprising nucleic acid sequences
encoding the heavy and light chains of a human monoclonal antibody whose heavy

chain comprises the amino acid sequence of SEQ ID NO: 70 and whose light chain

comprises the amino acid sequence of SEQ ID NO: 71;
- a mammalian host cell line comprising nucleic acid sequences
encoding the heavy and light chains of a human monoclonal antibody that
comprises
the heavy chain FR1 through FR4 amino acid sequence in SEQ ID NO: 1 and the
light chain FR1 through FR4 amino acid sequence in SEQ ID NO: 14, wherein said

human monoclonal antibody inhibits binding of human CTLA-4 to human B7-1 and
human B7-2;
- a method for expressing and recovering a human monoclonal antibody
or an antigen-binding portion thereof, wherein said antibody comprises a heavy
chain

CA 02356215 2014-12-17
54405-2
19c
comprising the heavy chain CDR1, CDR2, and CDR3 amino acid sequences in
SEQ ID NO: 70 and a light chain comprising the light chain CDR1, CDR2, and
CDR3
amino acid sequences in SEQ ID NO: 71, said method comprising the steps of:
(a)
culturing a mammalian host cell comprising nucleic acid sequences encoding the
heavy chain or an antigen-binding portion thereof, and the light chain or an
antigen-
binding portion thereof, of said antibody or portion; and (b) recovering said
antibody
or portion;
- a method for expressing and recovering a human monoclonal antibody
that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
70
and a light chain comprising the amino acid sequence of SEQ ID NO: 71, said
method comprising the steps of: (a) culturing a mammalian host cell comprising

nucleic acid sequences encoding the heavy and light chains of said human
monoclonal antibody; and (b) recovering said human monoclonal antibody;
- a method for expressing and recovering a human monoclonal antibody
or an antigen-binding portion thereof, wherein said antibody comprises a heavy
chain
comprising the heavy chain CDR1, CDR2, and CDR3 amino acid sequences in
SEQ ID NO: 1 and a light chain comprising the light chain CDR1, CDR2, and CDR3

amino acid sequences in SEQ ID NO: 14, and wherein said human monoclonal
antibody inhibits binding of human CTLA-4 to human B7-1 and human B7-2, said
method comprising the steps of: (a) culturing a mammalian host cell comprising
nucleic acid sequences encoding the heavy chain or an antigen-binding portion
thereof, and the light chain or an antigen-binding portion thereof, of said
antibody or
portion; and (b) recovering said antibody or portion;
- a method for expressing and recovering a human monoclonal
antibody, wherein the heavy chain of said antibody comprises the amino acid
sequence of SEQ ID NO: 1 and the light chain of said antibody comprises the
amino
acid sequence of SEQ ID NO: 14, wherein said human monoclonal antibody
inhibits
binding of human CTLA-4 to human B7-1 and human B7-2, said method comprising
the steps of: (a) culturing a mammalian host cell comprising nucleic acid
sequences

CA 02356215 2014-12-17
54405-2
19d
encoding the heavy and light chains of said antibody; and (b) recovering said
antibody;
- an isolated nucleic acid that comprises a nucleotide sequence that
encodes the heavy chain amino acid sequence or an antigen-binding portion
thereof
of SEQ ID NO: 70 and the light chain amino acid sequence or an antigen-binding
portion thereof of SEQ ID NO: 71; and
- an isolated nucleic acid that comprises a nucleotide sequence that
encodes the heavy chain amino acid sequence or an antigen-binding portion
thereof
of SEQ ID NO: 1 and the light chain amino acid sequence or an antigen-binding
portion thereof of SEQ ID NO: 14.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In accordance with the present invention, there are provided fully
human monoclonal antibodies against human CTLA-4. Nucleotide sequences
encoding and amino acid sequences comprising heavy and light chain
immunoglobulin molecules, particularly sequences corresponding to a contiguous

heavy and light chain sequences from FR1 and CDR1 through CDR3 and FR4, are
provided. Further provided are antibodies having similar binding properties
and
antibodies (or other antagonists) having similar functionality as antibodies
disclosed
herein. Hybridomas expressing such immunoglobulin molecules and monoclonal
antibodies are also provided.

CA 02356215 2006-12-29
61009-491
Definitions
Unless otherwise defined herein, scientific and technical terms used in
connection with the present invention shall have the meanings that are
5 commonly understood by those of ordinary skill in the art. Further,
unless
otherwise required by context, singular terms shall include pluralities and
plural
terms shall include the singular. Generally, nomenclatures utilized in
connection
with, and techniques of, cell and tissue culture, molecular biology, and
protein
and oligo- or polynucleotide chemistry and hybridization described herein are
o those well known and commonly used in the art. Standard techniques are
used
for recombinant DNA., oligonucleotide synthesis, and tissue culture and
transformation (e.g., electroporation, lipofection). Enzymatic reactions and
purification techniques are performed according to manufacturer's
specifications
or as commonly accomplished in the art or as described herein. The foregoing
techniques and procedures are generally performed according to conventional
methods well known in the art and as described in various general and more
specific references that are cited and discussed throughout the present
specification. See e.g., Sambrook et al. Molecular Cloning: A Laboratory
Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
N.Y. (1989)). The nomenclatures utilized in connection
with, and the laboratory procedures and techniques of,
analytical chemistry, synthetic organic chemistry, and medicinal and
pharmaceutical chemistry described herein are those well known and commonly
used in the art. Standard techniques are used for chemical syntheses, chemical
analyses, pharmaceutical preparation, formulation, and delivery, and treatment
of patients.
As utilized in accordance with the present disclosure, the following
terms, unless otherwise indicated, shall be understood to have the following
meanings:

CA 02356215 2001-06-21
WO 00/37504
PCIYUS99/30895
21
The term "isolated polynucleotide" as used herein shall mean a
polynucleotide of genomic, cDNA, or synthetic origin or some combination
thereof, which by virtue of its origin the "isolated polynucleotide" (1) is
not
associated with all or a portion of a polynucleotide in which the "isolated
polynucleotide" is found in nature, (2) is operably linked to a polynucleotide
which it is not linked to in nature, or (3) does not occur in nature as part
of a
larger sequence.
The term "isolated protein" referred to herein means a protein of cDNA,
recombinant RNA, or synthetic origin or some combination thereof, which by
virtue of its origin, or source of derivation, the "isolated protein" (1) is
not
associated with proteins found in nature, (2) is free of other proteins from
the
same source, e.g. free of murine proteins, (3) is expressed by a cell from a
different species, or (4) does not occur in nature.
The term "polypeptide" as used herein as a generic term to refer to
native protein, fragments, or analogs of a polypeptide sequence. Hence, native

protein, fragments, and analogs are species of the polypeptide genus.
Preferred
polypeptides in accordance with the invention comprise the human heavy chain
immunoglobulin molecules and the human kappa light chain immunoglobulin
molecules represented in Figure 1, as well as antibody molecules formed by
combinations comprising the heavy chain immunoglobulin molecules with light
chain immunoglobulin molecules, such as the kappa light chain
immunoglobulin molecules, and vice versa, as well as fragments and analogs
thereof.
The term "naturally-occurring" as used herein as applied to an object
refers to the fact that an object can be found in nature. For example, a
polypeptide or polynucleotide sequence that is present in an organism
(including viruses) that can be isolated from a source in nature and which has
not been intentionally modified by man in the laboratory or otherwise is
naturally-occurring.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
22
The term "operably linked" as used herein refers to positions of
components so described are in a relationship permitting them to function in
their intended manner. A control sequence "operably linked" to a coding
sequence is ligated in such a way that expression of the coding sequence is
achieved under conditions compatible with the control sequences.
The term "control sequence" as used herein refers to polynucleotide
sequences which are necessary to effect the expression and processing of
coding
= 10 sequences to which they are ligated. The nature of such control
sequences
differs depending upon the host organism; in prokaryotes, such control
sequences generally include promoter, ribosomal binding site, and
transcription
termination sequence; in eukaryotes, generally, such control sequences include
promoters and transcription termination sequence. The
term "control
sequences" is intended to include, at a minimum, all components whose
presence is essential for expression and processing, and can also include
additional components whose presence is advantageous, for example, leader
sequences and fusion partner sequences.
The term "polynucleotide" as referred to herein means a polymeric form
of nucleotides of at least 10 bases in length, either ribonucleotides or
deoxynucleotides or a modified form of either type of nucleotide. The term
includes single and double stranded forms of DNA.
The term "oligonucleotide" referred to herein includes naturally
occurring, and modified nucleotides linked together by naturally occurring,
and
non-naturally occurring oligonucleotide linkages. Oligonucleotides are a
polynucleotide subset generally comprising a length of 200 bases or fewer.
Preferably oligonucleotides are 10 to 60 bases in length and most preferably
12,
13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are
usually single stranded, e.g. for probes; although oligonucleotides may be
double stranded, e.g. for use in the construction of a gene mutant.

CA 02356215 2006-12-29
61009-491
23
Oligonucleotides of the invention can be either sense or antisense
oligonucleotides.
The term "naturally occurring nucleotides" referred to herein includes
deoxyribonucleotides and ribonucleotides. The term "modified nucleotides"
referred to herein includes nucleotides with modified or substituted sugar
groups and the like. The term "oligonucleotide linkages" referred to herein
includes oligonucleotides linkages such as
phosphorothioate,
phosphorodithioate, phosphoroselenoate,
phosphorodiselenoate,
phosphoroanilothioate, phoshoraniladate, phosphoroamidate, and the like. See
e.g., LaPlanche et al. Nucl. Acids Res. 14:9081 (1986); Stec et al. J. Am.
Chem.
Soc. 106:6077 (1984); Stein et al. Nud Acids Res. 16:3209 (1988); Zon et al.
Anti-Cancer Drug Design 6:539 (1991); Zon et al. Oligonucleotides and
Analogues: A Practical Approach, pp. 87-108 (F. Eckstein, Ed., Oxford
University Press, Oxford England (1991)); Stec et al. U.S. Patent No.
5,151,510; Uhlmann and Peyman Chemical Reviews 90:543 (1990).
An oligonucleotide can include a label for detection, if desired.
The term "selectively hybridize" referred to herein means to detectably
and specifically bind. Polynucleotides, oligonucleotides and fragments thereof

in accordance with the invention selectively hybridize to nucleic acid strands

under hybridization and wash conditions that minimize appreciable amounts of
detectable binding to nonspecific nucleic acids. High stringency conditions
can
be used to achieve selective hybridization conditions as known in the art and
discussed herein. Generally, the nucleic acid sequence hom*ology between the
polynucleotides, oligonucleotides, and fragments of the invention and a
nucleic
acid sequence of interest will be at least 80%, and more typically with
preferably increasing hom*ologies of at least 85%, 90%, 95%, 99%, and 100%.
Two amino acid sequences are hom*ologous if there is a partial or complete
identity between their sequences. For example, 85% hom*ology means that 85%
of the amino acids are identical when the two sequences are aligned for

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
24
maximum matching. Gaps (in either of the two sequences being matched) are
allowed in maximizing matching; gap lengths of 5 or less are preferred with 2
or
less being more preferred. Alternatively and preferably, two protein sequences

(or polypeptide sequences derived from them of at least 30 amino acids in
length) are hom*ologous, as this term is used herein, if they have an alignment
score of at more than 5 (in standard deviation units) using the program ALIGN
with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff,
M.O., in Atlas of Protein Sequence and Structure, pp. 101-110 (Volume 5,
National Biomedical Research Foundation (1972)) and Supplement 2 to this
volume, pp. 1-10. The two sequences or parts thereof are more preferably
hom*ologous if their amino acids are greater than or equal to 50% identical
when
optimally aligned using the ALIGN program. The term "corresponds to" is
used herein to mean that a polynucleotide sequence is hom*ologous (i.e., is
identical, not strictly evolutionarily related) to all or a portion of a
reference
polynucleotide sequence, or that a polypeptide sequence is identical to a
reference polypeptide sequence. In contradistinction, the term "complementary
to" is used herein to mean that the complementary sequence is hom*ologous to
all or a portion of a reference polynucleotide sequence. For illustration, the

nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC"
and is complementary to a reference sequence "GTATA".
The following terms are used to describe the sequence relationships
between two or more polynucleotide or amino acid sequences: "reference
sequence", "comparison window", "sequence identity", "percentage of sequence
identity", and "substantial identity". A "reference sequence" is a defined
sequence used as a basis for a sequence comparison; a reference sequence may
be a subset of a larger sequence, for example, as a segment of a full-length
cDNA or gene sequence given in a sequence listing or may comprise a complete
cDNA or gene sequence. Generally, a reference sequence is at least 18
nucleotides or 6 amino acids in length, frequently at least 24 nucleotides or
8
amino acids in length, and often at least 48 nucleotides or 16 amino acids in
length. Since two polynucleotides or amino acid sequences may each (1)

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
comprise a sequence (i.e., a portion of the complete polynucleotide or amino
acid sequence) that is similar between the two molecules, and (2) may further
comprise a sequence that is divergent between the two polynucleotides or amino

acid sequences, sequence comparisons between two (or more) molecules are
5 typically performed by comparing sequences of the two molecules over a
"comparison window" to identify and compare local regions of sequence
similarity. A "comparison window", as used herein, refers to a conceptual
segment of at least 18 contiguous nucleotide positions or 6 amino acids
wherein
a polynucleotide sequence or amino acid sequence may be compared to a
10 reference sequence of at least 18 contiguous nucleotides or 6 amino acid
sequences and wherein the portion of the polynucleotide sequence in the
comparison window may comprise additions, deletions, substitutions, and the
like (i.e., gaps) of 20 percent or less as compared to the reference sequence
(which does not comprise additions or deletions) for optimal alignment of the
15 two sequences. Optimal alignment of sequences for aligning a comparison
window may be conducted by the local hom*ology algorithm of Smith and
Waterman Adv. App!. Math. 2:482 (1981), by the hom*ology alignment
algorithm of Needleman and Wunsch J. MoL Biol. 48:443 (1970), by the search
for similarity method of Pearson and Lipman Proc. Natl. Acad. ScL (U.S.A.)
20 85:2444 (1988), by computerized implementations of these algorithms
(GAP,
BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package
Release 7.0, (Genetics Computer Group, 575 Science Dr., Madison, Wis.),
Geneworlcs, or MacVector software packages), or by inspection, and the best
alignment (i.e., resulting in the highest percentage of hom*ology over the
25 comparison window) generated by the various methods is selected.
The term "sequence identity" means that two polynucleotide or amino
acid sequences are identical (i.e., on a nucleotide-by-nucleotide or residue-
by-
residue basis) over the comparison window. The term "percentage of sequence
identity" is calculated by comparing two optimally aligned sequences over the
window of comparison, determining the number of positions at which the
identical nucleic acid base (e.g., A, T, C, G, U, or I) or residue occurs in
both
_ _ _

CA 02356215 2006-12-29
61009-491
26
sequences to yield the number of matched positions, dividing the number of
matched positions by the total number of positions in the comparison window
(i.e., the window size), and multiplying the result by 100 to yield the
percentage
of sequence identity. The terms "substantial identity" as used herein denotes
a
characteristic of a polynucleotide or amino acid sequence, wherein the
polynucleotide or amino acid comprises a sequence that has at least 85 percent

sequence identity, preferably at least 90 to 95 percent sequence identity,
more
usually at least 99 percent sequence identity as compared to a reference
sequence over a comparison window of at least 18 nucleotide (6 amino acid)
positions, frequently over a window of at least 24-48 nucleotide (8-16 amino
acid) positions, wherein the percentage of sequence identity is calculated by
comparing the reference sequence to the sequence which may include deletions
or additions which total 20 percent or less of the reference sequence over the

comparison window. The reference sequence may be a subset of a larger
sequence.
As used herein, the twenty conventional amino acids and their
abbreviations follow conventional usage. See Immunology - A Synthesis (2nd
Edition, E.S. Golub and D.R. Gre-ii, Eds., Sinauer Associates, Sunderland,
Mass.
( 1 9 9 )). Stereoisomers (e.g., D-amino acids) of the
twenty conventional amino acids, unnatural amino acids
such as a-, a-disubstituted amino acids, N-alkyl amino acids, lactic acid, and

other unconventional amino acids may also be suitable components for
polypeptides of the present invention. Examples of unconventional amino acids
include: 4-hydroxyproline, 7 -carboxyglutamate, s-N,N,N-trimethyllysine, s-N-
acetyllysine, 0-phosphoserine, N-acetylserine, N-forrnylmethionine, 3-
methylhistidine, 5-hydroxylysine, a-N-methylarginine, and other similar amino
acids and imino acids.(e.g., 4-hydroxyproline). In the polypeptide notation
used
herein, the lefthand direction is the amino terminal direction and the
righthand
direction is the carboxy-terminal direction, in accordance with standard usage
and convention.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
27
Similarly, unless specified otherwise, the leflhand end of single-stranded
polynucleotide sequences is the 5' end; the lefthand direction of double-
stranded
polynucleotide sequences is referred to as the 5' direction. The direction of
5' to
3' addition of nascent RNA transcripts is referred to as the transcription
direction; sequence regions on the DNA strand having the same sequence as the
RNA and which are 5' to the 5' end of the RNA transcript are referred to as
"upstream sequences"; sequence regions on the DNA strand having the same
sequence as the RNA and which are 3' to the 3' end of the RNA transcript are
referred to as "downstream sequences".
As applied to polypeptides, the term "substantial identity" means that
two peptide sequences, when optimally aligned, such as by the programs GAP
or BESTFIT using default gap weights, share at least 80 percent sequence
identity, preferably at least 90 percent sequence identity, more preferably at
least 95 percent sequence identity, and most preferably at least 99 percent
sequence identity. Preferably, residue positions which are not identical
differ
by conservative amino acid substitutions.
Conservative amino acid
substitutions refer to the interchangeability of residues having similar side
chains. For example, a group of amino acids having aliphatic side chains is
glycine, alanine, valine, leucine, and isoleucine; a group of amino acids
having
aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids

having amide-containing side chains is asparagine and glutamine; a group of
amino acids having aromatic side chains is phenylalanine, tyrosine, and
tryptophan; a group of amino acids having basic side chains is lysine,
arginine,
and histidine; and a group of amino acids having sulfur-containing side chains
is
cysteine and methionine. Preferred conservative amino acids substitution
groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-
arginine,
alanine-valine, glutamic-aspartic, and asparagine-glutamine.
As discussed herein, minor variations in the amino acid sequences of
antibodies or immunoglobulin molecules are contemplated as being
encompassed by the present invention, providing that the variations in the

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
28
amino acid sequence maintain at least 75%, more preferably at least 80%, 90%,
95%, and most preferably 99%. In particular, conservative amino acid
replacements are contemplated. Conservative replacements are those that take
place within a family of amino acids that are related in their side chains.
Genetically encoded amino acids are generally divided into families: (1)
acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-
polar=alanine, valine, leucine, isoleucine, proline, phenylalanine,
methionine,
tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine,
serine, threonine, tyrosine. More preferred families are: serine and threonine
are
aliphatic-hydroxy family; asparagine and glutamine are an amide-containing
family; alanine, valine, leucine and isoleucine are an aliphatic family; and
phenylalanine, tryptophan, and tyrosine are an aromatic family. For example,
it
is reasonable to expect that an isolated replacement of a leucine with an
isoleucine or valine, an aspartate with a glutamate, a threonine with a
serine, or
a similar replacement of an amino acid with a structurally related amino acid
will not have a major effect on the binding or properties of the resulting
molecule, especially if the replacement does not involve an amino acid within
a
framework site. Whether an amino acid change results in a functional peptide
can readily be determined by assaying the specific activity of the polypeptide
derivative. Assays are described in detail herein. Fragments or analogs of
antibodies or inununoglobulin molecules can be readily prepared by those of
ordinary skill in the art. Preferred amino- and carboxy-termini of fragments
or
analogs occur near boundaries of functional domains. Structural and functional

domains can be identified by comparison of the nucleotide and/or amino acid
sequence data to public or proprietary sequence databases. Preferably,
computerized comparison methods are used to identify sequence motifs or
predicted protein conformation domains that occur in other proteins of known
structure and/or function. Methods to identify protein sequences that fold
into a
known three-dimensional structure are known. Bowie et al. Science 253:164
(1991). Thus, the foregoing examples demonstrate that those of skill in the
art
can recognize sequence motifs and structural conformations that may be used to

define structural and functional domains in accordance with the invention.

CA 02356215 2006-12-29
61009-491
29
Preferred amino acid substitutions are those which: (I) reduce
susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3)
alter
binding affinity for forming protein complexes, (4) alter binding affinities,
and
(4) confer or modify other physicochemical or functional properties of such
analogs. Analogs can include various muteins of a sequence other than the
naturally-occurring peptide sequence. For example, single or multiple amino
acid substitutions (preferably conservative amino acid substitutions) may be
made in the naturally-occurring sequence (preferably in the portion of the
polypeptide outside the domain(s) forming intermolecular contacts. A
conservative amino acid substitution should not substantially change the
structural characteristics of the parent sequence (e.g., a replacement amino
acid
should not tend to break a helix that occurs in the parent sequence, or
disrupt
other types of secondary structure that characterizes the parent sequence).
Examples of art-recognized polypeptide secondary and tertiary structures are
described in Proteins, Structures and Molecular Principles (Creighton, Ed., W.

H. Freeman and Company, New York (1984)); Introduction to Protein
Structure (C. Branden and 1. Tooze, eds., Garland Publishing, New York, N.Y.
(1991)); and Thornton et at. Nature 354:105 (1991).
The term "polypeptide fragment" as used herein refers to a polypeptide
that has an amino-terminal and/or carboxy-terminal deletion, but where the
remaining amino acid sequence is identical to the corresponding positions in
the
naturally-occurring sequence deduced, for example, from a full-length cDNA
sequence. Fragments typically are at least 5, 6, 8 or 10 amino acids long,
preferably at least 14 amino acids long, more preferably at least 20 amino
acids
long, usually at least 50 amino acids long, and even more preferably at least
70
amino acids long. The term "analog" as used herein refers to polypeptides
which are comprised of a segment of at least 25 amino acids that has
substantial
identity to a portion of a deduced amino acid sequence and which has at least
one of the following properties: (1) specific binding to CTLA-4, under
suitable

CA 02356215 2006-12-29
61009-491
binding conditions, (2) ability to block CTLA-4 binding with its receptors, or

(3) ability to inhibit CTLA-4 expressing cell growth in vitro or in vivo.
Typically, polypeptide analogs comprise a conservative amino acid substitution

(or addition or deletion) with respect to the naturally-occurring sequence.
5 Analogs typically are at least 20 amino acids long, preferably at least
50 amino
acids long or longer, and can often be as long as a full-length naturally-
occurring polypeptide.
Peptide analogs are commonly used in the pharmaceutical industry as
lo non-peptide drugs with properties analogous to those of the template
peptide.
These types of non-peptide compound are termed "peptide mimetics" or
"peptidomimetics". Fauchere, J. Adv. Drug Res. 15:29 (1986); Veber and
Freidinger TINS p.392 (1985); and Evans et al. .1 Med. Chem. 30:1229 (1987).
Such compounds are often developed with the aid of
15 computerized molecular modeling. Peptide mimetics
that are structurally similar to therapeutically useful peptides may be used
to
produce an equivalent therapeutic or prophylactic effect. Generally,
peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a
polypeptide that has a biochemical property or pharmacological activity), such
20 as human antibody, but have one or more peptide linkages optionally
replaced
by a linkage selected from the group consisting of: ¨CH2NH--, --CH2S--, --
CH2-CH2--, --CH=CH--(cis and trans), --COCH2--, --CH(OH)CH2--, and ¨
CH2S0--, by methods well known in the art. Systematic substitution of one or
more amino acids of a consensus sequence with a D-amino acid of the same
25 type (e.g., D-lysine in place of L-lysine) may be used to generate more
stable
peptides. In addition, constrained peptides comprising a consensus sequence or

a substantially identical consensus sequence variation may be generated by
methods known in the art (Rizo and Gierasch Ann. Rev, Biochem. 61:387
(1992); for example, by adding internal
30 cysteine residues capable of forming intramolecular disulfide bridges
which
cyclize the peptide.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
31
"Antibody" or "antibody peptide(s)" refer to an intact antibody, or a
binding fragment thereof that competes with the intact antibody for specific
binding. Binding fragments are produced by recombinant DNA techniques, or
by enzymatic or chemical cleavage of intact antibodies. Binding fragments
include Fab, Fab', F(ab')2, Fv, and single-chain antibodies. An antibody other
than a "bispecific" or "bifunctional" antibody is understood to have each of
its
binding sites identical. An antibody substantially inhibits adhesion of a
receptor
to a counterreceptor when an excess of antibody reduces the quantity of
receptor
bound to counterreceptor by at least about 20%, 40%, 60% or 80%, and more
usually greater than about 85% (as measured in an in vitro competitive binding
assay).
The term "epitope" includes any protein determinant capable of specific
binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually
consist of chemically active surface groupings of molecules such as amino
acids
or sugar side chains and usually have specific three dimensional structural
characteristics, as well as specific charge characteristics. An antibody is
said to .
specifically bind an antigen when the dissociation constant is 51 1..LM,
preferably
5 100 nM and most preferably 5 10 nM.
The term "agent" is used herein to denote a chemical compound, a
mixture of chemical compounds, a biological macromolecule, or an extract
made from biological materials.
As used herein, the terms "label" or "labeled" refers to incorporation of a
detectable marker, e.g., by incorporation of a radiolabeled amino acid or
attachment to a polypeptide of biotinyl moieties that can be detected by
marked
avidin (e.g., streptavidin containing a fluorescent marker or enzymatic
activity
that can be detected by optical or colorimetric methods). In certain
situations,
the label or marker can also be therapeutic. Various methods of labeling
polypeptides and glycoproteins are known in the art and may be used.
Examples of labels for polypeptides include, but are not limited to, the

CA 02356215 2006-12-29
61009-491
32
following: radioisotopes or radionuclides (e.g., 3H, 14C, 15N, 35S, 9017,
99Tc,
"'In, 125..1 2 13
-- II), fluorescent labels (e.g., FITC, rhodarnine, lanthanide
phosphors), enzymatic labels (e.g., horseradish peroxidase, p-galactosidase,
luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups,
predetermined polypeptide epitopes recognized by a secondary reporter (e.g.,
leucine zipper pair sequences, binding sites for secondary antibodies, metal
binding domains, epitope tags). In some embodiments, labels are attached by
spacer arms of various lengths to reduce potential steric hindrance.
io The term "pharmaceutical agent or drug" as used herein refers to a
chemical compound or composition capable of inducing a desired therapeutic
effect when properly administered to a patient. Other chemistry terms herein
are used according to conventional usage in the art, as exemplified by The
McGraw-Hill Dictionary of Chemical Terms (Parker, S., Ed., McGraw-Hill, San
Francisco (1985)).
The term "antineoplastic agent" is used herein to refer to agents that
have the functional property of inhibiting a development or progression of a
neoplasm in a human, particularly a malignant (cancerous) lesion, such as a
carcinoma, sarcoma, lymphoma, or leukemia. Inhibition of metastasis is
frequently a property of antineoplastic agents.
As used herein, "substantially pure" means an object species is the
predominant species present (i.e., on a molar basis it is more abundant than
any
other individual species in the composition), and preferably a substantially
purified fraction is a composition wherein the object species comprises at
least
about 50 percent (on a molar basis) of all macromolecular species present
Generally, a substantially pure composition will comprise more than about 80
percent of all macromolecular species present in the composition, more
preferably more than about 85%, 90%, 95%, and 99%. Most preferably, the
object species is purified to essential hom*ogeneity (contaminant species
cannot

CA 02356215 2006-12-29
61009-491
33
be detected in the composition by conventional detection methods) wherein the
composition consists essentially of a single macromolecular species.
The term patient includes human and veterinary subjects.
Antibody Structure
The basic antibody structural unit is known to comprise a tetramer.
Each tetramer is composed of two identical pairs of polypeptide chains, each
to pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-
70 .
kDa). The amino-terminal portion of each chain includes a variable region of
about 100 to 110 or more amino acids primarily responsible for antigen
recognition. The carboxy-terminal portion of each chain defines a constant
region primarily responsible for effector function. Human light chains are
classified as kappa and lambda light chains. Heavy chains are classified as
mu,
delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM,
IgD,
IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable
and
constant regions are joined by a "J" region of about 12 or more amino acids,
with the heavy chain also including a "D" region of about 10 more amino acids.
See generally, Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven
Press, N.Y. (1989)). The variable regions of each light/heavy chain pair form
the antibody binding site.
Thus, an intact IgG antibody has two binding sites. Except in
bifunctional or bispecific antibodies, the two binding sites are the same.
The chains all exhibit the same general structure of relatively conserved
framework regions (FR) joined by three hyper variable regions, also called
complementarity determining regions or CDRs. The CDRs from the two chains
of each pair are aligned by the framework regions, enabling binding to a
specific epitope. From N-terminal to C-terminal, both light and heavy chains
comprise the domains FR1, CDR1, FR2, CDR2, FR3,. CDR3 and FR4. The
assignment of amino acids to each domain is in accordance with the definitions

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
34
of Kabat Sequences of Proteins of Immunological Interest (National Institutes
of
Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J. MoL Biol.
196:901-917 (1987); Chothia et al. Nature 342:878-883 (1989).
A bispecific or bifunctional antibody is an artificial hybrid antibody
having two different heavy/light chain pairs and two different binding sites.
Bispecific antibodies can be produced by a variety of methods including fusion
of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann
Clin. Exp. ImmunoL 79: 315-321 (1990), Kostelny et al. J. ImmunoL 148:1547-
1553 (1992). In addition, bispecific antibodies may be formed as "diabodies"
(Holliger et al. "Diabodies': small bivalent and bispecific antibody
fragments"
PNAS USA 90:6444-6448 (1993)) or "Janusins" (Traunecker et al. "Bispecific
single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected

cells" EMBO J 10:3655-3659 (1991) and Traunecker et al. "Janusin: new
molecular design for bispecific reagents" Int J Cancer Suppl 7:51-52 (1992)).
Production of bispecific antibodies can be a relatively labor intensive
process
compared with production of conventional antibodies and yields and degree of
purity are generally lower for bispecific antibodies. Bispecific antibodies do
not
exist in the form of fragments having a single binding site (e.g., Fab, Fab',
and
Fv).
Human Antibodies and Humanization of Antibodies
Human antibodies avoid certain of the problems associated with
antibodies that possess murine or rat variable and/or constant regions. The
presence of such murine or rat derived proteins can lead to the rapid
clearance
of the antibodies or can lead to the generation of an immune response against
the antibody by a patient. In order to avoid the utilization of murine or rat
derived antibodies, it has been postulated that one can develop humanized
antibodies or generate fully human antibodies through the introduction of
human antibody function into a rodent so that the rodent would produce
antibodies having fully human sequences.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
Human Antibodies
The ability to clone and reconstruct megabase-sized human loci in
YACs and to introduce them into the mouse germline provides a powerful
5 approach to elucidating the functional components of very large or
crudely
mapped loci as well as generating useful models of human disease.
Furthermore, the utilization of such technology for substitution of mouse loci

with their human equivalents could provide unique insights into the expression

and regulation of human gene products during development, their
10 communication with other systems, and their involvement in disease
induction
and progression.
An important practical application of such a strategy is the
"humanization" of the mouse Inunoral immune system. Introduction of human
imtnunoglobulin (Ig) loci into mice in which the endogenous Ig genes have
15 been inactivated offers the opportunity to study the mechanisms
underlying
programmed expression and assembly of antibodies as well as their role in B-
cell development. Furthermore, such a strategy could provide an ideal source
for production of fully human monoclonal antibodies (Mabs) an important
milestone towards fulfilling the promise of antibody therapy in human disease.
20 Fully human antibodies are expected to minimize the immunogenic and
allergic
responses intrinsic to mouse or mouse-derivatized Mabs and thus to increase
the
efficacy and safety of the administered antibodies. The use of fully human
antibodies can be expected to provide a substantial advantage in the treatment
of
chronic and recurring human diseases, such as inflammation, autoinununity, and
25 cancer, which require repeated antibody administrations.
One approach towards this goal was to engineer mouse strains deficient
in mouse antibody production with large fragments of the human Ig loci in
anticipation that such mice would produce a large repertoire of human
antibodies in the absence of mouse antibodies. Large human Ig fragments
30 would preserve the large variable gene diversity as well as the proper
regulation
of antibody production and expression. By exploiting the mouse machinery for
antibody diversification and selection and the lack of immunological tolerance

CA 02356215 2006-12-29
61009-491
36
to human proteins, the rcproduced human antibody repertoire in these mouse
strains should yield high affinity antibodies against any antigen of interest,

including human antigens. Using the hybridoma technology, antigen-specific
human Mabs with the desired specificity could be readily produced and
selected.
This general strategy was demonstrated in connection with our
generation of the first XenoMouseTm strains as published in 1994. See Green et

al. Nature Genetics 7:13-21 (1994). The XenoMousem strains were
engineered with yeast artificial chromosomes (YACs) containing 245 kb and
190 kb-sized germline configuration fragments of the human heavy chain locus
and kappa light chain locus, respectively, which contained core variable and
constant region sequences. Id. The human Ig containing YACs proved to be
compatible with the mouse system for both rearrangement and expression of
antibodies and were capable of substituting for the inactivated mouse Ig
genes.
This was demonstrated by their ability to induce B-cell development, to
produce
an adult-like human repertoire of fully human antibodies, and to generate
antigen-specific human Mabs. These results also suggested that introduction of

. larger portions of the human Ig loci containing greater numbers of V genes,
additional regulatory elements, and human Ig constant regions might
recapitulate substantially the full repertoire that is characteristic of the
human
humoral response to infection and immunization. The work of Green et al. was
recently extended to the introduction of greater than approximately 80% of the

human antibody repertoire through introduction of megabase sized, germline
configuration YAC fragments of the human heavy chain loci and kappa light
chain loci, respectively, to produce XenoMouseTm mice. See Mendez et al.
Nature Genetics 15:146-156 (1997), Green and Jakobovits J. Exp. Med.
188:483-495 (1998), and U.S. Patent Application Serial No. 08/759,620, filed
December 3, 1996.
Such approach is further discussed and delineated in U.S. Patent
Application Serial Nos. 07/466,008, filed January 12, 1990, 07/610,515, filed
November 8, 1990, 07/919,297, filed July 24, 1992, 07/922,649, filed July 30,

CA 02356215 2006-12-29
61009-491
37
1992, filed 08/031,801, filed March 15,1993, 08/112,848, filed August 27,
1993, 08/234,145, filed April 28, 1994, 08/376,279, filed January 20, 1995,
08/430, 938, April 27, 1995, 0$/464,584, filed June 5, 1995, 08/464,582, filed

June 5, 1995, 08/463,191, filed June 5, 1995, 08/462,837, filed June 5, 1995,
08/486,853, filed June 5, 1995, 08/486,857, filed June 5, 1995, 08/486,859,
filed June 5, 1995, 08/462,513, filed June 5, 1995, 08/724,752, filed October
2,
1996, and 08/759,620, filed December 3, 1996. See also Mendez et al. Nature
Genetics 15:146-156 (1997) and Green and Jakobovits .1. Exp. Med. 188:483-
495 (1998). See also European Patent No., EP 0 463 151 BI, grant published
to June 12,
1996, International Patent Application No., WO 94/02602, published
February 3, 1994, International Patent Application No., WO 96/34096,
published October 31, 1996, and WO 98/24893, published June 11, 1998.
In an alternative approach, others, including GenPharm International,
Inc., have utilized a "minilocus" approach. In the minilocus approach, an
exogenous Ig locus is -mimicked through the inclusion of pieces (individual
genes) from the Ig locus. Thus, one or more VH genes, one or more DH genes,
one or more .1H genes, a mu constant region, and a second constant region
(preferably a gamma constant region) are formed into a construct for insertion
into an animal. This approach is described in U.S. Patent No. 5,545,807 to
Surani et al. and U.S. Patent Nos. 5,545,806, 5,625,825, 5,625,126, 5,633,425,

5,661,016, 5,770,429, 5,789,650, and 5,814,318 each to Lonberg and Kay, U.S.
Patent No. 5,591,669 to Krimpenfort and Berns, U.S. Patent Nos. 5,612,205,
5,721,367, 5,789,215 to Berns et al., and U.S. Patent No. 5,643,763 to Choi
and
Dunn, and GenPharm International U.S. Patent Application Serial Nos.
07/574,748, filed August 29, 1990, 07/575,962, filed August 31, 1990,
07/810,279, filed December 17, 1991, 07/853,408, filed March 18, 1992,
07/904,068, filed June 23, 1992, 07/990,860, filed December 16, 1992,
08/053,131, filed April 26, 1993, 08/096,762, filed July 22, 1993, 08/155,301,
filed November 18, 1993, 08/161,739, filed December 3, 1993, 08/165,699,
filed December 10, 1993, 08/209,741, filed March 9, 1994. See also

CA 02356215 2006-12-29
61009-491
38
European Patent No. 0 546 073 Bl, International Patent
Application Nos. WO 92/03918, WO 92/22645,
WO 92/22647, WO 92/22670, WO 93/12227,
WO 94/00569, WO 94/25585, WO 96/14436,
WO 97/13852, and WO 98/24884. See further Taylor
et al., 1992, Chen et al., 1993, Tuaillon et al., 1993, Choi et al., 1993,
Lonberg
et al., (1994), Taylor et al., (1994), and Tuaillon et al., (1995), Fishwild
et al.,
(1996), the disclosures of which are hereby incorporated by reference in their

entirety.
The inventors of Surani et al., cited above and assigned to the Medical
Research Counsel (the "MRC"), produced a transgenic mouse possessing an Ig
locus through use of the minilocus approach. The inventors on the GenPharm
International work, cited above, Lonberg and Kay, following the lead of the
present inventors, proposed inactivation of the endogenous mouse Ig locus
coupled with substantial duplication of the Surani et al. work.
An advantage of the minilocus approach is the rapidity with which
constructs including portions of the Ig locus can be generated and introduced
into animals. Commensurately, however, a significant disadvantage of the
minilocus approach is that, in theory, insufficient diversity is introduced
through
the inclusion of small numbers of V, D, and I genes. Indeed, the published
work appears to support this concern. B-cell development and antibody
production of animals produced through use of the minilocus approach appear
stunted. Therefore, research surrounding the present invention has
consistently
been directed towards the introduction of large portions of the Ig locus in
order
to achieve greater diversity and in an effort to reconstitute the immune
repertoire of the animals.
Human anti-mouse antibody (HAMA) responses have led the industry to
prepare chimeric or otherwise humanized antibodies. While
chimeric
antibodies have a human constant region and a murine variable region, it is
expected that certain human anti-chimeric antibody (HACA) responses will be
observed, particularly in chronic or multi-dose utilizations of the antibody.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
39
Thus, it would be desirable to provide fully human antibodies against CTLA-4
in order to vitiate concerns and/or effects of HAMA or HACA response.
Humanization and Display Technologies
As was discussed above in connection with human antibody generation,
there are advantages to producing antibodies with reduced immunogenicity. To
a degree, this can be accomplished in connection with techniques of
humanization and display techniques using appropriate libraries. It will be
to appreciated that murine antibodies or antibodies from other species can
be
humanized or primatized using techniques well known in the art. See e.g.,
Winter and Harris Immunol Today 14:43-46 (1993) and Wright et al. Grit.
Reviews in Immunol. 12125-168 (1992). The antibody of interest may be
engineered by recombinant DNA techniques to substitute the CH1, CH2, CH3,
hinge domains, and/or the framework domain with the corresponding human
sequence (see WO 92/02190 and U.S. Patent Nos. 5,530,101, 5,585,089,
5,693,761, 5,693,792, 5,714,350, and 5,777,085). Also, the use of Ig cDNA for
construction of chimeric immtmoglobulin genes is known in the art (Liu et al.
P.N.A.S. 84:3439 (1987) and lImmunol.139:3521 (1987)). mRNA is isolated
from a hybridoma or other cell producing the antibody and used to produce
cDNA. The cDNA of interest may be amplified by the polymerase chain
reaction using specific primers (U.S. Pat. Nos. 4,683,195 and 4,683,202).
Alternatively, a library is made and screened to isolate the sequence of
interest.
The DNA sequence encoding the variable region of the antibody is then fused to
human constant region sequences. The sequences of human constant regions
genes may be found in Kabat et al. (1991) Sequences of Proteins of
Immunological Interest, N.I.H. publication no. 91-3242. Human C region genes
are readily available from known clones. The choice of isotype will be guided
by the desired effector functions, such as complement fixation, or activity in
antibody-dependent cellular cytotoxicity. Preferred isotypes are IgGl, IgG2,
IgG3 and IgG4. Particularly preferred isotypes for antibodies of the invention

are IgG2 and IgG4. Either of the human light chain constant regions, kappa or

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
lambda, may be used. The chimeric, humanized antibody is then expressed by
conventional methods.
Antibody fragments, such as Fv, F(ab')2 and Fab may be prepared by
cleavage of the intact protein, e.g. by protease or chemical cleavage.
5
Alternatively, a truncated gene is designed. For example, a chimeric gene
encoding a portion of the F(abt)2 fragment would include DNA sequences
encoding the CH1 domain and hinge region of the H chain, followed by a
translational stop codon to yield the truncated molecule.
In one approach, consensus sequences encoding the heavy and light
10 chain J
regions may be used to design oligonucleotides for use as primers to
introduce useful restriction sites into the J region for subsequent linkage of
V
region segments to human C region segments. C region cDNA can be modified
by site directed mutagenesis to place a restriction site at the analogous
position
in the human sequence.
15 Expression
vectors include plasmids, retroviruses, cosmids, YACs, EBV
derived episomes, and the like. A convenient vector is one that encodes a
functionally complete human CH or CL immunoglobulin sequence, with
appropriate restriction sites engineered so that any VH or VL sequence can be
easily inserted and expressed. In such vectors, splicing usually occurs
between
20 the splice
donor site in the inserted J region and the splice acceptor site
preceding the human C region, and also at the splice regions that occur within

the human CH exons. Polyadenylation and transcription termination occur at
native chromosomal sites downstream of the coding regions. The resulting
chimeric antibody may be joined to any strong promoter, including retroviral
25 LTRs, e.g.
SV-40 early promoter, (Okayama et al. Mol. Cell. Bio. 3:280
(1983)), Rous sarcoma virus LTR (Gorman et al. P.N.A.S. 79:6777 (1982)), and
moloney murine leukemia virus LTR (Grosschedl et al. Cell 41:885 (1985));
native lg promoters, etc.
Further, human antibodies or antibodies from other species can be
30 generated through display-type technologies, including, without limitation,

phage display, retroviral display, ribosomal display, and other techniques,
using
techniques well known in the art and the resulting molecules can be subjected
to

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
41
additional maturation, such as affinity maturation, as such techniques are
well
known in the art. Wright and Hams, supra., Hanes and Plucthau PNAS USA
94:4937-4942 (1997) (ribosomal display), Parmley and Smith Gene 73:305-318
(1988) (phage display), Scott TIBS 17:241-245 (1992), Cwirla et al. PNAS USA
87:6378-6382 (1990), Russel et al. Nucl. Acids Research 21:1081-1085 (1993),
Hoganboom et al. Immunol. Reviews 130:43-68 (1992), Chiswell and
McCafferty TIBTECH 10:80-84 (1992), and U.S. Patent No. 5,733,743. If
display technologies are utilized to produce antibodies that are not human,
such
antibodies can be humanized as described above.
Using these techniques, antibodies can be generated to CTLA-4
expressing cells, CTLA-4 itself, forms of CTLA-4, epitopes or peptides
thereof,
and expression libraries thereto (see e.g. U.S. Patent No. 5,703,057) which
can
thereafter be screened as described above for the activities described above.
Additional Criteria for Antibody Therapeutics
As will be appreciated, it is generally not desirable to kill CTLA-4
expressing cells. Rather, one generally desires to simply inhibit CTLA-4
binding with its ligands to mitigate T cell down regulation. One of the major
mechanisms through which antibodies kill cells is through fixation of
complement and participation in CDC. The constant region of an antibody
plays an important role in connection with an antibody's ability to fix
complement and participate in CDC. Thus, generally one selects the isotype of
an antibody to either provide the ability of complement fixation, or not. In
the
case of the present invention, generally, as mentioned above, it is generally
not
preferred to utilize an antibody that kills the cells. There are a number of
isotypes of antibodies that are capable of complement fixation and CDC,
including, without limitation, the following: murine IgM, murine IgG2a, murine

IgG2b, murine IgG3, human IgM, human IgGl, and human IgG3. Those
isotypes that do not include, without limitation, human IgG2 and human IgG4.
It will be appreciated that antibodies that are generated need not initially
possess a particular desired isotype but, rather, the antibody as generated
can

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
42
possess any isotype and the antibody can be isotype switched thereafter using
conventional techniques that are well known in the art. Such techniques
include
the use of direct recombinant techniques (see e.g., U.S. Patent No.
4,816,397),
cell-cell fusion techniques (see e.g., U.S. Patent Application No. 08/730,639,
filed October 11, 1996), among others.
In the cell-cell fusion technique, a myeloma or other cell line is prepared
that possesses a heavy chain with any desired isotype and another myeloma or
other cell line is prepared that possesses the light chain. Such cells can,
thereafter, be fused and a cell line expressing an intact antibody can be
isolated.
By way of example, the majority of the CTLA-4 antibodies discussed
herein are human anti-CTLA-4 IgG2 antibody. Since such antibodies possess
desired binding to the CTLA-4 molecule, any one of such antibodies can be
readily isotype switched to generate a human IgG4 isotype, for example, while
still possessing the same variable region (which defines the antibody's
specificity and some of its affinity).
Accordingly, as antibody candidates are generated that meet desired
"structural" attributes as discussed above, they can generally be provided
with
at least certain additional "functional" attributes that are desired through
isotype
switching.
Design and Generation of Other Therapeutics
In accordance with the present invention and based on the activity of the
antibodies that are produced and characterized herein with respect to CTLA-4,
the design of other therapeutic modalities including other antibodies, other
antagonists, or chemical moieties other than antibodies is facilitated. Such
modalities include, without limitation, antibodies having similar binding
activity
or functionality, advanced antibody therapeutics, such as bispecific
antibodies,
inununotoxins, and radiolabeled therapeutics, generation of peptide
therapeutics, gene therapies, particularly intrabodies, antisense
therapeutics, and
small molecules. Furthermore, as discussed above, the effector function of the

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
43
antibodies of the invention may be changed by isotype switching to an IgG1 ,
IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM for various therapeutic uses.
In connection with the generation of advanced antibody therapeutics,
where complement fixation is a desirable attribute, it may be possible to
sidestep the dependence on complement for cell killing through the use of
bispecifics, immunotoxins, or radiolabels, for example.
In connection with bispecific antibodies, bispecific antibodies can be
generated that comprise (i) two antibodies one with a specificity to CTLA-4
and
another to a second molecule that are conjugated together, (ii) a single
antibody
that has one chain specific to CTLA-4 and a second chain specific to a second
molecule, or (iii) a single chain antibody that has specificity to CTLA-4 and
the
other molecule. Such bispecific antibodies can be generated using techniques
that are well known for example, in connection with (i) and (ii) see e.g.,
Fanger
et al. Immunol Methods 4:72-81 (1994) and Wright and Harris, supra. and in
connection with (iii) see e.g., Traunecker et al. Int. i Cancer (Suppl) 7:51-
52
(1992).
In addition, "Kappabodies" (Ill et al. "Design and construction of a
hybrid inununoglobulin domain with properties of both heavy and light chain
variable regions" Protein Eng 10:949-57 (1997)), "Minibodies" (Martin et al.
"The affinity-selection of a minibody polypeptide inhibitor of human
interleulcin-6" EMBO J 13:5303-9 (1994)), "Diabodies" (Holliger et al.
"'Diabodies': small bivalent and bispecific antibody fragments" PNAS USA
90:6444-6448 (1993)), or "Janusins" (Traunecker et al. "Bispecific single
chain
molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells"
EMBO J 10:3655-3659 (1991) and Traunecker et al. "Janusin: new molecular
design for bispecific reagents" Int J Cancer Suppl 7:51-52 (1992)) may also be

prepared.
In connection with immunotoxins, antibodies can be modified to act as
immunotoxins utilizing techniques that are well known in the art. See e.g.,
Vitetta Immunol Today 14:252 (1993). See also U.S. Patent No. 5,194,594. In
connection with the preparation of radiolabeled antibodies, such modified
antibodies can also be readily prepared utilizing techniques that are well
known

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
44
in the art. See e.g., Junghans et al. in Cancer Chemotherapy and Biotherapy
655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996)). See
also U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (RE 35,500),
5,648,471, and 5,697,902. Each of immunotoxins and radiolabeled molecules
would be likely to kill cells expressing CTLA-4, and particularly those cells
in
which the antibodies of the invention are effective.
In connection with the generation of therapeutic peptides, through the
utilization of structural information related to CTLA-4 and antibodies
thereto,
such as the antibodies of the invention (as discussed below in connection with
small molecules) or screening of peptide libraries, therapeutic peptides can
be
generated that are directed against CTLA-4. Design and screening of peptide
therapeutics is discussed in connection with Houghten et al. Biotechniques
13:412-421 (1992), Houghten PNAS USA 82:5131-5135 (1985), Pinalla et al.
Biotechniques 13:901-905 (1992), Blake and Litzi-Davis BioConjugate Chem.
3:510-513 (1992). Immunotoxins and radiolabeled molecules can also be
prepared, and in a similar manner, in connection with peptidic moieties as
discussed above in connection with antibodies.
Important information related to the binding of an antibody to an antigen
can be gleaned through phage display experimentation. Such experiments are
generally accomplished through panning a phage library expressing random
peptides for binding with the antibodies of the invention to determine if
peptides
can be isolated that bind. If successful, certain epitope information can be
gleaned from the peptides that bind.
In general, phage libraries expressing random peptides can be purchased
from New England Biolabs (7-mer and 12-mer libraries, Ph.D.-7 Peptide 7-mer
Library Kit and Ph.D.-12 Peptide 12-mer Library Kit, respectively) based on a
bacteriophage M13 system. The 7-mer library represents a diversity of
approximately 2.0 x 109 independent clones, which represents most, if not all,

of the 207 = 1.28 x le possible 7-mer sequences. The 12-mer library contains
approximately 1.9 x 109 independent clones and represents only a very small
sampling of the potential sequence space of 2012 = 4.1 x 1015 12-mer
sequences.
Each of 7-mer and 12-mer libraries are panned or screened in accordance with
_

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
the manufacturer's recommendations in which plates were coated with an
antibody to capture the appropriate antibody (a goat anti-human IgG Fc for an
IgG antibody for example) followed by washing. Bound phage are eluted with
0.2 M glycine-HC1, pH 2.2. After 3 rounds of selection/amplification at
5 constant stringency (0.5% Tween), through use of DNA sequencing, one can
characterize clones from the libraries that are reactive with one or more of
the
antibodies. Reactivity of the peptides can be determined by ELISA. For an
additional discussion of epitope analysis of peptides see also Scott, J.K. and

Smith, G.P. Science 249:386-390 (1990); Cwirla et al. PNAS USA 87:6378-
10 6382 (1990); Felici et al. J. MoL Biol. 222:301-310 (1991), and Kuwabara
et al.
Nature Biotechnology 15:74-78 (1997).
The design of gene and/or antisense therapeutics through conventional
techniques is also facilitated through the present invention. Such modalities
can
be utilized for modulating the function of CTLA-4. In connection therewith the
15 antibodies of the present invention facilitate design and use of
functional assays
related thereto. A design and strategy for antisense therapeutics is discussed
in
detail in International Patent Application No. WO 94/29444. Design and
strategies for gene therapy are well known. However, in particular, the use of

gene therapeutic techniques involving intrabodies could prove to be
particularly
20 advantageous. See e.g., Chen et al. Human Gene Therapy 5:595-601 (1994)
and
Marasco Gene Therapy 4:11-15 (1997). General design of and considerations
related to gene therapeutics is also discussed in International Patent
Application
No. WO 97/38137. Genetic materials encoding an antibody of the invention
(such as the 4.1.1, 4.8.1, or 6.1.1, or others) may be included in a suitable
25 expression system (whether viral, attenuated viral, non-viral, naked, or
otherwise) and administered to a host for in vivo generation of the antibody
in
the host.
Small molecule therapeutics can also be envisioned in accordance with
the present invention. Drugs can be designed to modulate the activity of CTLA-
30 4 based upon the present invention. Knowledge gleaned from the structure
of
the CTLA-4 molecule and its interactions with other molecules in accordance
with the present invention, such as the antibodies of the invention, CD28, B7,

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
46
B7-1, B7-2, and others can be utilized to rationally design additional
therapeutic
modalities. In this regard, rational drug design techniques such as X-ray
crystallography, computer-aided (or assisted) molecular modeling (CAMM),
quantitative or qualitative structure-activity relationship (QSAR), and
similar
technologies can be utilized to focus drug discovery efforts. Rational design
allows prediction of protein or synthetic structures which can interact with
the
molecule or specific forms thereof which can be used to modify or modulate the

activity of CTLA-4. Such structures can be synthesized chemically or
expressed in biological systems. This approach has been reviewed in Capsey et
al. Genetically Engineered Human Therapeutic Drugs (Stockton Press, NY
(1988)). Indeed, the rational design of molecules (either peptides,
peptidomimetics, small molecules, or the like) based upon known, or
delineated,
structure-activity relationships with other molecules (such as antibodies in
accordance with the invention) has become generally routine. See, e.g., Fry et
al. "Specific, irreversible inactivation of the epidermal growth factor
receptor
and erbB2, by a new class of tyrosine kinase inhibitor" Proc Nat! Acad Sci U S

A 95:12022-7 (1998); Hoffman et at. "A model of Cdc25 phosphatase catalytic
domain and Cdk-interaction surface based on the presence of a rhodanese
hom*ology domain" J Mol Biol 282:195-208 (1998); Ginalski et al. "Modelling
of active forms of protein Icinases: p38--a case study" Acta Biochim Pol
44:557-
64 (1997); Jouko et al. "Identification of csk tyrosine phosphorylation sites
and
a tyrosine residue important for kinase domain structure" Biochem J322:927-35
(1997); Singh et at. "Structure-based design of a potent, selective, and
irreversible inhibitor of the catalytic domain of the erbB receptor subfamily
of
protein tyrosine kinases" J Med Chem 40:1130-5 (1997); Mandel et al.
"ABGEN: a knowledge-based automated approach for antibody structure
modeling" Nat Biotechnol 14:323-8 (1996); Monfardini et al. "Rational design,
analysis, and potential utility of GM-CSF antagonists" Proc Assoc Am
Physicians 108:420-31 (1996); Furet et al. "Modelling study of protein kinase
inhibitors: binding mode of staurosporine and origin of the selectivity of CGP
52411" J Comput Aided Mol Des 9:465-72 (1995).

CA 02356215 2006-12-29
6 1 0 0 9-4 9 1
47
Further, combinatorial libraries can be designed and synthesized and
used in screening programs, such as high throughput screening efforts.
Therapeutic Administration and Formulations
It will be appreciated that administration of therapeutic entities in
accordance with the invention will be administered with suitable carriers,
excipients, and other agents that are incorporated into formulations to
provide
improved transfer, delivery, tolerance, and the like. A multitude of
appropriate
formulations can be found in the formulary known to all pharmaceutical
chemists: Remington's Pharmaceutical Sciences (15th ed, Mack Publishing
Company, Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour,
therein. These formulations include, for example, powders, pastes, ointments,
jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles
(such as
Lipofectinm), DNA conjugates, anhydrous absorption pastes, oil-in-water and
water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various
molecular weights), semi-solid gels, and semi-solid mixtures containing
carbowax. Any of the foregoing mixtures may be appropriate in treatments and
therapies in accordance with the present invention, provided that the active
ingredient in the formulation is not inactivated by the formulation and the
formulation is physiologically compatible and tolerable with the route of
administration. See also Powell et al. "Compendium of excipients for
parenteral formulations" PD.4 J Pharm Sci Technol. 52:238-311(1998) and the
citations therein for additional information related to excipients and
carriers
well known to pharmaceutical chemists.
Preparation of Antibodies
Antibodies in accordance with the invention are preferably prepared
through the utilization of a transgenic mouse that has a substantial portion
of the
human antibody producing genome inserted but that is rendered deficient in the

production of endogenous, murine, antibodies. Such mice, then, are capable of

CA 02356215 2006-12-29
61009-491
48
producing human immunoglobulin molecules and antibodies and are deficient
in the production of murine immunoglobulin molecules and antibodies.
Technologies utilized for achieving the same are disclosed in the patents,
applications, and references disclosed in the Background, herein. In
particular,
however, a preferred embodiment of transgenic production of mice and
antibodies therefrom- is disclosed in U.S. Patent Application Serial No.
08/759,620, filed December 3, 1996, the disclosure of which is hereby
incorporated by reference. See also Mendez et al. Nature Genetics 15:146-156
(1997).
Through use of such technology, we have produced fully human
monoclonal antibodies to a variety of antigens. Essentially, we immunize
XenoMouseTm lines of mice with an antigen of interest, recover lymphatic cells

(such as B-cells) from the mice that express antibodies, fuse such recovered
cells with a myeloid-type cell line to prepare immortal hybridoma cell lines,
and
such hybridoma cell lines are screened and selected to identify hybridoma cell
lines that produce antibodies specific to the antigen of interest. We utilized

these techniques in accordance with the present invention for the preparation
of
antibodies specific to CTLA-4. Herein, we describe the production of multiple
hybridoma cell lines that produce antibodies specific to CTLA-4. Further, we
provide a characterization of the antibodies produced by such cell lines,
including nucleotide and amino acid sequence analyses of the heavy and light
chains of such antibodies.
The antibodies derived from hybridoma cell lines discussed herein are
designated 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1,
11.7.1, 12.3.1.1, and 12.9.1.1. Each of the antibodies produced by the
aforementioned cell lines are either fully 'human IgG2 or Ig04 heavy chains
with human kappa light chains. In general, antibodies in accordance with the
invention possess very high affinities, typically possessing Kd's of from
about
1 0-9 through about 10'11 M, when measured by either solid phase or solution
phase.
As will be appreciated, antibodies in accordance with the present
invention can be expressed in cell lines other than hybridoma cell lines.

CA 02356215 2006-12-29
61 0 0 9-4 9 1
49
Sequences encoding the cDNAs or genomic clones for the particular antibodies
can be used for transformation of a suitable mammalian or not-mammalian host
cells, Transformation can be by any known method for introducing
polynucleotides into a host cell, including, for example packaging the
'polynucleotide in a virus (or into a viral vector) and transducing a host
cell with
the virus (or vector) or by transfection procedures known in the art, as
exemplified by U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461, and
4,959,455. The transformation procedure
used depends upon the host to be transformed.
Methods for introduction of heterologous polynucleotides into mammalian cells
are well known in the art and include, but are not limited to, dextran-
mediated
transfection, calcium phosphate precipitation, polybrene mediated
transfection,
protoplast fusion, electroporation, particle bombardment, encapsulation of the

polynucleotide(s) in liposomes, peptide conjugates, dendrimers, and direct
microinjection of the DNA into nuclei.
Mammalian cell lines available as hosts for expression are well known
in the art and include many immortalized cell lines available from the
American
Type Culture Collection (ATCC), including but not limited to Chinese hamster
ovary (CHO) cells, NSOD, HeLa cells, baby hamster kidney (BHK) cells,
monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep
G2), and a number of other cell lines. Non-mammalian cells including but not
limited to bacterial, yeast, insect, and plants can also be used to express
recombinant antibodies. Site directed mutagenesis of the antibody 0H2 domain
to eliminate glycdsylation may be preferred in order to prevent changes in
either
the immunogenicity, pharmaco*kinetic, and/or effector functions resulting from
non-human glycosylation. The expression methods are selected by determining
.=
which system generates the highest expression levels and produce antibodies
with constitutive CTLA-4 binding properties.
Further, expression of antibodies of the invention (or other moieties
therefrom) from production cell lines can be enhanced using a number of known
techniques. For example, the glutamine synthetase and DHFR gene expression
systems are common approaches for enhancing expression under certain

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
conditions. High expressing cell clones can be identified using conventional
techniques, such as limited dilution cloning and Microdrop technology. The GS
system is discussed in whole or part in connection with European Patent Nos. 0

216 846, 0 256 055, and 0 323 997 and European Patent Application No.
5 89303964.4.
Antibodies of the invention can also be produced transgenically through
the generation of a mammal or plant that is transgenic for the immunoglobulin
heavy and light chain sequences of interest and production of the antibody in
a
recoverable form therefrom. In connection with the transgenic production in
10 mammals, antibodies can be produced in, and recovered from, the milk of
goats,
cows, or other mammals. See, e.g., U.S. Patent Nos. 5,827,690, 5,756,687,
5,750,172, and 5,741,957.
Antibodies in accordance with the present invention have been analyzed
structurally and functionally. In connection with the structures of the
15 antibodies, amino acid sequences of the heavy and kappa light chains
have been
predicted based on cDNA sequences obtained through RT-PCR of the
hybridomas. See Examples 3 and 4 and Figures 1-8. N-terminal sequencing of
the antibodies was also conducted in confirmation of the results discussed in
Examples 3 and 4. See Example 5 and Figure 9. Kinetic analyses of the
20 antibodies were conducted to determine affinities. See Example 2.
Antibodies
in accordance with the invention (and particularly the 4.1.1, 4.8.1, and 6.1.1

antibodies of the invention) have high affinities (4.1.1:1.63 X 1010 1/M;
4.8.1:3.54 X 1010 1/M; and 6.1.1:7.2 X 109 1/M). Further, antibodies were
analyzed by isoelectric focusing (IEF), reducing gel electrophoresis (SDS-
25 PAGE), size exclusion chromatography, liquid chromatography/mass
spectroscopy, and mass spectroscopy and antibody production by the
hybridomas was assessed. See Example 6 and Figure 10.
In connection with functional analysis of antibodies in accordance with
the present invention, such antibodies proved to be potent inhibitors of CTLA-
4
30 and its binding to its ligands of the B7 family of molecules. For
example,
antibodies in accordance with the present invention were demonstrated to block

CTLA-4 binding to either B7-1 or B7-2. See Example 7. Indeed, many of the

CA 02356215 2001-06-21
WO 00137504
PCT/US99/30895
51
antibodies in accordance with the invention possess nanomolar and
subnanomolar ICsos with respect to inhibiting CTLA-4 binding to B7-1 and B7-
2. Further, antibodies of the invention possess excellent selectivity for CTLA-
4
as compared to CD28, CD44, B7-2, or hIgGl. See Example 8. Selectivity is a
ratio that reflects the degree of preferential binding of a molecule with a
first
agent as compared to the molecules binding with a second, and optionally other

molecules. Herein, selectivity refers to the degree of preferential binding of
an
antibody of the invention to CTLA-4 as compared to the antibody's binding to
other molecules such as CD28, CD44, B7-2, or hIgGl. Selectivity values of
antibodies of the invention greater than 500:1 are common. Antibodies of the
invention have also been demonstrated to induce or enhance expression of
certain cytokines (such as IL-2 and IFN-y) by cultured T cells in a T cell
blast
model. See Examples 9 and 10 and Figures 12-17. Further, it is expected that
antibodies of the invention will inhibit the growth of tumors in appropriate
in
vivo tumor models. The design of which models are discussed in Example 11
and 12.
The results demonstrated in accordance with the present invention
indicate that antibodies of the present invention possess certain qualities
that
may make the present antibodies more efficacious than current therapeutic
antibodies against CTLA-4.
In particular, the 4.1.1, 4.8.1, and 6.1.1 antibodies of the invention
possess highly desirable properties. Their structural characteristics,
functions,
or activities provide criteria that facilitate the design or selection of
additional
antibodies or other molecules as discussed above. Such criteria include one or
more of the following:
Ability to compete for binding to CTLA-4 with one or more of the
antibodies of the invention;
Similar binding specificity to CTLA-4 as one or more of the antibodies
of the invention;
A binding affinity for CTLA-4 of about 10-9 M or greater and preferably
of about 10-1 M or greater;

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
52
Does not cross react with lower mammalian CTLA-4, including,
preferably, mouse, rat, or rabbit and preferably mouse or rat CTLA-4;
Cross reacts with primate CTLA-4, including, preferably, cynomolgous
and rhesus CTLA-4;
A selectivity for CTLA-4 over CD28, B7-2, CD44, or hIgG1 of at least
about 100:1 or greater and preferably of about 300, 400, or 500:1 or greater;
An IC50 in blocking CTLA-4 binding to B7-2 of about 100 nM or lower
and preferably 5, 4, 3, 2, 1, 0.5, or 0.38 nM or lower;
An IC50 in blocking CTLA-4 binding to B7-1 of about of about 100 nM
or lower and preferably 5, 4, 3, 2, 1,0.5, or 0.50 nM or lower;
An enhancement of cytokine production in one or more in vitro assays,
for example:
An enhancement of IL-2 production in a T cell blast/Raji assay of about
500 pg/ml or greater and preferably 750, 1000, 1500, 2000, 3000, or 3846 pg/ml
or greater;
An enhancement of IFNI, production in a T cell blast/Raji assay of
about 500 pg/ml or greater and preferably 750, 1000, or 1233 pg/ml or greater;

or
An enhancement of IL-2 production in a hPBMC or whole blood
superantigen assay of about 500 pg/ml or greater and preferably 750, 1000,
1200, or 1511 pg/ml or greater. Expressed another way, it is desirable that IL-
2
production is enhanced by about 30, 35, 40, 45, 50 percent or more relative to

control in the assay.
It is expected that antibodies (or molecules designed or synthesized
therefrom) having one or more of these properties will possess similar
efficacy
to the antibodies described in the present invention.
The desirable functional properties discussed above can often result
from binding to and inhibition of CTLA4 by a molecule (i.e., antibody,
antibody
fragment, peptide, or small molecule) in a similar manner as an antibody of
the
invention (i.e., binding to the same or similar epitope of the C'TLA4
molecule).

CA 02356215 2006-12-29
61009-491
53
The molecule may either be administered directly (i.e., direct administration
to a
patient of such molecules). Or, alternatively, the molecule may be
"administered" indirectly (i.e., a peptide or the like that produces an immune

response in a patient (similar to a vaccine) wherein the immune response
includes the generation of antibodies that bind to the same or similar epitope
or
an antibody or fragment that is produced in situ after administration of
genetic
materials that encode such antibodies or fragments thereof which bind to the
same or similar epitope). Thus, it will be appreciated that the epitope on
CTLA4 to which antibodies of the invention bind to can be useful in connection
with the preparation and/or design of therapeutics in accordance with the
invention. In drug design, negative information is often useful as well (Le.,
the
fact that an antibody which binds to CTLA4 does not appear to bind to an
epitope that acts as an inhibitor of CTLA4 is useful). Thus, the epitope to
which antibodies of the invention bind that do not lead to the desired
.15 functionality can also be very useful. Accordingly, also contemplated
in
accordance with the present invention are molecules (and particularly
antibodies) that bind to the same or similar epitopes as antibodies of the
invention.
In addition to the fact that antibodies of the invention and the epitopes to
which they bind are contemplated in accordance with the invention, we have
conducted some preliminary epitope mapping studies of certain antibodies in
accordance with the invention and particularly the 4.1.1 and the 11.2.1
antibodies of the invention.
As a first step, we conducted BlAcore*competition studies to generate .a
rough map of binding as between certain antibodies of the invention in
connection with their ability to compete for binding to CTLA4. To this end,
CTLA4 was bound to a BlAcore chip and a first antibody, under saturating
conditions, was bound thereto and competition of subsequent secondary
antibodies binding to CTLA4 was measured. This technique enabled generation
of a rough map in to which families of antibodies can be classified,
*Trade-mark

CA 02356215 2001-06-21
WO 00/37504
PCFAUS99/30895
54
Through this process, we determined that the certain antibodies in
accordance with the invention could be categorized as falling into the
following
epitopic categories:
Category Antibodies Competition for CTLA4 Binding
A BO1M* Freely cross-compete with one another; cross-
BO2M** compete with category B; some cross-
competition with category D
4.1.1 Freely cross-compete with one another; cross-
4.13.1 compete with category A, C and D.
6.1.1 Freely cross-compete with one another; cross-
3.1.1 compete with category B and category D
4.8.1
11.2.1
11.6.1
11.7.1
4.14.3 Cross-compete with category C and B; some
cross-competition with category A
4.9.1 BNI3 blocks 4.9.1 binding to CTLA4 but not
BNI3*** the reverse
(*) (**) Available from Biostride.
(***) Available from Pharmingen.
As a next step, we endeavored to determine if the antibodies of the
invention recognized a linear epitope on CTLA4 under reducing and non-
reducing conditions on Western blots. We observed that none of the 4.1.1,
3.1.1, 11.7.1, 11.6.1, or 11.2.1 antibodies of the invention appeared to
recognize
a reduced form of CTLA4 on Western blot. Accordingly, it appeared likely that
the epitope to which each of these antibodies bound was not a linear epitope
but
more likely was a conformational epitope the structure of which may have been
abrogated under reducing conditions.
Therefore, we sought to determine whether we could learn about
residues within the CTLA4 molecule that are important for binding of
antibodies of the invention. One manner that we utilized was to conduct
kinetic
assessments of off-rates as between human CTLA4 and two highly conserved
primate CTLA4 molecules (cynomologous and marmoset CTLA4). BIAcore

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
studies demonstrated that the 4.1.1 antibody of the invention bound to human,
cynomologous, and marmoset CTLA4 at the same rate. However, with respect
to off-rates (affinity), the 4.1.1 antibody had the highest affinity (slowest
off-
rate) for human, a faster off-rate with cynomologous, and a much faster off-
rate
5 for marmoset. The 11.2.1 antibody of the invention, on the other hand,
binds to
human, cynomologous, and marmoset CTLA4 at the about the same rate and
has about the same relative off-rate for each of the three. This information
further indicates that the 4.1.1 and 11.2.1 antibodies of the invention bind
to
different epitopes on CTLA4.
10 To further
study the epitope to which the category B and C antibodies of
the invention bind, we conducted certain site directed mutagenesis studies.
Marmoset CTLA4 possesses two important changes at residues 105 and 106
relative to human CTLA4. Such differences are a leucine to methionine change
at residue 105 and a glycine to serine change at residue 106. Accordingly, we
15 mutated cDNA encoding human CTLA4 to encode a mutated CTLA4 having
the L105M and G106S changes. The hom*ologue replacement mutant CTLA4
did not effect binding of a B7.2-IgG1 fusion protein. Further, binding with
the
11.2.1 antibody of the invention was not effected. However, such molecule was
significantly inhibited in its ability to bind with the 4.1.1 antibody of the
20 invention (similar to marmoset). Next, we mutated a cDNA encoding
marmoset
CTLA4 to create a mutant marmoset CTLA4 having a S106G change. Such
change resulted in restoration of stable binding between the 4.1.1 antibody
and
the marmoset CTLA4 mutant. In addition, we mutated a cDNA encoding
marmoset CTLA4 to create a mutant marmoset CTLA4 having a M105L
25 change. Such change partially restored binding between the 4.1.1
antibody and
the mutant CTLA4.
Each of the category B through D antibodies of the invention appear to
possess similar functional properties and appear to have the potential to act
as
strong anti-CTLA4 therapeutic agents. Further, each of the molecules certain
30 cross-competition in their binding for CTLA4. However, as will be
observed
from the above discussion, each of the molecules in the different categories
appear to bind to separate conformational epitopes on CTLA4.

CA 02356215 2001-06-21
WO 00/37504
PC11E1599/30895
56
From the foregoing, it will be appreciated that the epitope information
discussed above indicates that antibodies (or other molecules, as discussed
above) that cross-compete with antibodies of the invention will likely have
certain therapeutic potential in accordance with the present invention.
Further,
it is expected that antibodies (or other molecules, as discussed above) that
cross-
compete with antibodies of the invention (i.e., cross-compete with category B,

C and/or D antibodies) will likely have certain additional therapeutic
potential
in accordance with the present invention. Additionally, it is expected that
antibodies (or other molecules, as discussed above) that cross-compete with
antibodies of the invention (i.e., cross-compete with category B, C and/or D
antibodies) and that (i) are not reduced in their binding to marmoset CTLA4
(similar to the 11.2.1 antibody) or (ii) are reduced in their binding to
marmoset
CTLA4 (similar to the 4.1.1 antibody) will likely have certain additional
therapeutic potential in accordance with the present invention. Antibodies (or
other molecules, as discussed above) that compete with categories A and E may
also have certain therapeutic potential.
EXAMPLES
The following examples, including the experiments conducted and
results achieved are provided for illustrative purposes only and are not to be

construed as limiting upon the present invention.
EXAMPLE 1
Generation of Anti-CTLA-4-Antibody Producing Hybridomas
Antibodies of the invention were prepared, selected, and assayed in
accordance with the present Example.
Antigen Preparation: Three distinct imrramogens were prepared for
immunization of the XenoMousell" mice: (i) a CTLA-4-IgG fusion protein,
(ii) a CTLA-4 peptide, and (iii) 300.19 murine lymphoma cells transfected with
_ _

CA 02356215 2008-02-01
61009-491
57
a mutant of CTLA-4 (Y201V) that is constitutively expressed on the cell
surface.
(i) CTLA-4-IgG1 Fusion Protein:
Expression Vector Construction:
The cDNA encoding the mature extracellular domain of CTLA-4 was
PCR amplified from human thymus cDNA library (Clontech) using primers
designed to published sequence (Eur. J Irnmunol 18:1901-1905 (1988)). The
fragment was directionally subcloned into pSR5, a Sindbis virus expression
plasmid (InVitrogen), between the human oncostatin M signal peptide and
human IgG gamma 1 (IgG1) CH1/CH2/CH3 domains. The fusion protein does
not contain a hinge domain but contains cysteine 120 in the extracellular
is domain of CTLA-4 to form a covalent dimer. The resulting vector was
called
CTLA-4-IgGl/pSR5. The complete CTLA-4-IgG1 cDNA in the vector was
sequence confirmed in both strands. The amino acid sequence the CTLA4-Ig
protein is shown below. The mature extracellular domain for CD44 was PCR
amplified from human lymphocyte library (Clontech) and subcloned into
pSinRep5 to generate a control protein with the identical IgG1 tail.
OM-CTLA4-IgG1 Fusion Protein (SEQ ID NO: 100):
MGVLLTORTLLSLVLALLFPSMASMAMIIVAQPAVYLASSRGIASFVC
EYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICT
GTSSGNQVNLTI QGLRAMDTGLYI CKVELMY PP PYYLGIGNGTQIY
VIDPEPCPDSDLEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNA_KTKPREEQYNSTYRVVSVLTVLHODWLNGKE
YKCKVSNKALPTPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
VKGFYPSDIAVEWESNG QPENNYK.TTPPVLDSD GSFFLYSKLTVDKSR
WQQGNVESCSVMHEALHNHYTQKSLSLSPGK

CA 02356215 2001-06-21
WO 00/37504
PCTMS99/30895
58
Underlined: signal peptide
Bold: CTLA4 extracellular domain
The cDNAs for mature extracellular domain of CD28 were PCR
amplified from human lymphocyte library (Clontech) and then subcloned into
pCDM8 (J. Immunol. 151: 5261-71 (1993)) to produce a human IgG1 fusion
protein containing both thrombin cleavage and hinge regions. Marmoset,
Cynomologous, and Rhesus CTLA4 were cloned from mRNA isolated from
PHA stimulated PBMCs using standard techniques of degenerate PCR.
Sequencing demonstrated that rhesus and cynomologous amino acid sequence
were identical with three differences from mature human CTLA4 extracellular
domain (S13N, 117T and L105M). Marmoset demonstrated ten amino acid
differences from the mature human CTLA4 extracellular domain (V21A, V33I,
A41T, A51G, 541, S71F, Q75K, T88M, L105M and G106S). Site directed
mutagenesis was used to make single point mutations of all amino acids
different in marmoset CTLA4 to map amino acids important for interation of
the antibodies with human CTLA4-IgG. Mutations of human and marmoset
CTLA-IgG for epitope mapping were generated by matchmaker site-directed
mutagenesis (Promega). The IgG fusion proteins were produced by transient
transfection of Cos7 cells and purified using standard Protein A techniques.
Mutant CTLA4-IgG proteins were evaluated for binding to antibodies by
inununoblotting and using BIAcore analyses.
Recombinant Protein Expression/Purification:
Recombinant sindbis virus was generated by electroporating (Gibco)
Baby Hamster Kidney cells with SP6 in vitro transcribed CTLA-4-IgGl/pSR5
mRNA and DH-26S helper mRNA as described by InVitrogen. Forty eight
hours later recombinant virus was harvested and titered for optimal protein
expression in Chinese hamster ovary cells (CHO-K1). CHO-Kl cells were
cultured in suspension in DMEM/F12 (Gibco) containing 10% heat-inactivated
_ _

CA 02356215 2008-02-01
61009-491
59
feta bovine StrilIT: (Gibco), non-essential amino a.Thiis (Ciib(30), 4mM
EjuIamint
(Gibco), penicillin/streptomycin (Gibco), I &mM Hepes pH 7.5 (Gibco). To
product CTLA-4-1G, the CHO-Ki cells were resuspended at 1x107 cellsimi in
DivfEM/I-712 and incubated with sindbis virus for one hour at room
temperature.
Cells were then diluted to 1x106/m1 in DIVIEr.ifF12 containing 1% fetal bovine
scrum depleted of bovine IgG using protein A sepharose*(Pharmacia), non-
essential amino acids, 4m1vI glutamine, 12.5rnM Hepes pH 7.5, and
penicillin/streptomycin. Forty eight hours-post-infection cells were
pelleted
and conditioned media was harvested and supplemented with complete protease
inhibitor tablets (Boehringer Mannheim), pH adjusted to 7.5, and filtered
(Nalgene). FPLC (Pharmacia) was used to affinity purify the fusion
protein using a 5m1 protein A HiTrap column (Pharmacia) at a 10mIlinin flow
rate. The column was washed with 30 bed volumes of PBS and eluted with
0.1M glycine/HC1 pH 2.8 at lml/min. Fractions (1m1) were immediately
neutralized to pH 7.5 with Tris pH -9. The fractions containing CTLA-4-IgG1
were identified by SDS-PAC-E and then concentrated using centriplus*50
(Amicon) before applying to sepharose*200 column (Pharmacia) at imlfinin
using PBS as the solvent. Fractions containing CTLA-4-IgG1 were pooled,
sterile filtered 0.24 (Millipore), aliquoted and frozen at -80 C. CD44-1gC.1
was
expressed and purified using the same methods. CD28-IgG was purified from
conditioned media from transiently transfected Cos7 cells.

CA 02356215 2008-02-01
61009-491
59a
Characterization CTLA-4-IgGl:
The purified CTLA-4-IgG1 migrated as a single band
on SDS-PAGE using colloidal coomassie staining (Novex).
Under non-reducing conditions CTLA-4-IgG1 was a dimer
(100kDa), that reduced to a 50kDa monomer when treated with
50mM DTT. Amino acid sequencing of the purified CTLA-4-IgG1
in solution confirmed the N-terminus of CTLA-4(MHVAQPAVVLAS)
(SEQ ID NO: 101), and that the oncostatin-M signal peptide
was cleaved from the mature fusion protein. The CTLA-4-IgG1
bound to immobilized B7.1-IgG in a concentration dependent
manner and the binding was blocked by a hamster-anti-human
anti-CTLA-4 antibody (BNI3: PharMingen). The sterile
CTLA-4-IgG was endotoxin free and quantitated by 0D280 using
1.4 as the extinction coefficient. The yield of purified
CTLA-4-IgG ranged between 0.5-3mgs/liter of CHO-Kl cells.

CA 02356215 2008-02-01
6100 9-4 91
6C
(ii) CTL4-4 Pentidc:
The following CTLA-4 peptide (SEQ ID NO: 102) was prepared as
described below:
NH2:MHVACRAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVT
EVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIOGLRA_MDTGLYICK
VELMYPPPYYLGIGNGTQIYVIDPEPC-CONH2
o Abbreviations/Materials:
NMP, N-Methylpyrrolidinone; TFE, 2,2,2-Trifluoroethanol; DCM,
DiChloromethane; FMOC, Fluorenyl Methoxycarbonyl. All reagents were
supplied by Perkin Elmer, with the following exceptions: 1.1'E, Aldrich
Chemical, FMOC-PAL-PEG resin, Perseptive Biosystems. Fmoc-Arg(PMC)-
OH, FM0C-Asn(Trt)-0H, FM0C-Asp(tBu)-OH, FM0C-Cys(Trt)-0H, FM0C-
Glu(tBu)-0H, FM0C-Gln(Trt)-OH, FM0C-His(Boc)-0H, FM0C-Lys(BOC)-
OH, FM0C-Ser(tBu)-0H, FM0C-Thr(tBu)-OH and FM0C-Tyr(tBu)-OH were
used for those amino acids requiring side chain protecting groups
Peptide Synthesis:
Peptide synthesis was performed on a Perkin-Elmer 431A*, retrofitted
with feedback monitoring via UV absorbance at 30Inm (Perkin-Elmer Model
759A detector), The peptide sequence was assembled on a FMOC-PAL-PEG
resin using conditional double coupling cycles. Forced double couplings were
*Trade-mark

CA 02356215 2006-12-29
6100 9-4 91
=
60a
performed at cycles 10,11,18,19,20 and 28 through 33. The resin was washed
with a 50% mixture of DCM and TFE at the completion of each acylation cycle,

CA 02356215 2006-12-29
6 1 0 0 9-4 9 1
61
followed by capping of unreacted amino groups with acetic anhydride in NMP.
Resin was removed from the reactor after completing cycle 49 and the
remainder continued to completion. Peptide cleavage from the resin was
performed using Reagent K*(King et al. International Journal of Protein and
Peptide Research 36:255-266 (1990)) for 6 hours on 415mg of resin affording
186mg crude CTLA-4 peptide.
Peptide Characterization:
25mg aliquots of the crude CTLA-4 peptide were dissolved in 5m1 6M
Guanidine HC1/100mM K2P03 at pH6.4 and eluted over a Pharmacia Hi Load
Superdex 75 16/60 column (16mm x 600mm, 120m1 bed volume) with 2M
Guanidine.HC1/ 100mM K2P03 at p1-16.4 at 2 ml / min for 180 minutes
collecting 5 ml fractions. The fractions were analyzed by loading 1.7 1 of
fractions onto a NuPAGELaemeli gel running with MES running buffer and
visualizing via Daichii silver stain protocol. Those fractions exhibiting a
molecular weight of 12 KDa, as judged versus molecular weight standards,
were pooled together and stored at 4 C. The combined fractions were analyzed
by UV and gel electrophoresis. Amino acid sequencing was performed by
absorbing a 100 microliter sample in a ProSorb cartridge (absorbed onto a
PVDF membrane) and washing to remove the buffer salts. Sequencing was
performed on an Applied Biosystems 420. The expected N-terminal sequence
(M HVAQPAVVL A) (SEQ ID NO: 103) was observed. Immunoblotting
demonstrated that the peptide was recognized by the BNI3 anti-human CTLA-4
(PharMingen). To desalt, an aliquot containing 644tg of material was placed in
.
3500 Da MWCO dialysis tubing and dialyzed against 0.1% TFA / H20 at 4 C
for 9 days with stirring. The entire contents of the dialysis bag was
lyophilized
to a powder.
*Trade-mark

CA 02356215 2006-12-29
61009-491
=
62
(iii) 300.19 cells rransfected with CTLA-4 (Y201 V)
The full length CTLA-4 cDNA was PCR amplified from human thymus
cDNA library (Stratagene) and subcloned into pIRESneo (Clontech). A
mutation of CTLA-4 that results in constitutive cell surface expression was
introduced using MatchMaker Mutagenesis System*(Promega). Mutation of
tyrosine, Y201 to valine inhibits binding of the adaptin protein AP50 that is
responsible for the rapid internalization of CTLA-4 (Chuang et al. J. Immunol.

159:144-151(1997)). Mycoplasma-free 300.19 murine lymphoma cells were
cultured in RPMI-1640 containing 10% fetal calf serum, non-essential amino
acids, penicillin/streptomycin, 2rnM glutamine, 12.5mM Hepes pH 7.5, and
25uM beta-mercaptoethanol. Cells were electroporated (3x106/0.4m1 serum
free RPMI) in a lml chamber with 2Oug CTLA-4-Y201V/pIRESneo using
200V/1180uF (Gibco CellPorator). Cells were rested for 10 minutes and then
8mls of prewarmed complete RPM' media. At 48 hours cells were diluted to
0.5 x106/m1 in complete RPMI media containing 1mg/m1 G418 (Gibco).
Resistant cells were expanded and shown to express CTLA-4 on the cell surface
using the BNI3 antibody conjugated with phycoerythrin (PharMingen). High
level expressing cells were isolated by sterile sorting.
Immunization and hvbridoma generation: XenoMouse mice (8 to 10
weeks old) were immunized (i) subcutaneously at the base of tails with 1x107
300.19 cells that were transfected to express CTLA-4 as described above,
resuspended in phosphate buffered saline (PBS) with complete Freund's
adjuvant, or (ii) subcutaneously at the base of tail with (a) 10 lig the CTLA-
4
fusion protein or (b) 10 g CTLA-4 peptide, emulsified with complete Freund's
adjuvant: In each case, the dose was repeated three or four times in
incomplete
Freund's adjuvant. Four days before fusion, the mice received a final
injection
of the immunogen or cells in PBS. Spleen and/or lymph node lymphocytes
from immunized mice were fused with the [murine non-secretory myeloma P3
cell line] and were subjected to HAT selection as previously described
(Galfre,
G. and Milstein, C., "Preparation of monoclonal antibodies: strategies and
*Trade-mark

CA 02356215 2006-12-29
61009-491
= 63
procedures." Methods Etrzymol. 73:3-46 (1981)). A large panel of hybridomas
all secreting CTLA-4 specific human IgG2K or IgG4x (as detected below)
antibodies were recovered.
ELISA assay: ELISA for determination of antigen-specific antibodies
in mouse serum and in hybridoma supernatants was carried out as described
(Coligan et al., Unit 2.1, "Enzyme-linked inununosorbent assays," in Current
protocols in immunology (1994)) using CTLA-4-Ig fusion protein to capture the
antibodies. For animals that are immunized with the CTLA-4-Ig fusion protein,
we additionally screen for non-specific reactivity against the human Ig
portion
of the fusion protein. This is accomplished using ELISA plates coated with
human IgG1 as a negative control for specificity.
In a preferred ELISA assay, the following techniques are used:
ELISA plates are coated with 100 p.1/well of the antigen in plate coating
buffer (0.1 M Carbonate Buffer, pH 9.6 and NaHCO3 (MW 84) 8.4g/L). Plates
are then incubated at 4 C overnight. After incubation, coating buffer is
removed and the plate is blocked with 200 p.1/well blocking buffer (0.5% BSA,
0.1% Tween* 20, 0.01% Thimerosal* in lx PBS) and incubated at room
temperature for 1 hour. Alternatively, the plates are stored in refrigerator
with
blocking buffer and plate sealers. Blocking buffer is removed and 50 p.1/well
of
= hybridoma supernatant, serum or other hybridoma supernatant (positive
control)
and HAT media or blocking buffer (negative control) is added. The plates are
incubated at room temperature for 2 hours. After incubation, the plate is
washed with washing buffer (lx PBS). The detecting antibody (i.e., mouse anti-
human IgG2-HRP (SB, #9070-05) for IgG2 antibodies or mouse anti-human
IgG4-HRP (SB #9200-05) for IgG4 antibodies) is added at 100 1/well (mouse
anti-human IgG2-HRP @ 1:2000 or mouse anti-human IgG4-HRP @ 1:1000
(each diluted in blocking buffer)). The plates are incubated at room
temperature
for 1 hour and then washed with washing buffer. Thereafter, 100 ul/well of
freshly prepared developing solution (10 ml Substrate buffer, 5 mg OPD (o-
phenylenediamine, Sigma Cat No, P-7288), and 10 p.1 30% H202 (Sigma)) is
added to the wells. The plates are allowed to develop 10-20 minutes, until
*Trademark

CA 02356215 2006-12-29
61009-491
64
negative control wells barely start to show color. Thereafter, 100111/well of
stop solution (2 M H2SO4) is added and the plates are read on an ELISA plate
reader at wavelength 490 nm.
Determination of affinity constants of fully human Mahs bp BIAcore:
Affinity measurement of purified human monoclonal antibodies, Fab fragments,
or hybridoma supernatants by plasmon resonance was carried out using the
BIAcore 2000 instrument, using general procedures outlined by the
manufacturers.
io Kinetic analysis of the antibodies was carried out using antigens
immobilized onto the sensor surface at a low density. Three surfaces of the
BlAcore sensorchip were immobilized with the CTLA-4-Ig fusion protein at a
density ranging from approximately 390-900 using CTLA-4-Ig fusion protein at
20 or 50 pg/m1 in 10 mM sodium acetate at pH 5.0 using the amine coupling kit
supplied by the manufacturer (BIAcore, Inc.). The fourth surface of the
BIAcore sensorchip was immobilized with IgG1 (900 RU) and was used as a
negative control surface for non-specific binding. Kinetic analysis was
performed at a flow rate of 25 or 50 microliters per minute and dissociation
OW
or kw) and association (ka or km) rates were determined using the software
provided by the manufacturer (BIA evaluation*3.0) that allows for global
fitting
calculations.
EXAMPLE 2
Affinity Measurement of Anti-CTLA-4-Antibodies
In the following Table, affinity measurements for certain of the
antibodies selected in this manner are provided:
*Trade-mark

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
TABLE I
Solid Phase
(by BIAcore) .
Hybridoma On-rates Off-rates Association Dissociation Surface
Ka Ka Constant Constant Density
(M4S-Ix106) (S-1x104) KA (1/M)= KD(M)= [RU]
ka/lcdx101" Kdk.x10-10
Moab01 0.68 1.01 0.67 1.48 878.7
0.70 4.66 0.15 6.68 504.5
0.77 6.49 0.19 8.41 457.2
0.60 3.08 0.20 5.11 397.8
4.1.1 1.85 0.72 2.58 0.39 878.7
1.88 1.21 1.55 0.64 504.5
1.73 1.54 1.13 0.88 457.2
1.86 1.47 , 1.26 0.79 397.8
4.8.1 0.32 0.07 4.46 0.22 878.7
0.31 0.23 1.33 0.75 504.5
0.28 0.06 4.82 0.21 397.8
4.14.3 2.81 3.04 0.92 1.08 878.7
2.88 3.97 0.73 1.38 504.5
2.84 6.66 0.43 2.35 457.2
3.17 5.03 0.63 1.58 397.8
6.1.1 0.43 0.35 1.21 0.83 878.7
0.46 0.90 0.51 1.98 504.5
0.31 0.51 0.61 1.63 457.2
0.45 0.79 0.57 1.76 397.8
3.1.1 1.04 0.96 1.07 0.93 878.7
0.95 1.72 0.55 1.82 504.5
0.73 1.65 0.44 2.27 457.2
0.91 2.07 0.44 2.28 397.8
4.9.1 1.55 13.80 0.11 8.94 878.7
1.43 19.00 0.08 13.20 504.5
1.35 20.50 0.07 15.20 397.8
4.10.2 1.00 2.53 0.39 2.54 878.7
0.94 4.30 0.22 4.55 504.5
0.70 5.05 0.14 7.21 457.2
1.00 5.24 0.19 5.25 397.8
2.1.3 1.24 9.59 0.13 7.72 878.7
1.17 13.10 0.09 11.20 504.5
1.11 13.00 0.09 11.70 397.8
4.13.1 1.22 5.83 0.21 4.78 878.7
1.29 6.65 0.19 5.17 504.5
1.23 7.25 0.17 5.88 397.8
-

CA 02356215 2006-12-29
61009-491
66
As will be observed, antibodies prepared in accordance with the
invention possess high affinities and binding constants.
EXAMPLE 3
Structures of Anti-CTLA-4-Antibodies Prepared in Accordance with the
Invention
In the following discussion, structural information related to antibodies
io prepared in accordance with the invention is provided.
In order to analyze structures of antibodies produced in accordance with
the invention, we cloned genes encoding the heavy and light chain fragments
out of the particular hybridoma. Gene cloning and sequencing -was
accomplished as follows:
Poly(A)+ mRNA was isolated from approximately 2 X 1 05 hybridoma
cells derived from immunized XenoMouse mice using a Fast-Track kit
(Invitrogen). The generation of random primed cDNA was followed by PCR.
Human VII or human Võ family specific variable region primers (Marks et al.,
"Oligonucleotide primers for polymerase chain reaction amplification of human
immunoglobulin variable genes and design of family-specific oligonucleotide
probes." Eur. J. Immunol. 21:985-991 (1991)) or a universal human VH primer,
MG-30 (CAGGTGCAGCTGGAGCAGTCIGG) (SEQ ID NO: 104) was used in
conjunction with primers specific for the human C72 constant region (MG-40d;
5'-GCTGAGGGAGTAGAGTCCTGAGGA-3') (SEQ ID NO: 105) or Clc
constant region (hkP2; as previously described in Green et al., 1994).
Sequences of human Mabs-derived heavy and kappa chain transcripts from
hybridomas were obtained by direct sequencing of PCR products generated
from poly(A) RNA using the primers described above. PCR products were
also cloned into pCRII using a TA cloning kit (Invitrogen) and both strands
were sequenced using Prism dye-terminator sequencing kits and an ABI 377
sequencing machine. All sequences were analyzed by alignments to the "V
BASE sequence directory"
*Trademark

CA 02356215 2006-12-29
61009-491
67
(Tomlinson et al., MRC Centre for Protein Engineering, Cambridge, UK) using
MacVector and Geneworks software programs.
Further, each of the antibodies 4.1.1, 4.8.1, 11.2.1, and 6.1.1 were
subjected to full length DNA sequences. For such sequencing, Poly(A) + mRNA
was isolated from approximately 4 X 106 hybridoma cells using mRNA Direct
kit (Dynal). The mRNA was reverse transcribed using oligo-dT(18) and the
Advantage RT/PCR kit*(Clonetech). The Variable region database (V Base)
was used to design amplification primers beginning at the ATG start site of
the
heavy chain DP50 gene (5'-TATCTAAGCTTCTAGACTCGACCGCCACC
io ATGGAGTTTGGGCTGAGCTG-3') (SEQ ID NO: 106) and to the stop codon
of the IgG2 constant region (5'-TTCTCTGATCAGAATTCCTATCATTTACC
CGGAGACAGGGAGAGCT-3') (SEQ ID NO: 107). An optimal Kozak
sequence (ACCGCCACC) (SEQ ID NO: 108) was added 5' to the ATG start
site. The same method was used to design a primer to the ATG start site of the
kappa chain A27 gene (5'-TCTTCAAGCTTGCCCGGGCCCGCCACCATG
GAAACCCCAGCGCAG-3') (SEQ ID NO: 109) and the stop codon of the
kappa constant region (5'-TTCTTTGATCAGAATTCTCACTAACACTCTCC
CCTGTTGAAGC-3') (SEQ ID NO: 110). The 012 cDNA was cloned by using
a primer to the ATG start site (5'-TCTTCAAGCTTGCCCOGGCCCGCCACC
ATGGACATGAGGGTCCCCGCT-3) (SEQ ID NO: 111) and the kappa
constant region stop codon primer above. The heavy chain cDNAs were also
cloned as genomic constructs by site directed mutagenesis to add an NheI site
at
the end of the variable J domain and subcloning an NheI-fragment containing
the genomic IgG2 CH1/Hinge/CH2/CH3 regions. The point mutation to
generate NheI site does not alter the amino acid sequence from germline. The
primer pairs were used to amplify the cDNAs using Advantage High Fidelity
PCR Kit*(Clonetech). Sequence of the PCR was obtained by direct sequencing
using dye-terminator sequencing kits and an ABI sequencing machine. The
PCR product was cloned into pEE glutamine synthetase mammalian expression
vectors (Lonza) and three clones were sequenced to confirm somatic mutations.
For each clone, the sequence was verified on both strands in at least three
reactions. An aglycosylated 4.1.1
*Trade-mark

CA 02356215 2006-12-29
61009-491
68
antibody was generated by site directed mutagenesis of N294Q in the CH2
domain. Recombinant antibodies were produced by transient transfection of
Cos7 cells in IgO depleted FCS and purified using standard Protein A sepharose

techniques. Stable transfectants were generated by electroporation of murine
NSO cells and selection in glutamine free media. Recombinant 4.1.1 with or
without glycosylation exhibited identical specificity and affinity for CTLA4
in
the in vitro ELISA and BIAcore assays.
Gene Utilization Analysis
The following Table sets forth the gene utilization evidenced by selected
hybridoma clones of antibodies in accordance with the invention:

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
69
TABLE II
Heavy and Light Chain Gene Utilization
Clone Heavy Chain Kappa Light Chain
VII D JH VK JK
4.1 DIR4 or.1 DP-50 JH4 A27 JK1
DIR3
4.8.1 DP-50 7-27 JH4 A27 JK4
4.14.3 DP-50 7-27 1114 t- A27 JK3
6.1.1 DP-50 DIR5 orJH4 A27 JK3
DIR5rc
3.1.1 DP-50 3-3 JH6 012 JK3
4.10.2 DP-50 7-27 JH4 A27 JK3
2.1.3 DP-65 1-26 JH6 A 1 0/A26 JK4
4.13.1 DP-50 7-27 JH4 A27 JK3
11.2.1 DP-50 D1-26 JH6 t_D2-2 or 012 JK3
11.6.1 DP-50 1H6 r 012 JK3
D4 ,
D3-22
11.7.1 DP-50 or D21- .1114 j, 012 JK3
9
D3-3 or
12.3.1.1 DP-50 1H6 r A17 JK1
DXP4
12.9.1.1 DP-50 D6-19 JH4 1 A3/A19 JK4
5-24
4.9.1 DP-47 and/or JH4 " L5 JK1
6-19
As will be observed, antibodies in accordance with the present invention
were generated with a strong bias towards the utilization of the DP-50 heavy
chain variable region. The DP-50 gene is also referred to as a VH 3-33 family
gene. Only one antibody that was selected on the basis of CTLA-4 binding and
preliminary in vitro functional assays showed a heavy chain gene utilization
other than DP-50. That clone, 2.1.3, utilizes a DP-65 heavy chain variable
region and is an IgG4 isotype. The DP-65 gene is also referred to as a VH 4-31

family gene. On the other hand, the clone, 4.9.1, which possesses a DP-47
heavy chain variable region binds to CTLA-4 but does not inhibit binding to
B7-1 or B7-2. In XenoMouse mice, there are more than 30 distinct functional

CA 02356215 2006-12-29
6100 9-4 91
heavy chain variable genes with which to generate antibodies. Bias, therefore,

is indicative of a preferred binding motif of the antibody-antigen interaction

with respect to the combined properties of binding to the antigen and
functional
activity.
5
Mutation Analysis
As will be appreciated, gene utilization analysis provides only a limited
overview of antibody structure. As the B-cells in XenoMouse animals
10 stochastically generate V-D-J heavy or V-J kappa light chain
transcripts, there
are a number of secondary processes that occur, including, without limitation,

somatic hypermutation, n-additions, and CDR3 extensions. See, for example,
Mendez et al. Nature Genetics 15:146-156 (1997) and U.S. Patent Application
Serial No. 08/759,620, filed December 3, 1996. Accordingly, to further
15 examine antibody structure predicted amino acid sequences of the
antibodies
were generated from the cDNAs obtained from the clones. In addition, N-
terminal amino acid sequences were obtained through protein sequencing.
Figure 1 provides nucleotide and predicted amino acid sequences of the
heavy and kappa light chains of the clones 4.1.1 (Figure 1A), 4.8.1 (Figure
1B),
20 4.14.3 (Figure IC), 6.1.1 (Figure 1D),3.1.1 (Figure 1E),4.10.2 (Figure
1F),
2.1.3 (Figure 10), 4.13.1 (Figure 1H), 11.2.1 (Figure 1I), 11.6.1 (Figure 13),

11.7.1 (Figure 1K), 12.3.1.1 (Figure 1L), and 12.9.1.1 (Figure 1M). In Figures

IA, 1B, and ID, extended sequences of the antibodies 4.1.1, 4.8.1, and 6.1.1
were obtained by full length cloning of the cDNAs as described above. In such
25 Figures, the signal peptide sequence (or the bases encoding the same)
are
indicated in bold and sequences utilized for the 5' PCR reaction are
underlined.
Figure 2 provides a sequence alignment between the predicted heavy
chain amino acid sequences from the clones 4.1.1, 4.8.1, 4.14.3, 6.1.1, 3.1.1,

4.10.2, 4.13.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, and 12.9.1.1 and the
germline
30 DP-50 (3-33) amino acid sequence. Differences between the DP-50
germline
sequence and that of the sequence in the clones are indicated in bold. The

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
71
Figure also shows the positions of the CDR1, CDR2, and CDR3 sequences of
the antibodies as shaded.
Figure 3 provides a sequence alignment between the predicted heavy
chain amino acid sequence of the clone 2.1.3 and the germline DP-65 (4-31)
amino acid sequence. Differences between the DP-65 germline sequence and
that of the sequence in the clone are indicated in bold. The Figure also shows

the positions of the CDR1, CDR2, and CDR3 sequences of the antibody as
underlined.
Figure 4 provides a sequence alignment between the predicted kappa
light chain amino acid sequence of the clones 4.1.1, 4.8.1, 4.14.3, 6.1.1,
4.10.2,
and 4.13.1 and the germline A27 amino acid sequence. Differences between the
A27 germline sequence and that of the sequence in the clone are indicated in
bold. The Figure also shows the positions of the CDR1, CDR2, and CDR3
sequences of the antibody as underlined. Apparent deletions in the CDR1s of
clones 4.8.1, 4.14.3, and 6.1.1 are indicated with "Os".
Figure 5 provides a sequence alignment between the predicted kappa
light chain amino acid sequence of the clones 3.1.1, 11.2.1, 11.6.1, and
11.7.1
and the germline 012 amino acid sequence. Differences between the 012
germline sequence and that of the sequence in the clone are indicated in bold.
The Figure also shows the positions of the CDR1, CDR2, and CDR3 sequences
of the antibody as underlined.
Figure 6 provides a sequence alignment between the predicted kappa
light chain amino acid sequence of the clone 2.1.3 and the germline A10/A26
amino acid sequence. Differences between the A10/A26 germline sequence and
that of the sequence in the clone are indicated in bold. The Figure also shows
the positions of the CDR1, CDR2, and CDR3 sequences of the antibody as
underlined.
Figure 7 provides a sequence alignment between the predicted kappa
light chain amino acid sequence of the clone 12.3.1 and the germline A17
amino acid sequence. Differences between the A17 germline sequence and that
of the sequence in the clone are indicated in bold. The Figure also shows the

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
72
positions of the CDR1, CDR2, and CDR3 sequences of the antibody as
underlined.
Figure 8 provides a sequence alignment between the predicted kappa
light chain amino acid sequence of the clone 12.9.1 and the germline A3/A19
amino acid sequence. Differences between the A3/A19 germline sequence and
that of the sequence in the clone are indicated in bold. The Figure also shows

the positions of the CDR1, CDR2, and CDR3 sequences of the antibody as
underlined.
Figure 22 provides a series of additional nucleotide and amino acid
sequences of the following anti-CTLA-4 antibody chains:
4.1.1:
full length 4.1.1 heavy chain (cDNA 22(a), genomic 22(b), and
amino acid 22(c));
full length aglycosylated 4.1.1 heavy chain (cDNA 22(d) and
amino acid 22(e));
4.1.1 light chain (cDNA 22(f) and amino acid 22(g));
4.8.1:
full length 4.8.1 heavy chain (cDNA 22(h) and amino acid 22(i));
4.8.1 light chain (cDNA 22(j) and amino acid 22(k));
6.1.1:
full length 6.1.1 heavy chain (cDNA 22(1) and amino acid
22(m));
6.1.1 light chain (cDNA 22(n) and amino acid 22(o));
11.2.1:
full length 11.2.1 heavy chain (cDNA 22(p) and amino acid
22(q)); and
11.2.1 light chain (cDNA 22 (r) and amino acid 22(s)).

CA 02356215 2006-12-29
6 1 0 0 9-4 9 1
73
Signal peptide sequences are shown in bold and large text. The open
reading frames in the full length 4.1.1 genomic DNA sequence (Fig. 22(b)) are
underlined. And, the mutations introduced to make the aglycosylated 4.1.1
heavy chain and the resulting change (N294Q) are shown in double underline
and bold text (cDNA (Fig. 22(b) and amino acid (Fig. 22(c)).
EXAMPLE 4
Analysis of Heavy and Light Chain Amino Acid Substitutions
In Figure 2, which provides a sequence alignment between the predicted
heavy chain amino acid sequences from the clones 4.1.1, 4.8.1, 4.14.3, 6.1.1,
3.1.1, 4.10.2, 4.13.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, and 12.9.1.1 and the
germline DP-50 (3-33) amino acid sequence, an interesting pattern emerges. In
addition to the fact of the bias for heavy chain DP-50 in the majority of the
clones, there is relatively limited hypermutation in the antibodies relative
to the
germline DP-50 gene. For example, clones 3.1.1 and 11.2.1 have no mutations.
Moreover, the mutations in the other clones are generally conservative
changes,
involving substitutions of amino acids with similar properties to the amino
acids
in the germline. Mutations within many of the CDR1 and CRD2 sequences are
particularly conservative in nature. Three of the heavy chains represented in
Figure 2, 4.10.2, 4.13.1, and 4.14.3, are clearly derived from a single
recombination event (i.e., derive from an identical germinal center) and are
nearly identical in sequence. If these three are considered as a single
sequence,
then, among the 10 different antibodies containing the DP50 heavy chain, in
CDR1 and CDR2 there are 3 positions in which a nonpolar residue is replaced
by another nonpolar residue, 12 in which a polar uncharged residue is replaced

by another polar uncharged residue, and 1 in which a polar charged residue is
replaced by another polar charged residue. Further, there are two positions in

which two residues which are very similar structurally, glycine and alanine,
are
substituted for one another. The only mutations not strictly conservative
involve 3 substitutions of a polar charged residue for a polar uncharged
residue
and one substitution of a nonpolar residue for a polar residue.

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
74
The light chains of these antibodies are derived from 5 different Vk
genes. The A27 gene is the most heavily represented and is the source of 6
different light chains. Comparison of these 6 sequences reveals two noteworthy

features. First, in three of them, 4.8.1, 4.14.3, and 6.1.1, contain deletions
of
one or two residues in CDR1, a rare event. Second, there is a strong prejudice
against the germline serine at position six in CDR3 in that the serine has
been
replaced in every sequence. This suggests that a serine at this position is
incompatible with CTLA4 binding.
It will be appreciated that many of the above-identified amino acid
substitutions exist in close proximity to or within a CDR. Such substitutions
would appear to bear some effect upon the binding of the antibody to the
CTLA-4 molecule. Further, such substitutions could have significant effect
upon the affinity of the antibodies.
EXAMPLE 5
N-Terminal Amino Acid Sequence Analysis of Antibodies in Accordance
with the Invention
In order to further verify the composition and structure of the antibodies
in accordance with the invention identified above, we sequenced certain of the
antibodies using a Perkin-Elmer sequencer. Both heavy and kappa light chains
of the antibodies were isolated and purified through use of preparative gel
electrophoresis and electroblotting techniques and thereafter directly
sequenced
as described in Example 6. A majority of the heavy the heavy chain sequences
were blocked on their amino terminus. Therefore, such antibodies were first
treated with pyroglutamate aminopeptidase and thereafter sequenced.
The results from this experiment are shown in Figure 9. Figure 9 also
provides the molecular weight of the heavy and light chains as determined by
mass spectroscopy (MALDI).

CA 02356215 2006-12-29
61009-491
EXAMPLE 6
Additional Characterization of Antibodies in Accordance with the
Invention
5 Figure 10 provides certain additional characterizing information about
certain of the antibodies in accordance with the invention. In the Figure,
data
related to clones 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.14.3, and 6.1.1 is
summarized.
The following data is provided: Concentration, isoelectric focusing (IEF), SDS-

PAGE, size exclusion chromatography, FACS, mass spectroscopy (MALDI),
10 and light chain N-terminal sequences.
Generally, the data was generated as follows:
Materials and Methods
15 Protein concentration was determined at 280 nm from a UV scan (200-
350 rim), where 1.58 absorbance units at 280 rim equaled lmg/ml.
SDS-PAGE was performed using the Novex NuPAGE electrophoresis
system with a 10% NuPAGE gel and MES running buffer. Samples were
20 prepared by diluting 3:1 with 4x NuPAGE sample buffer (+/-)
beta-mercaptoethanol, heated and ¨ 5 ug of protein was loaded onto the gel.
The gel was then stained with Brilliant Blue R*Staining solution (Sigma cat.#
B-
6529) and molecular size estimates were made by comparing stained bands to
"Perfect Protein Markers"*(Novagen cat# 69149-3).
For N-terminal sequencing, samples were run as above on NuPAGE
gels, transferred to Pro Blot immobilization membrane (Applied Biosystems)
then stained with Coomassie Blue*R-250. The stained protein bands were
excised and subjected to sequence analysis by automated alman degradation on
an Applied Biosystems 494 Procise I-IT Sequencer.*
*Trade-mark

CA 02356215 2006-12-29
61009-491
76
Isoelectric focusine (IEF) was performed using Pharrnacia IEF 3-9
pHast gels (cat # 17-0543-01) . Samples were diluted in 10% glycerol to -0.8
mg/m1 and l ul was loaded onto gel and then silver stained. The pI estimates
were made by comparing stained bands to broad range (pI-13-10) IEF standards
(Pharmacia cat # 17-0471-01)
Size exclusion chromatoprraphy (SEC) was carried in phosphate buffered
saline (PBS) on the Pharmacia SMART system* using the Superdex 75 PC
3.2/30* column. Molecular size estimates were made by comparing peak
to retention time to the retention times of gel
For FACS studies, human peripheral T cells were prepared and
stimulated for 48 hours. T cells were washed once, resuspended in FACS
buffer at lx106 cells/100 ul and stained for CD3 surface expression with 10 ul
of anti-CD3-FITC (Immunotech, Marseille, France) for 30 minutes at room
temperature. Cells were washed twice, then fixed, permeabilized (Fix and
Perm*,
Caltag), and stained for intracellular CTLA-4 expression with 10 ul anti-
CD152-PE (Pharmingen). Flow cytometry was performed using a Becton
Dickinson FACSore Quadrants were set by analysis of relevant isotype control
antibodies (Caltag).
As was discussed above, anti-CTLA-4 antibodies have been
demonstrated to possess certain powerful immune modulation activities. The
following experiments were carried out in order to determine if antibodies in
accordance with the present invention possessed such activities. In general,
the
experiments were designed to assess ability of the antibodies to inhibit the
_interaction between CTLA-4 and B7 molecules, be selective as between CTLA-
4 and B7 molecules and CD28, and promote T cell cytokine production,
including, but not limited to IL-2 and/or IFN-7 expression. Further,
examination of cross-reactivity of antibodies of the invention with certain
*Trade-mark

CA 02356215 2006-12-29
61009-491
77
human tissues and CTLA-4 molecules in other species (e.g., mouse and
primate) was undertaken.
EXAMPLE 7
Competition ELISA: Inhibition of CTLA-4/B7-1 or B7-2 Interaction by
Antibodies in Accordance with the Invention
An in vitro assay was conducted to determine if antibodies in
accordance with the present invention were capable of inhibiting the binding
of
CTLA-4 with either B7-1 or B7-2. As will be appreciated, antibodies of the
invention that are capable of inhibiting the binding of CTLA-4 with B7
molecules would be expected to be candidates for immune regulation through
the CTLA-4 pathway. In the assay, the following materials and methods were
utilized:
Materials and Methods
=
3 nM B7.1-Ig(G1) or B7.2-Ig(G1) (Repligen, Inc. Needham, MA) in
Dulbecco's PBS was coated on 96-well MaxiSorp*plates (Nunc, Denmark,
#439454) and incubated at 4 C overnight. On day 2, B7-Ig was removed and
plates were blocked with I% BSA plus 0.05% Tweent20 in D-PBS for two
hours. Plates were washed 3X with wash buffer (0.05% Tweent2.0 in D-PBS).
Antibody at appropriate test concentrations and CTLA-4-Ig(G4) (0.3 nM final
conc.) (Repligen, Inc. Needham, MA) were pre-mixed for 15 minutes and then
added to the B7-Ig coated plate (60 ul total volume) and incubated at RT for
1:5
hours. Plates were washed 3X and 501.d of a 1 to 1000 dilution of HRP-labeled
mouse anti-human IgG4 antibody (Zymed, San Francisco, CA, #05-3820) was
added and incubated at RT for 1 hour. Plates were washed 3X and 50 TMB
Microweeperoxidase substrate (Kirkegaard & Perry, Gaithersburg, MD, #50-
76-04) was added and incubated at RT for 20 minutes, and then 50 .L1 1N H2SO4
was added to the plate. Plates were read at 450 TIM using a Molecular Devices
plate reader*(Sunnyvale, CA). All samples were tested in duplicate. Maximal
*Trade-mark

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
78
signal was defined as CTLA-4-Ig binding in the absence of test antibody. Non-
specific binding was defined as absorbance in the absence of CTLA-4-Ig and
test antibody.
The results from the assay are provided in Table IIIA and IIIB. In Table
IIIA, results are shown for a variety of antibodies in accordance with the
invention. In Table IIIB, results are shown comparing the 4.1.1 antibody of
the
invention with the 11.2.1 antibody of the invention from a separate
experiment.
TABLE IIIA
Clone Isotype CTLA4/B7.2 CTLA4/B7.1
CTLA-4-Ig Comp. ELISA Comp. ELISA
IC50 (nM) IC50 (nM)
CT3.1.1 IgG2 0.45 0.07 (n=3) 0.63 0.10
(n=2)
CT4.1.1 IgG2 0.38 0.06 (n=5) 0.50 0.05
(n=2)
CT4.8.1 IgG2 0.57 0.03 (n=3) 0.17 0.28
(n=2)
CT4.9.1 IgG2 Non-competitive non-competitive
(n=3) (n=2)
CT4.10.2 IgG2 1.50 0.37 (n=3) 3.39 0.31
(n=2)
CT4.13.1 IgG2 0.49 0.05 (n=3) 0.98 0.11
(n=2)
CT4.14.3 IgG2 0.69 0.11 (n=3) 1.04 0.15
(n=2)
CT6.1.1 IgG2 0.39 0.06 (n=3) 0.67 0.07
(n=2)
TABLE IIIB
Clone Isotype CTLA4/B7.2 CTLA4/B7.1
CTLA-4-Ig Comp. ELISA Comp. ELISA
IC50 (nM) IC50 (nM)
CT4.1.1 IgG2 0.55 0.08 (n=4) 0.87 0.14
(n=2)
CT11.2.1 IgG2 0.56 0.05 (n=4) 0.81 0.24
(n=2)
=

CA 02356215 2006-12-29
61009-491
79
EXAMPLE 8
Selectivity Ratios of Antibodies of the Invention with Respect to CTLA-4
Versus Either CD28 or B7-2
Another in vitro assay was conducted to determine the selectivity of
antibodies of the invention with respect to CTLA-4 versus either CD28 or B7-2.

The following materials and methods were utilized in connection with the
experiments:
CT'LA-4 Selectivity ELISA.: Materials and Methods
A 96-well FluroNUNC plate (Nunc Cat No.475515) was platecoated
with four antigens: CTLA-4/Ig, CD44/Ig, CD28/Ig, and B7.2/Ig (antigens
generated in-house). The antigens were platecoated overnight at +4 C at lug/ml
100u1/well in 0.1M sodium bicarbonate buffer, pH 9.6. The plate was then
washed with PBST (PBS + 0.1% Tweeri-20) three times using a NUNC plate
washer. The plate was blocked with PBST+0.5%BSA at 150 ul/well. The plate
was incubated at RT for 1 hour then washed with PBST three times. Next the
anti-CTLA-4 antibodies of the invention were diluted in block at 1 ps/m1 and
were added to the plate. The plate was incubated at RT for 1 hour then washed
with PBST three times. The wells that contained the antibodies of the
invention
were then treated with 100 1/well anti-human IgG2-HRP (Southern Biotech
Cat No.9070-05) at a 1:4000 dilution in block. Also, one row was treated with
anti-human IgG (Jackson Cat No. 209-035-088) to normalize for platecoating.
This antibody was diluted to 1:5000 in block and added at 100 ul/well.
one row was treated with anti-human CTLA-4-HRP (Pharrningen Cat No.
345815/Custom HRP conjugated) as a positive control. This antibody was used
at 0.05 ug/ml diluted in block. The plate was incubated at RT for 1 hour then
washed with PBST three times. LBA chemiluminescent substrate*(Pierce) was
added at 100 p.1/well and the plate was incubated on a plateshaker for 5 min.
The plate was then read using a lumi-imager for a 2 min. exposure.
*Trade-mark

CA 02356215 2006-12-29
61009-491
IGEN CTLA-4-Ig Selectivity Binding Assay: Materials and Methods
M-450 Dynabeads*(Dynal A.S, Oslo, Norway 4140.02) were washed 3X
with Na phosphate buffer, pH 7.4 and resuspended in Na phosphate buffer. 1.0
5 g CTLA-4-Ig(G1), 1.0 vg CD28-Ig(G1) or 1.0 to 3.0 g B7.2-1g(G1)
(Repligen, Inc. Needham, MA) were added to 100 1 of beads and incubated
overnight on a rotator at 4 C. On day 2 the beads were washed 3X in 1% BSA
plus 0.05% Tween*-20 in Dulbecco's PBS and blocked for 30 minutes. Beads
were diluted 1 to 10 with blocking buffer and 25 p.I of the coated beads were
10 added to 12x75 mm polypropylene tubes. All samples were tested in
duplicate.
50 I test antibody (1 g/m1 final concentration) or blocking buffer was added

to the tubes and incubated for 30 minutes on the Origen 1.5 Analyzer*carousel
(IGEN International, Inc., Gaithersburg, MD) at RT, vortexing at 100 rpm. 25
p.1 of ruthenylated murine anti-human IgGl, IgG2 or Ig04 (Zymed, Inc. San
15 Francisco, CA #05-3300, 05-3500 and 05-3800) (final concentration of 3
Kg/m1
in 100 I total volume) was .added to the tubes. Tubes were incubated for 30
minutes at RT on the carousel vortexing at 100 rpm. 200 p.1 of Origen assay
buffer*(IGEN International, Inc., Gaithersburg, MD #402-050-03) per tube was
added and briefly vortexed and then the tubes were counted in the Origen
20 Analyzer and ECL (electrochemiluminescence) units were determined for
each
tube. Normalization factors were determined to correct for differences in
binding of fusion proteins to Dynabeads, and ECL units were corrected for non-
specific binding before calculating selectivity ratios.
25 The results from the assays are provided in Tables IVA and IVB.
*Trade-mark

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
81
TABLE IVA
Clone Isotype CTLA4/CD28 CTLA4/B7.2 CTLA4/CD44 CTLA4/CD28 CTLA4/B7.2
ELI SA ELISA ELI SA IGEN IGEN
3.1.1 lgG2 >500:1 (n=3) >500:1 (n=3) >500:1
(n=3) >500:1 (n=2) >500:1 (n=1)
195:1 (n=1)
4.1.1 IgG2 >500:1 (n=3) >500:1 (n=2) >500:1
(n=3) >500:1 (n=1) >500:1 (n=1)
485:1 (n=1) 261:1 (n=1) 107:1 (n=1)
4.8.1 IgG2 >500:1 (n=3) >500:1 (n=2) >500:1
(n=3) >500:1 (n=2) >500:1 (n=2)
190:1 (n=1)
4.9.1 IgG2 >500:1 (n=2) >500:1 (n=2) >500:1
(n=3) >500:1 (n=1) >500:1 (n=1)
244:1 (n=1) 33:1 (n=1)
4.10.2 IgG2 >500:1 (n=3) >500:1 (n=3) >500:1
(n=3) >500:1 (n=1) >500:1 (n=1)
4.13.1 IgG2 >500:1 (n=2) >500:1 (n=3) >500:1
(n=3) >500:1 (n=1) >500:1 (n=2)
46:1 (n=1) 329:1 (n=1)
4.14.3 102 >500:1 (n=2) >500:1 (n=2) >500:1
(n=2) >413:1 (n=1) >234:1 (n=1)
80:1(n=1) 10:1(n=1) 126:1(n1)
6.1.1 Ig02 >500:1 (n=2) >500:1 (n=3) >500:1
(n=3) >500:1 (n=2) >500:1 (n=2)
52:1 (n=1)
TABLE IVB
Clone Isotype CTLA4/CD28 CTLA4/137.2 CTLA4/hIgG
ELISA ELISA ELI SA
4.1.1 IgG2 >500:1 (n=3) >500:1 (n=2)
>500:1 (n=3)
11.2.1 IgG2 >500:1 (n=3) >500:1 (n=3)
>500:1 (n=3)
EXAMPLE 9
Human T-Cell Signal Model
In order to further define the activity of antibodies in accordance with
the invention to act as immune regulators, we developed certain T-cell assays
in
order to quantify the enhancement of T-cell IL-2 production upon blockade of

CA 02356215 2006-12-29
61009-491
82
CTLA-4 signal with the antibodies. The following materials and methods were
utilized in connection with the experiments:
Materials and Methods
Freshly isolated human T cells were prepared by using Histopaque*
(Sigma, St. Louis, MO #A-70543) and T-kvvik (Lympho-Kwik, One Lambda,
Canoga Park, CA, #LK-50-T), and stimulated with PHA (1 gimp (Purified
Phytohemagglutinin, Murex Diagnostics Ltd. Dartford, England, #HA 16) in
o medium (RPM1 1640 containing L-glutamine, MEM non-essential amino acids,
penicillin, streptomycin, 25 mM Hepes and 10% FBS) at a concentration of
1x106 cells/ml and incubated at 37 C for 2 days. The cells were washed and
diluted in medium to 2x106 cells/ml. Raji cells (Burkitt lymphoma, Human
ATCC No.: CCL 86 Class II American Type Culture Collection Rockville, MD)
were treated with mitomycin C (Sigma St. Louis, MO, # M-4287) (25 gg/m1)
for one hour at 37 C. The Raji cells were washed 4X in PBS and resuspended
at 2x106 cells/ml. Human T cell blasts (5x105/m1), Raji cells (5x105/m1) and
anti-CTLA-4 antibodies or an isotyped-matched control antibody at various
concentrations were added to 96-well microtiter plates and the plates were
incubated at 37 C for 72 hours. Total volume per well was 200 p.l. Seventy-
two hours post stimulation, the plates were spun down and supernatant removed
and frozen for _later dettzimination of IL-2 (Quantikine IL-2 ELISA kit*, R&D
Systems, Minneapolis, MN, #D2050) and IFN-y (Quantildne IFN-g ELISA kit;
R&D Systems). Cytokine enhancement was defined as the difference between
cYtokine levels in cultures containing an anti-CTLA-4 blocking mAb versus an
isotype-matched control antibody. For flow cytometry experiments, Raji cells
were washed lx with FACS buffer (PBS containing 2% heat inactivated FCS,
0.025% sodium azide). Cell pellets were resuspended in FACS buffer at 1x106
cells/100 p.1 and incubated with 10 p.1 of anti-CD8O-PE (Becton Dickinson, San
Jose, CA) or anti-CD86-PE (Pharmingen, San Diego, CA) for 30 minutes at
room temperature. Cells were washed twice and resuspended in 1 ml FACS
buffer. Flow cytometry was performed using a Becton Dickinson FACSort.
*Trade-mark

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
83
Histogram markers were set by analysis of relevant isotype control antibodies
(Caltag, Burlingame, CA).
In general, we have developed an assay that can be used for rapid
determination of T-cell IL-2 upregulation. As will be appreciated, stimulation
of T cells is B7 and CD28 dependent. Further, washed T blasts do not make
detectable IL-2 and Raji cells do not make detectable IL-2 even when
stimulated with LPS or PWM. However, in combination, the T blasts co-
cultured with Raji cells can model B7, CTLA-4, and CD28 signaling events and
the effects of antibodies thereon can be assessed.
Figure 11 shows the expression of B7-1 and B7-2 on Raji cells using
anti-CD8O-PE and anti-CD86-PE mAbs using flow cytometry (FACs) as
described in Example 6.
Figure 12 shows the concentration dependent enhancement of IL-2
production in the T cell blast/Raji assay induced by CTLA-4 blocking
antibodies (BNI3 (PharMingen) and the 4.1.1, 4.8.1, and 6.1.1 antibodies of
the
invention).
Figure 13 shows the concentration dependent enhancement of FFN-T
production in the T cell blast/Raji assay induced by CTLA-4 blocking
antibodies (BNI3 (PharMingen) and the 4.1.1, 4.8.1, and 6.1.1 antibodies of
the
invention) (same donor T cells).
Figure 14 shows the mean enhancement of IL-2 production in T cells
from 6 donors induced by CTLA-4 blocking antibodies in the T cell blast/Raji
assay. It is interesting to consider that the mAb, CT4.9.1, binds to CTLA4 but
does not block B7 binding. Thus, simply binding to CTLA-4 is insufficient by
itself to provide a functional antibody of the invention.
Figure 15 shows the mean enhancement of ITN-y production in T cells
from 6 donors induced by CTLA-4 blocking antibodies in the T cell blast/Raji
assay.
Figure 19 shows a comparison between the 4.1.1 and 11.2.1 antibodies
of the invention at a concentration of 304ml in the 72 hour T cell blast/Raji

CA 02356215 2006-12-29
61009-491
84
assay as described in this Example 9 and the Superantigen assay described in
Example 10.
Figure 20 shows the concentration dependent enhancement of IL-2
production in the T cell blast/Raji assay induced by the 4.1.1 and 11.2.1
CTLA4
antibodies of the invention.
The following Table IVc provides information related to mean
enhancement and range of enhancement of cytokine response in the Raji and
SEA assays of the invention. Each of the experiments included in the results
are based on antibody at a dose of 30 1.1.g/m1 and measured at 72 hours.
Numbers of donors used in the experiments as well as responses are shown.
TABLE WC
Assay mAb Cytokine Mean SEM Range n Donor
Enhancement Enhancement Response
138/1111 138/m1
T cell blast/Raji 4.1.1 IL-2 3329 408 0 to 8861 42 19 of
21
T cell blast/Raji 4.1.1 IFN-y 3630 . 980 600 to 13939
17 13 of 13
T cell blast/Raji 11.2.1 IL-2 3509 488 369 to 6424 18
14 of 14
SEA (PBMC) 4.1.1 IL-2 2800 312 330 to 6699 42 17 of
17
SEA (PBMC) 11.2.1 IL-2 = 2438 366 147 to 8360 25 15
of 15
SEA 4.1.1 IL-2 6089 665 -168 to 18417 46
15 of 17
(Whole Blood)
SEA 11.2.1 IL-2 6935 700 -111 to 11803 25 12 of 14
(Whole Blood)
EXAMPLE 10
Human T-Cell Signal Model
We developed a second cellular assay in order to quantify the
enhancement of T-cell IL-2 upregulation upon blockade of CTLA-4 signal with
the antibodies. The following materials and methods were utilized in
connection with the experiments:
=

CA 02356215 2006-12-29
6100 9-4 91
Materials and Methods
Human PBMC were prepared using Accuspin. Microtiter plates were
precoated with an anti-CD3 antibody (leu4, Becton Dickinson) (60 ng/ml) and
5 incubated for 2 hours at 37 C. hPBMC were added to the wells at 200,000
cells
per well. Staphylcoccus enterotoxin A (SEA) (Sigma) was added to the wells at
100 rig/mi. Antibodies were added to the wells, usually at 30 jig/mi. Cells
were
then stimulated for 48, 72 or 96 hours. Plates were centrifuged at the desired

time-point and supernatants were removed from the wells. Thereafter,
10 supernatants were checked for IL-2 production using ELISA (R&D Systems).
Results from these experiments are shown in Figures 16, 17, and 21. In
Figure 16, induction of IL-2 production in hPBMC from 5 donors was measured
72 hours after stimulation. In Figure 17, results are shown from measurement
15 of whole blood, analyzing the difference in induction of IL-2 production
in the
blood of 3 donors as measured at 72 and 96 hours after stimulation.
In Figure 21, the enhancement of IL-2 production in whole blood of 2
donors as measured at 72 hotirs after stimulation.
20 EXAMPLE 11
Tumor Animal Model
We have established an animal tumor model for the in vivo analysis of
anti-murine-CTLA-4 antibodies in inhibiting tumor growth. In the model, a
25 murine fibrosarcorna tumor is grown and the animals are treated with
anti-
murine-CTLA-4 antibodies. The materials and methods for establishment of
the model are provided below:
Materials and Methods
Female A/J mice (6-8 weeks old) were injected subcutaneously on the
dorsal side of the neck with 0.2 ml of SalN tumor cells (1x106) (Baskar 1995).
*Trade-mark

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
86
Anti-murine CTLA-4 or an isotype matched control antibody (PharMingen,
San Diego, CA, 200 ug/animal) were injected intraperitioneally on days 0, 4, 7

and 14 following the injection of tumor cells. Tumor measurements were taken
during the course of the 3-4 week experiments using a Starrett SPC Plus
electronic caliper (Athol, MA) and tumor size was expressed as the surface
area
covered by tumor growth (mm2).
Figure 18 shows the inhibition of tumor growth with an anti-murine
CTLA-4 antibody in a murine fibrosarcoma tumor model. As shown in Figure
18, animals treated with anti-CTLA-4 had a reduction in tumor growth as
compared to animals treated with an isotype control antibody. Accordingly,
anti-murine CTLA4 mAbs are capable of inhibiting growth of a fibrosarcoma in
a mouse tumor model.
It is expected that antibodies that are cross-reactive with murine CTLA-
4 would perform similarly in the model. However, of the antibodies of the
invention that have been checked for cross-reactivity, none are cross-reactive
with murine CTLA-4.
EXAMPLE 12
Tumor Animal Model
In order to further investigate the activity of antibodies in accordance
with the invention, a xenograft SCUD mouse model was designed to test the
eradication of established tumors and their derived metastases. In the model,
SCID mice are provided with grafted human T cells and are implanted with
patient-derived non-small cell lung cell (NSCL) or colorectal carcinoma (CC)
cells. Implantation is made into the gonadal fat pads of SCUD mice. The
tumors are allowed to grow, and thereafter removed. The mice develop human-
like tumor and liver metastases. Such a model is described in Bumpers et al J.

Surgical Res. 61:282-288 (1996).
It is expected that antibodies of the invention will inhibit growth of
tumors formed in such mice.

CA 02356215 2006-12-29
61009-491
87
REFERENCE
Alegre et al. J Immunol 157:4762-70 (1996)
Allison and Krummel Science 270:932-933 (1995)
Balzano et al. In! J Cancer Suppl 7:28-32 (1992)
Blair et.al. J Immunol 160:12-5 (1998)
Blake and Litzi-Davis BioConjugate Chem. 3:510-513 (1992)
Boussiotis et al. Proc Nat! Acad Sci USA 90:11059-63 (1993)
Bowie et al. Science 253:164 (1991)
Bruggeman et al. PNAS USA 86:6709-6713 (1989)
Bruggeman, M. and Neuberger, M.S. in Methods: A companion to Methods in
Enzymology 2:159-165 (Lerner et al. eds. Academic Press (1991))
Bruggemann et al., "Human antibody production in transgenic mice: expression
from 100 kb of the human IgH locus." Eur. J. Immunol. 21:1323-1326 (1991)
Bruggemann, M. and Neuberger, M.S. "Strategies for expressing human
antibody repertoires in transgenic mice." Immunology Today 17:391-397 (1996)
Brunet et al. Nature 328:267-270 (1987)
Bumpers et al J. Surgical Res. 61:282-288 (1996)
CapSey et al. Genetically Engineered Human Therapeutic Drugs (Stockton
Press, NY (1988))
Castan et al. Immunology 90:265-71 (1997)

CA 02356215 2006-12-29
6 1 0 0 9-4 9 1
88
Cepero et al, J Exp Med 188:199-204 (1998)
Chen et al, "Immunoglobulin gene rearrangement in B-cell deficient mice
generated by targeted deletion of the JH locus" International /n1771201010gy
5:647-
656 (1993)
Chen et al. Cell 71:1093-1102 (1992)
to Chen et al. Human Gene Therapy 5:595-601 (1994)
Chiswell and McCafferty TIB TECH 10:80-84 (1992)
Choi et al, "Transgenic mice containing a human heavy chain immunoglobulin
gene fragment cloned in a yeast artificial chromosome" Nature Genetics 4:117-
123 (1993)
Chothia & Lesk .1. MoL Biol. 196:901-917 (1987)
Chothia et al. Nature 342:878-883 (1989)
Chuang et al. J. Immunol. 159:144-151(1997)
Coligan et al., Unit 2.1, "Enzyme-linked immunosorbent assays," in Current
Protocols in Immunology (1994)
Cwirla et al. PNAS USA 87:6378-6382 (1990)
Dariavach et al. Eur. Immunol. 18:1901-1905 (1988)
Dayhoff, M.O., in Atlas of Protein Sequence and Structure, pp. 101-110
(Volume 5, National Biomedical Research Foundation (1972)) and Supplement
2 to this volume, pp. 1-10
de Boer et al. Eur J Immunol 23:3120-5 (1993)
Eckstein, Ed., Oxford University Press, Oxford England (1991))
Evans et al. J. Med. Chem. 30:1229 (1987)
Fallarino etal. J Exp Med 188:205-10 (1998)
Fanger et al. Immunol Methods 4:72-81 (1994)
Fauchere, J. Adv. Drug Res. 15:29 (1986)
Fishwild et al., "High-avidity human IgCry monoclonal antibodies from a novel
strain of minilocus transgenic mice," Nature Biotech. 14:845-851 (1996).

CA 02356215 2001-06-21
WO 00/37504
PCT/U599/30895
89
Freeman et al. J Exp Med 178:2185-92 (1993)
Freeman et al. J Immuno1161 :2708-15 (1998)
Freeman et al. Science 262:907-9 (1993)
Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y.
(1989))
Galfre, G. and Milstein, C., "Preparation of monoclonal antibodies: strategies

and procedures." Methods Enzymol. 73:3-46 (1981)
Gorman et al. P.N.A.S. 79:6777 (1982)
Green and Jalcobovits J. Exp. Med. 188:483-495 (1998)
Green et al. Nature Genetics 7:13-21 (1994) ,
Grosschedl et al. Cell 41:885 (1985)
Hanes and Plucthau PNAS USA 94:4937-4942 (1997)
Harding et al. Nature 356:607-609 (1994)
Harper et al. J Immuno1147:1037-44 (1991)
Hathco*ck et al. Science 262:905-7 (1993)
Hoganboom et al. Immunol. Reviews 130:43-68 (1992)
Horspool et al. J Immunol 160:2706-14 (1998)
Houghten et al. Biotechniques 13:412-421 (1992)
Houghten PNAS USA 82:5131-5135 (1985)
Hurwitz et al. J Neuroimmunol 73:57-62 (1997)
Hurwitz et al. Proc Natl Acad Sci USA 95:10067-71 (1998)
Immunology - A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer

Associates, Sunderland, Mass. (1991))
Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland
Publishing, New York, N.Y. (1991))

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
Jakobovits et al., "Germ-line transmission and expression of a human-derived
yeast artificial-chromosome." Nature 362:255-258 (1993)
Jakobovits, A. et al., "Analysis of hom*ozygous mutant chimeric mice: Deletion
5 of the immunoglobulin heavy-chain joining region blocks B-cell
development
and antibody production." Proc. Natl. Acad. Sci. USA 90:2551-2555 (1993)
Jakobovits, A., "Humanizing the mouse genome." Current Biology 4:761-763
(1994)
Jakobovits, A., "Production of fully human antibodies by transgenic mice."
Current Opinion in Biotechnology 6:561-566 (1995)
Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition,
Chafner and Longo, eds., Lippincott Raven (1996))
Kabat et al. (1991) Sequences of Proteins of Immunological Interest, N.I.H.
publication no. 91-3242
Kabat Sequences of Proteins of Immunological Interest (National Institutes of
Health, Bethesda, Md. (1987 and 1991))
Kostelny et al. J. ImmunoL 148:1547-1553 (1992)
Krwmnel and Allison J Exp Med 182:459-65 (1995)
Krumtnel et al. Int Immunol 8:519-23 (1996)
Kuchroo et al. Cell 80:707-18 (1995)
Kwon et al. PNAS USA 94:8099-103 (1997)
LaPlanche et al. NucL Acids Res. 14:9081 (1986)
Lenschow et al. Proc Natl Acad Sci USA 90:11054-8 (1993)
Lenschow et al. Science 257:789-792 (1992)
Lin et al. J Exp Med 188:199-204 (1998)
Linsley et al. J Exp Med 176:1595-604 (1992)
Linsley et al. J. Exp. Med. 174:561-569 (1991)
Linsley et al. Science 257:792-795 (1992)
Liu et al. JImmunoL 139:3521 (1987)

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
91
Liu et al. P.N.A.S. 84:3439 (1987)
Lonberg et al., "Antigen-specific human antibodies from mice comprising four
distinct genetic modifications." Nature 368:856-859 (1994).
Luhder et al. J Exp Med 187:427-32 (1998)
Marasco Gene Therapy 4:11-15 (1997)
Markees et al. J Clin Invest 101:2446-55 (1998)
Marks et at., "Oligonucleotide primers for polymerase chain reaction
amplification of human immunoglobulin variable genes and design of
family-specific oligonucleotide probes." Eur. J. ImmunoL 21:985-991 (1991)
McCoy et al. J Exp Med 186:183-7 (1997)
Mendez et al. Nature Genetics 15:146-156 (1997)
Needleman and Wunsch J. MoL Biol. 48:443 (1970)
Okayama et al. MoL Cell. Bio. 3:280 (1983)
Parmley and Smith Gene 73:305-318 (1988)
Pearson and Lipman Proc. Natl. Acad. ScL (U.S.A.) 85:2444 (1988)
Perez et al. Immunity 6:411-7 (1997)
Perrin et al. Immunol Res 14:189-99 (1995)
Perrin et al. J Immuno1157:1333-6 (1996)
Pinalla et al. Biotechniques 13:901-905 (1992)
Proteins, Structures and Molecular Principles (Creighton, Ed., W. H. Freeman
and Company, New York (1984))
Razi-Wolf et at. Proc Nat! Acad Sci USA 90:11182-6 (1993)
ao
Remington's Pharmaceutical Sciences (15th ed, Mack Publishing Company,
Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour
Rizo and Gierasch Ann. Rev. Biochem. 61:387 (1992)
Russel et at. NucL Acids Research 21:1081-1085 (1993)
Schwartz Cell 71:1065 (1992)

CA 02356215 2006-12-29
6100 9-4 91
92
Scott TIBS 17:241-245 (1992)
Smith and Waterman Adv, Appl. Math. 2:482 (1981)
Songsivilai & Lachmann Clin. Exp. lmmunol. 79: 315-321 (1990)
Stec et at. J. Am. Chem. Soc. 106:6077 (1984)
Stein et al. Nucl. Acids Res. 16:3209 (1988)
Taylor et al., "A transgenic mouse that expresses a diversity of human
sequence
heavy and light chain immunoglobulins." Nucleic Acids Research 20:6287-6295
(1992)
Taylor et al., "Human immunoglobulin transgenes undergo rearrangement,
somatic mutation and class switching in mice that lack endogenous IgM,"
International Immunology 6:579-591(1994)
The McGraw-Hill Dictionary of Chemical Terms (Parker, S., Ed., McGraw-Hill,
San Francisco (1985))
Thornton et at. Nature 354:105 (1991)
Tivol et al. Immunity 3:541-7 (1995)
Townsend and Allison Science 259:368 (1993)
Traunecker et al. Int. J. Cancer (Suppl.) 7:51-52 (1992)
Tuaillon et al. "Analysis of direct and inverted DJH rearrangements in a human

Ig heavy chain transgenic minilocus" I Immunol. 154:6453-6465 (1995)
Tuaillon et al., "Human immunoglobulin heavy-chain minilocus recombination
in transgenic mice: gene-segment use in II and y transcripts." Proc. Natl.
Acad.
Sci. USA 90:3720-3724 (1993)
Uhlmann and Peyman Chemical Reviews 90:543 (1990)
Van Parijs et al. J Exp Med 186:1119-28 (1997)
Veber and Freidinger TINS p.392 (1985)
Vitetta 17117712.0701 Today 14:252 (1993)
Walunas et al. hnmunity 1:405-13 (1994)
Walunas et al. J Exp Med 183:2541-50 (1996)

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
93
Waterhouse et al. Science 270:985-988 (1995)
Winter and Harris Immunol Today 14:43-46 (1993)
Wright et al. Crit. Reviews in Inzmunol. 12125-168 (1992)
Yang et al. Cancer Res 57:4036-41 (1997)
Yi-qun et al. Int Immunol 8:37-44 (1996)
Zon et al. Anti-Cancer Drug Design 6:539 (1991)
Zon et al. Oligonucleotides and Analogues: A Practical Approach, pp. 87-108
(F. Eckstein, Ed., Oxford University Press, Oxford England (1991))
Fry et al. "Specific, irreversible inactivation of the epidermal growth factor

receptor and erbB2, by a new class of tyrosine kinase inhibitor" Proc Nat!
Acad
Sci USA 95:12022-7 (1998)
Hoffman et al. "A model of Cdc25 phosphatase catalytic domain and Cdk-
interaction surface based on the presence of a rhodanese hom*ology domain" J
Mol Biol 282:195-208 (1998)
Ginalski et al. "Modelling of active forms of protein lcinases: p38--a case
study"
Acta Biochim Pol 44:557-64 (1997)
Jouko et al. "Identification of csk tyrosine phosphorylation sites and a
tyrosine
residue important for kinase domain structure" Biochem J322:927-35 (1997)
Singh et al. "Structure-based design of a potent, selective, and irreversible
inhibitor of the catalytic domain of the erbB receptor subfamily of protein
tyrosine lcinases" J Med Chem 40:1130-5 (1997)
Mandel et al. "ABGEN: a knowledge-based automated approach for antibody
structure modeling" Nat Biotechnol 14:323-8 (1996)
Monfardini et al. "Rational design, analysis, and potential utility of GM-CSF
antagonists" Proc Assoc Am Physicians 108:420-31(1996)
Furet et al. "Modelling study of protein kinase inhibitors: binding mode of
staurosporine and origin of the selectivity of CGP 52411" J Comput Aided Mol
Des 9:465-72 (1995)
Ill et al. "Design and construction of a hybrid immunoglobulin domain with
properties of both heavy and light chain variable regions" Protein Eng 10:949-
57 (1997)

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
94
Martin et al. "The affinity-selection of a minibody polypeptide inhibitor of
human interleulcin-6" EMBO J13:5303-9 (1994)
U.S. Patent Application Serial No. 07/466,008, filed January 12, 1990
U.S. Patent Application Serial No. 07/574,748, filed August 29, 1990
U.S. Patent Application Serial No. 07/575,962, filed August 31, 1990
U.S. Patent Application Serial No. 07/610,515, filed November 8, 1990
U.S. Patent Application Serial No. 07/810,279, filed December 17, 1991
U.S. Patent Application Serial No. 07/853,408, filed March 18, 1992
U.S. Patent Application Serial No. 07/904,068, filed June 23, 1992
U.S. Patent Application Serial No. 07/919,297, filed July 24, 1992
U.S. Patent Application Serial No. 07/922,649, filed July 30, 1992
U.S. Patent Application Serial No. 07/990,860, filed December 16, 1992
U. S . Patent Application Serial No. 08/031,801, filed March 15,1993
U.S. Patent Application Serial No. 08/053,131, filed April 26, 1993
U.S. Patent Application Serial No. 08/096,762, filed July 22, 1993
U.S. Patent Application Serial No. 08/112,848, filed August 27, 1993
U.S. Patent Application Serial No. 08/155,301, filed November 18, 1993
U.S. Patent Application Serial No. 08/161,739, filed December 3, 1993
U.S. Patent Application Serial No. 08/165,699, filed December 10, 1993
U.S. Patent Application Serial No. 08/209,741, filed March 9, 1994
U.S. Patent Application Serial No. 08/234,145, filed April 28, 1994
U.S. Patent Application Serial No. 08/724,752, filed October 2, 1996
U.S. Patent Application Serial No. 08/730,639, filed October 11, 1996
U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996
U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996
U. S . Patent No. 4,399,216
U.S. Patent No. 4,681,581
U.S. Patent No. 4,683,195
U.S. Patent No. 4,683,202
U.S. Patent No. 4,735,210
U.S. Patent No. 4,740,461
U.S. Patent No. 4,816,397
U.S. Patent No. 4,912,040
U.S. Patent No. 4,959,455
U.S. Patent No. 5,101,827
U. S . Patent No. 5,102,990 (RE 35,500)
U.S. Patent No. 5,151,510
U.S. Patent No. 5,194,594
U.S. Patent No. 5,434,131
U.S. Patent No. 5,530,101
U. S . Patent No. 5,545,806
U.S. Patent No. 5,545,807
U.S. Patent No. 5,585,089
U.S. Patent No. 5,591,669

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
U.S. Patent No. 5,612,205
U.S. Patent No. 5,625,126
U.S. Patent No. 5,625,825
U.S. Patent No. 5,633,425
5 U.S. Patent No. 5,643,763
U.S. Patent No. 5,648,471
U.S. Patent No. 5,661,016
U.S. Patent No. 5,693,761
U.S. Patent No. 5,693,792
10 U.S. Patent No. 5,697,902
U.S. Patent No. 5,703,057
U.S. Patent No. 5,714,350
U.S. Patent No. 5,721,367
U.S. Patent No. 5,733,743
15 U.S. Patent No. 5,770,197
U.S. Patent No. 5,770,429
U.S. Patent No. 5,773,253
U.S. Patent No. 5,777,085
U.S. Patent No. 5,789,215
20 U.S. Patent No. 5,789,650
U.S. Patent No. 5,811,097
European Patent No. EP 0 546 073 B1
25 European Patent No. EP 0 463 151 Bl, grant published June 12, 1996
International Patent Application No. WO 92/02190
International Patent Application No. WO 92/03918
= 30 International Patent Application No. WO 92/22645
International Patent Application No. WO 92/22647
International Patent Application No. WO 92/22670
International Patent Application No. WO 93/00431
International Patent Application No. WO 93/12227
35 International Patent Application No. WO 94/00569
International Patent Application No. WO 94/02602, published February 3, 1994
International Patent Application No. WO 94/25585
International Patent Application No. WO 94/29444
International Patent Application No. WO 95/01994
40 International Patent Application No. WO 95/03408
International Patent Application No. WO 95/24217
International Patent Application No. WO 95/33770
International Patent Application No. WO 96/14436
International Patent Application No. WO 96/34096, published October 31, 1996
45 International Patent Application No. WO 97/13852
International Patent Application No. WO 97/20574
International Patent Application No. WO 97/38137
International Patent Application No. WO 98/24884

CA 02356215 2001-06-21
WO 00/37504
PCT/US99/30895
96
International Patent Application No. WO 98/24893, published June 11, 1998
EOUTVALENTS
The foregoing description and Examples detail certain preferred
embodiments of the invention and describes the best mode contemplated by the
inventors. It will be appreciated, however, that no matter how detailed the
foregoing may appear in text, the invention may be practiced in many ways and
the invention should be construed in accordance with the appended claims and
any equivalents thereof.

CA 02356215 2008-02-01
1
SEQUENCE LISTING
<110> ABGENIX, INC.
PFIZER INC.
<120> HUMAN MONOCLONAL ANTIBODIES TO CTLA-4
<130> ABX-PF1 PCT
<140> PCT/US99/30895
<141> 1999-12-23
<150> 60/113,647
<151> 1998-12-23
<160> 147
<170> PatentIn Ver. 2.1
<210> 1
<211> 463
<212> PRT
<213> hom*o sapiens
<400> I
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1 5 10 15
Val Gin Cys Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin
20 25 30
Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe
35 40 45
Ser Ser His Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
50 55 60
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn Lys Tyr Tyr Ala
65 70 75 80
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
85 90 95
Thr Leu Phe Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Gly Gly His Phe Gly Pro Phe Asp Tyr Trp Gly
115 120 125
Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130 135 140
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
145 150 155 160
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165 170 175

CA 02356215 2008-02-01
2
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr PhePro Ala
180 185 190
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195 200 205
Pro Ser Ser Asn Phe Gly Thr Gin Thr Tyr Thr Cys Asn Val Asp His
210 215 220
Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
225 230 235 240
Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val
245 250 255
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
260 265 270
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
275 280 285
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
290 295 300
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser
305 310 315 320
Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
325 330 335
Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile
340 345 350
Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
355 360 365
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
370 375 380
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
385 390 395 400
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser
405 410 415
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
420 425 430
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
435 440 445
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
450 455 460
<210> 2
<211> 464
<212> PRT
<213> hom*o sapiens

CA 02356215 2008-02-01
3
<400> 2
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1 5 10 15
Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
20 25 30
Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr She
35 40 45
Ser Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
50 55 60
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys His Tyr Gly
65 70 75 80
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn
85 90 95
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Gly Glu Arg Leu Gly Ser Tyr She Asp Tyr Trp
115 120 125
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
130 135 140
Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr
145 150 155 160
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr She Pro Glu Pro Val Thr
165 170 175
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
180 185 190
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
195 200 205
Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp
210 215 220
His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys
225 230 235 240
Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser
245 250 255
Val She Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
260 265 270
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
275 280 285
Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
290 295 300
Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val
305 310 315 320

CA 02356215 2008-02-01
4
Ser Val Leu Thr Val Val His Gin Asp Trp Leu AsniGly Lys Glu Tyr
325 330 335
Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr
340 345 350
Ile Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu
355 360 365
Pro Pro Ser Arg Glu Glu Net Thr Lys Asn Gin Val Ser Leu Thr Cys
370 375 380
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
385 390 395 400
Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Net Leu Asp
405 410 415
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
420 425 430
Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
435 . 440 445
Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys
450 455 460
<210> 3
<211> 163
<212> PRT
<213> hom*o sapiens
<400> 3
Pro Gly Arg Her Leu Arg Leu Ser Cys Ala Ala Ser Gly She Thr Phe
1 5 10 15
Ser Ser His Gly Ile His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
20 25 30
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn Lys Asp Tyr Ala
35 40 45
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys
55 60
Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
65 70 75 80
50 Tyr Tyr Cys Ala Arg Val Ala Pro Leu Gly Pro Leu Asp Tyr Trp Gly
85 90 95
Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
100 105 110
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
115 120 125
Ala Leu Gly Cys Lou Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
130 135 140

CA 02356215 2008-02-01
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val :His Thr Phe Pro Ala
145 150 155- 160
Val Leu Gin
<210> 4
<211> 463
<212> PRT
<213> hom*o sapiens
<400> 4
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1 5 10 15
Val Gin Cys Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Glu
20 25 30
Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe
35 40 45
Ser Ser Tyr Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
50 55 60
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys His Tyr Ala
65 70 75 80
Asp Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
85 90 95
Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Ala Gly Leu Leu Gly Tyr Phe Asp Tyr Trp Gly
115 120 125
Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130 135 140
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
145 150 155 160
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165 170 175
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
180 185 190
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195 200 205
Pro Ser Ser Asn Phe Gly Thr Gin Thr Tyr Thr Cys Asn Val Asp His
210 215 220
Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
225 230 235 240
Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val
245 250 255

CA 02356215 2008-02-01
6
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
260 265 270
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
275 280 285
Val Gin Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
290 295 300
Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser Thr Phe Arg Val Val Ser
305 310 315 320
Val Leu Thr Val Val His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys
325 330 335
Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile
340 345 350
Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro
355 360 365
Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu
370 375 380
Val Lys Gly Phe Tyr Pro Ser Asp-Ile Ala Val Glu Trp Glu Ser Asn
385 390 395 400
Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser
405 410 415
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
420 425 430
Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
435 440 445
His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys
450 455 460
<210> 5
<211> 169
<212> PRT
<213> hom*o sapiens
<400> 5
Gly Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser
1 5 10 15
Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gin Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn
35 40 45
Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
50 55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80

CA 02356215 2008-02-01
7
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ala Arg Ile Ile Thr Pro
85 90 95
Cys Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala
100 105 110
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser
115 120 125
Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
130 135 140
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
145 150 155 160
Val His Thr Phe Pro Ala Val Leu Gin
165
<210> 6
<211> 167
<212> PRT
<213> hom*o sapiens
<400> 6
Gly Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser
1 5 10 15
Gly Phe Ile Phe Ser Ser His Gly Ile His Trp Val Arg Gin Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala 'Val Ile Trp Tyr Asp Gly Arg Asn
35 40 45
Lys Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
50 55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Ala Pro Leu Gly Pro Leu
85 90 95
Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
100 105 110
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser
115 120 125
Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
130 135 140
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
145 150 155 160
Thr Phe Pro Ala Val Leu Gin
165

CA 02356215 2008-02-01
8
<210> 7
<211> 172
<212> PRT
<213> hom*o sapiens
<400> 7
Ser Gly Pro Gly Leu Val Lys Pro Ser Gin Ile Leu Ser Leu Thr Cys
1 5 10 15
Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Gly His Tyr Trp Ser Trp
20 25 30
Ile Arg Gin His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr
35 40 45
Tyr Ile Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr
50 55 60
Ile Ser Val Asp Thr Ser Lys Asn Gin Phe Ser Leu Lys Leu Ser Ser
65 70 75 80
Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly
85 90 95
Asp Tyr Tyr Gly Ile Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val
100 105 110
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys
115 120 125
Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys
130 135 140
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
145 150 155 160
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin
165 170
<210> 8
<211> 153
<212> PRT
<213> hom*o sapiens
<400> 8
Pro Gly Arg Her Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
1 5 10 15
Ser Ser His Gly Ile His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
20 25 30
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn Lys Asp Tyr Ala
35 40 45
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
50 55 60
Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
65 70 75 80

CA 02356215 2008-02-01
9
Tyr Tyr Cys Ala Arg Val Ald Pro Leu Gly Pro Leu Asp Tyr Trp Gly
85 90 95
Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
100 105 110
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
115 120 125
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
130 135 140
Ser Trp Asn Ser Gly Ala Leu Thr Ser
145 150
<210> 9
<211> 167
<212> PRT
<213> hom*o sapiens
<220>
<221> MOD RES
<222> (10)
<223> Any amino acid
<400> 9
Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser
1 5 10 15
Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gin Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn
35 40 45
Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
50 55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Arg Gly Ala Thr Leu
85 90 95
Tyr Tyr Tyr Tyr Tyr Arg Xaa Asp Val Trp Gly Gin Gly Thr Thr Val
100 105 110
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
115 120 125
Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
130 135 140
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145 150 155 160
Ala Leu Thr Ser Gly Val His
165

CA 02356215 2008-02-01
<210> 10
<211> 151
<212> PRT
<213> hom*o sapiens
<400> 10
Gly Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser
1 5 10 15
10 Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gin Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser His
35 40 45
Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
50 55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ala Val Val Val Pro Ala
85 90 95
Ala Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala
100 105 110
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser
115 120 125
Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr She
130 135 140
Pro Glu Pro Val Thr Val Ser
145 150
<210> 11
<211> 146
<212> PRT
<213> hom*o sapiens
<220>
<221> MOD RES
<222> (22)
<223> Any amino acid
<400> 11
Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
1 5 10 15
She Thr Phe Ser Ser Xaa Gly Met His Trp Val Arg Gin Ala Pro Gly
20 25 30
Lys Gly Leu Glu Trp Val Ala Val Ile Trp Ser Asp Gly Ser His Lys
35 40 45
Tyr Tyr Ala Asp Ser Val Lys Gly Arg She Thr Ile Ser Arg Asp Asn
50 55 60

CA 02356215 2008-02-01
11
Ser Lys Asn Thr LeU Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
65 - 70 75 80
Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Met Ile Val Val Gly Thr
85 90 95
Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
100 105 110
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr
115 120 125
Ser Glu.Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
130 135 140
Glu Pro
145
<210> 12
<211> 174
<212> PRT
<213> hom*o sapiens
<400> 12
Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys
1 5 10 15
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Val His Trp Val Arg
20 25 30
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp
35 40 45
Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
50 55 60
Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu
65 70 75 80
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Tyr Tyr
85 90 95
Asp Phe Trp Ser Gly Arg Gly Gly Met Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
115 120 125
Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly
130 135 140
Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145 150 155 160
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170

CA 02356215 2008-02-01
12
<210> 13
<211> 163
<212> PRT
<213> hom*o sapiens
<400> 13
Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
1 5 10 15
Thr Phe Ser Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys
20 25 30
Gly Leu Glu Trp Val Val Val Ile Trp His Asp Gly Asn Asn Lys Tyr
35 40 45
Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
50 55 60
Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
65 70 75 80
Ala Val Tyr Tyr Cys Ala Arg Asp Gln Gly Thr Gly Trp Tyr Gly Gly
85 90 95
Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
100 105 110
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr
115 120 125
Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
130 135 140
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
145 150 155 160
His Thr Phe
<210> 14
<211> 235
<212> PRT
<213> hom*o sapiens
<400> 14
Met Glu Thr Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15
Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser
20 25 30
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
35 40 45
Ile Ser Ser Ser Phe Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala
50 55 60
Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro
65 70 75 80

CA 02356215 2008-02-01
13
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95
Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gin Gin Tyr
100 105 110
Gly Thr Ser Pro Trp Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
130 135 140
Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
145 150 155 160
Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin
165 170 175
Ser Gly Asn Ser Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser
180 185 190
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
195 200 205
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser
210 215 220
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235
<210> 15
<211> 233
<212> PRT
<213> hom*o sapiens
<400> 15
Met Glu Thr Pro Ala Gin Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15
Asp Thr Thr Gly Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser
20 25 30
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Val Ser
35 40 45
Ser Ser Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg
55 60
50 Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg
65 70 75 80
She Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg
85 90 95
Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gin Gin Tyr Gly Ile
100 105 110
Ser Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr
115 120 125

CA 02356215 2008-02-01
14
Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
V30 135 140
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
145 150 155 160
Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
165 170 175
Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
180 185 190
Ser Leu Set Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
195 200 205
Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
210 215 220
Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230
<210> 16
<211> 139
<212> PRT
<213> hom*o sapiens
<400> 16
Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg
1 5 10 15
Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro
20 25 30
Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr
35 40 45
Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
50 55 60
Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
65 70 75 80
Gln Gln Tyr Gly Arg Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val
85 90 95
Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
100 105 110
Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
115 120 125
Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln
130 135
<210> 17
<211> 234
<212> PRT
<213> hom*o sapiens

CA 02356215 2008-02-01
<A00> 17
get Glu Thr Pro Ala Gin Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15
Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser
20 25 30
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gin Ser
35 40 45
Val Ser Ser Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro
50 55 60
Arg Pro Leu Ile Tyr Gly Val Ser Ser Arg Ala Thr Gly Ile Pro Asp
65 70 75 80
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95
Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gin Gin Tyr Gly
100 105 110
Ile Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg
115 120 125
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin
130 135 140
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
145 150 155 160
Pro Arg Glu Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser
165 170 175
Gly Asn Ser Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr
180 185 190
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
195 . 200 205
His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro
210 215 220
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230
<210> 18
.<211> 152
<212> PRT
<213> hom*o sapiens
<400> 18
Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile
1 5 10 15
Thr Cys Arg Ala Ser Gin Ser Ile Asn Thr Tyr Leu Ile Trp Tyr Gin
20 25 30

CA 02356215 2008-02-01
16
I
Gin Lys Pro Gly Lys Ala Pro Asn Phe Leu Ile Ser Ala Thr Ser Ile
35 40 45
Leu Gin Ser Gly Val Pro Ser Arg Phe Arg Gly Ser Gly Ser Gly Thr
50 55 60
Asn Phe Thr Leu Thr Ile Asn Ser Leu His Pro Glu Asp Phe Ala Thr
65 70 75 80
Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly
85 90 95
Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
100 105 110
Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val
115 120 125
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys
130 135 140
Val Asp Asn Ala Leu Gin Ser Gly
145 150
<210> 19
<211> 142
<212> PRT
<213> hom*o sapiens
<400> 19
Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
1 5 10 15
Cys Arg Ala Ser Gin Ser Ile Ser Ser Asn Phe Leu Ala Trp Tyr Gin
20 25 30
Gin Lys Pro Gly Gin Ala Pro Arg Leu Leu Ile Tyr Arg Pro Ser Ser
35 40 45
Arg Ala Thr Gly Ile Pro Asp Ser Phe Ser Gly Ser Gly Ser Gly Thr
55 60
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Leu
65 70 75 80
Tyr Tyr Cys Gin Gin Tyr Gly Thr Ser Pro Phe Thr Phe Gly Pro Gly
85 90 95
50 Thr Lys
Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
100 105 110
Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val
115 120 125
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin
130 135 140

CA 02356215 2008-02-01
17
<210> 20
<211> 155
<212> PRT
<213> hom*o sapiens
<400> 20
Ser Pro Asp Phe Gin Ser Val Thr Pro Lys Glu Lys Val Thr Ile Thr
1 5 10 15
Cys Arg Ala Ser Gin Ser Ile Gly Ser Ser Leu His Trp Tyr Gin Gin
20 25 30
Lys Pro Asp Gin Ser Pro Lys Leu Leu Ile Lys Tyr Ala Ser Gin Ser
35 40 45
Phe Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
50 55 60
Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala Glu Asp Ala Ala Thr Tyr
65 70 75 80
Tyr Cys His Gin Ser Ser Ser Leu Pro Leu Thr Phe Gly Gly Gly Thr
85 90 95
Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
100 105 110
Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys
115 120 125
Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val
130 135 140
Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu
145 150 155
<210> 21
<211> 146
<212> PRT
<213> hom*o sapiens
<400> 21
Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu
1 5 10 15
Ser Cys Arg Ala Ser Gin Ser Val Ser Ser Tyr Leu Ala .Trp Tyr Gin
20 25 30
Gln Lys Pro Gly Gin Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser
35 40 45
Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
50 55 60
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val
65 70 75 80
Tyr Tyr Cys Gin Gin Tyr Gly Arg Ser Pro Phe Thr Phe Gly Pro Gly
85 90 95

CA 02356215 2008-02-01
18
Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
100 105 110
Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val
115 120. 125
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys
130 135 140
Gly Gly
145
<210> 22
<211> 139
<212> PRT
<213> hom*o sapiens
<400> 22
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys
1 5 10 15
Arg Ala Ser Gin Ser Ile Asn Ser Tyr Leu Asp Trp Tyr Gin Gin Lys
20 25 30
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln
35 40 45
Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
50 55 60
Thr Leu Thr Ile Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr
65 70 - 75 80
Cys Gin Gin Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys
85 90 95
Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
100 105 110
Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu
115 120 125
Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val
130 135
<210> 23
<211> 134
<212> PRT
<213> hom*o sapiens
<400> 23
Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
1 5 10 15
Ile Thr Cys Arg Ala Ser Gin Asn Ile Ser Arg Tyr Leu Asn Trp Tyr
20 25 30

CA 02356215 2008-02-01
19
Gin Gin Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Val Ala Ser
35 40 45
Ile Leu Gin Ser Gly Val Pro Ser Gly Phe Ser Ala Ser Gly Ser Gly
50 55 60
Pro Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro Glu Asp Phe Ala
65 70 75 80
Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Phe Thr Phe Gly Pro
85 90 95
Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
100 105 110
Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val
115 120 125
Val Cys Leu Leu Asn Asn
130
<210> 24
<211> 150
<212> PRT
<213> hom*o sapiens
<400> 24
Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
i 5 10 15
Ile Thr Cys Arg Ala Ser Gin Ser Ile Cys Asn Tyr Leu Asn Trp Tyr
20 25 30
Gin Gin Lys Pro Gly Lys Ala Pro Arg Val Leu Ile Tyr Ala Ala Ser
35 40 45
Ser Leu Gin Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
50 55 60
Ile Asp Cys Thr Leu Thr Ile Ser Ser Leu Gin Pro Glu Asp Phe Ala
65 70 75 80
Thr Tyr Tyr Cys Gin Gin Ser Tyr Ile Thr Pro Phe Thr Phe Gly Pro
85 90 95
Gly Thr Arg Val Asp Ile Glu Arg Thr Val Ala Ala Pro Ser Val Phe
100 105 110
Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val
115 120 125
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp
130 135 140
Lys Val Asp Asn Ala Tyr
145 150

CA 02356215 2008-02-01
<210> 25
<211> 139
<212> PRT
<213> hom*o sapiens
<400> 25
Pro Leu Ser Leu Pro Val Thr Leu Gly Gin Pro Ala Ser Ile Ser Cys
1 5 10 15
10 Arg Ser
Ser Gin Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr Leu Asn
20 25 30
Trp Phe Gin Gin Arg Pro Gly Gin Ser Pro Arg Arg Leu Ile Tyr Lys
35 40 45
Val Ser Asn Trp Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly
50 55 60
Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp
20 65 70 75 80
Val Gly Val Tyr Tyr Cys Met Gin Gly Ser His Trp Pro Pro Thr Phe
85 90 95
Gly Gin Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser
100 105 110
Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala
115 120 125
Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
130 135
<210> 26
<211> 133
<212> PRT
<213> hom*o sapiens
<400> 26
Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gin Ser Leu Leu
1 5 10 15
His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gin Lys Pro Gly
20 25 30
Gin Ser Pro Gin Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly
35 40 45
Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
50 55 60
Lys Leu Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Net
65 70 75 80
Gin Ala Leu Gin Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu
85 90 95
Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser
100 105 110

006 bpbbqbobbo Pbb4boPqb5 qoPpoqqbpo oqbbpb0000 pbppboPoob pbqbopbbqb 09
0178 bgbbqbobqb oeoqbbpbqo poopbb0004 oqpbqpoqoo oPopbbppoo OPPPP00000
ogL oqqogooqqo qbpo4boop5 bpobbq5400 poopobp000 bqbooP000b gbuboo,bqbq
OZL 4b4Peeobob ebqqbeoebe eoebbgbbee OOPOPPOE,P0 pobeepeoqe bpqboppobq
ogg ooeoPqoopb P000Pobbog 4oppobpooq 000b4boopb qbbgbobeob Poq0004oPq
009 oqoPbbeoqo ogbPop4004 b4obp000qq oopopobqbo bbobeoopbq ogobobbpoq
(21s oePbbgboqb qbboPbqbbo oppboopogq opqopbbppo 45E4=6;06 bbqopobbob
08f7 Ppeobebebo-pqopeobebb epogobqpoo bobbqoppoo 4qoq5bo4eo pobbbeepoe
oz ooqoobpogo ogogboopoq bbq000ppbb bpoobbbbqo pqopbqq4oP gooqbbbbqo
ogE pbpbPbPbbp bPbob4bqop q4pqbq5qob bopopbbpbo obpbebgoob POPP.64PPPO
ODE 5qoqP4b4ob DPOPebPPDO qqppopbgbp ooqogpoopo qqpboobbbe ebqboo4opb og
017Z PbbqPqopop Peqee4bppb b4ebqe4bbq eqe44beobb qbbbqbebbq obbbbppobb
pooqobbpoo booqbbbqop obapobbqpq opP4bpoqqo opoqqpbb4o 4bobeopqbq
ozT oo4o4o25P5 q0004bbpbb b400bpoogb bgbobbebbb bb4o4bPbbq bb4obpobqb
og bpoqbqbpoo 4b4bbpbepq qqqogobqqb ogoogqqqbb b4obebqobb b44qbpbbqp
8Z <00[7>
suaTdes owoH <ETZ>
VNO <ZTZ>
S6E1 <TTZ>
eZ <OTZ> 0f7
Z6ET eb
quee4bbboo
HET 4oq5qopoqo qoobebppbs obopopqopo oppopobqoq obbpbqeobq ebqboogobq
ozET poqoqqoqbo pebbbbeobp obbqbbpobp bppopbbqbo opoqobepob Poeqoqoo44
ogz-E ogqooqobbo pboo4o2bbq obmp000qoo PO.200'260 P4OPPOPPb? bboobeobbb
0OZT 4peobebebb bqbebbgboo bogeoebobe opope4pqqo bbeeepqbbq Dobqopebqp
N'TT obeoqbbpoo UP5P200-254 p5ebbe.65bo ooqp00000b qopopopqb4 bbeopoopeb
0801 P50000.5P0b b5PEPOOPPP poogoqpoop pppbpboqpo opoobp000g 006.6PPEOUP
ozoi oogoqbbPpo bqbpsopqbe bbppobbopp bqobbqopbb poopob4b4q booPo400qb 0E
096 obeoqbb4bq boo44boeob eopepq4beo bebbebbboe pobeeepebe eopb4eegeo
006 bqbbPbbgbo abopbbqbop qbbqoppo4q bpoogbbebo poopbee5op oobebqboeb
08 b4bb4bbgbo bqbopoqbbp 540000pbbo ooqogpbqeo g000poebbp 20002'2220D
ogL 0000q4oq00 qqoqbpogbo opbbpobbqb qoppoopobp opobqboopo oobqbeboqb
qbqqb4eepo bobebqqbeo ebeepebb4b 50020280 bepoobeeoe ogebegboeu
ogg obqoopoeqo oPbp000pob boqqoppobp oog000bqbo opbqbbqbob eo5eo4cooq
009 02q0402558 o400q52opq oo4b405200 oqqoopopob gbobbobpoo pbqogobobb
prig poqopPbbqb oqbgbboPbq bbooppb000 oq4o2qo25b ppoqbbqoob qobbbqopob
0817 bobPoPobpb Pboo400205 25b2oo4obq opobobbqoo 000qqoqbbo -4P000555ee
ozfi, ooPoogoobe oqoo4oq5oo 2oq5540002 pbbbpoobbb b4opqoeb4q qqoo455oT4 oz
ogE opoqbbpbbp bPbobqbqop 44pqbq54ob bopopbbebo ObP62b4D0b 2OPPb4P28D
opE bqoqqqb4ob 0202e52800 44PP025252 0340;2O28O qqpboobbbp pbgbooqopb
OD'Z pobqPqopqp PP4epp5pp5 b4pbqPqbbq pq-eqqbpobb qbbbqbPbbq obbbbppobb
081 pooqobbpoo boo4E55qo2 o5qpo55428 obpgbpoqqo opoggebbqo qbobpqb-abq
ozT oo4oqo252b 4opoqbb2b5 540052004b bqbobbebbb bb4oq525b4 bbqobeobqb
og bpoqbqbpoo qbqbbpbee; .44qoqob.445 oqoogmbb bgobebqobb bqqqbebbTe
LZ <00[7>
suaTdps omoH <ETz>
VNU <ZTZ> OT
Z6E1 <TTZ>
LZ <OTZ>
OET
bay oad aAL aqd usy
SZT OZT 011
usy naq naq 9A3 TPA TPA I9S 2TV al-II ATO Jag sArl naq LIT9 nT9 dsV
1O-Z0-800Z STZ9SEZO VD

09
Z6ET e6
4Pee4bbboo
HET 404.640o040 ;oobebeebp o50p0pqopo 0uP0205404 obbP.54.2064 P546004054
OZET Po4o4;o4bo ppbbbbpobe obbqbbpobp beepetbqbp 3eo4o5pPo5 eopqoq3044
09ZT 3qqop4obbo pboo4oPE64 3bqpooD400 poppoebpeo P4OPPOPPbP bboobPobbb
00zi TePob-e5Pbb 645.2664600 .6o4p0e505e 0o00e40440 bbEeP04654 pob40oP540
017TT 0.6Po455p00 epbs-200-ebo, pb-286-2565o 004e00000b ;000E0-2;64 bbp0P00P25

0801 e600po5e0b bbeeeopeep epo404-eooe eeebebo4e0 opoobe0004 oobbeeepee
OZOT Do434.6bppo b4E.ppopT6p bfrepobboee bqobb4pe65 poppo54.644 5oopo4=4b
096 06p04.65414
5004.4.60p0b popp044.6e0 6-266.265.50e 00beep0p6e e00b4pege0 os
006 6465e56460 650e554b0e 4.6.640upo44 be004b5pb0 opos62eboe opEceb460e5
0f78 6465456450 54b0e046.6p 540000p5b0 0o404p54E0 4000P0Pbbe PDOOPPeE00
08L 0003443qop 44046poq5p opE6pobb45 qooPoopobp opob4booPo pob4b-eboql.
OZL 4.644b4pepo bobPbqqbeo pbeepe5b4b bPPODPOPPO b2000.6PP3P 04P5Pqb0PP
099 06400eoe4o op5p0oopo5 63440epo5e 004o0ob4.60 0p541641505 PobP040004
009 0e4040pbbp 0400;6E0E4 004640beoo 04400e0u0b 450.65obeop p64040bo55
ops ep4peebb4b 0464bboeb4 bbopeeboDo o44op4oebb eeo;b64o0b 4obbbqopob
08p boEcepEobPb pbooqopeob pbbeop4o54 opobabb400 poo44a4bbo 4eopo5b5PP
On' poepo4pobp oqopqogboo 204654030p abbbp0ob66 64oP40p644 40e4466540
092 .640e65005E,
5e5o.64640e 44e4b454o5 50e0e55eb0 06p5p.64006 epupb4eeeo of7
00E 640245405 peo2e6eppo 442p0p5e5p 00404e00e0 44s6o06bbe e6050040e6
Of/Z P054p4opop pe4epobpPb 5qp6.4-24.654 p4e44beobb qbb5qbE.b.64 obbbbeeobb
08T eoo4p65pop booqbbbqop obqpa65qe4 qbegbeoqqo Dep4qpbbqo g5obuoe454
0zT 004340P6pb 4o00456pb5 54006E6046 645ob5e555 654046E1)64 b54ob-eo5gb
09 bPo454be0o 454.66-ebppg 4440405;45 040044;466 6405E54066 5444bp664E,
OE <0017>
suaTdes owoH <ETZ>
VNG <ZTZ>
Z6ET <TTZ> OE
OE <OTZ>
6817 5e0e40045
08p 4obeopo44o opopobgbob bobpoop640 qpbobbpogo eebb45p4b4 55opb4bboo
on, peboopoqqo P4oe5Ecepo4 5bqopb4o68 bqppobbobe opobpbeboo 400pobe55P
092 0040540006 05.5.4000004 40466042 o 0.6.66e-e00e0 04=5-20400 404bo0P045
00E 640o0Ppbbb poo555640e 40e6-440p00 b66b4op000 0M4ficebeb0 .54540P44p4
ciD,z .64.64o660p0 a66pb00be6 eb400bpopp .64eepob444 p454obopbp P6ppopq4pe
08T aebpbPoo4o qsoppo44eb pob55Pp545 poqopbEob4 P4oP6ppeqp epbePbb4pb
ozT 4P455Te-Teg 45Pobb4b5b 45p.554a6.65 bppo55Poo4 066eo06004 65640-20042
09 0.6.64p045e4 6po4400-204 4p66404.505 P064.640040 40.25p54000 455.2666400
6Z <00[7>
suaTdPs owoH <ETZ>
VNU <ZTZ>
6817 <TTZ>
6Z <OTZ>
OT
S6E1 E,64eu
e4.65600404.
08E1 b40004o40o 6-ebppbe06o POPq0PDOPP 0P0.64040bb P.64-2064254 53040b4p04
OZET 04404b0ppb bbbp05P0b5 46.6e0bEtee 0P5545opeo 4o5epobpop 4343044 4;
091 004obbopbo 340664064 p000430?0e 00e6ee0p40 ppoPubpbb0 05-B3E5542e
oozT a5p6p5.564b 554500.5o; 02606p000 0p4044055p up04164005 400u6-40o5p
OPTT 04.65popee5 eppoe.64a6p bbp.66.60004 2000oo5qo0 oe0e4b45bp peopeebebo
0801 opobPobbbe EPODUPPPOO 404EDOPPPP bcebo4poppo o5eopp4opb bppeopupo4
OZOT oqbbesobqb esopqbebbe sobbaepb4.0 5540e55E00 e0b4b44.600 s0400460.5.e
096 0465454600 4450E0beop p0446.205e6 6p6bbo-2006 UPPOPbePOO 64-ep4p054b
ZZ
1O-Z0-800Z STZ9SEZO VD

CA 02356215 2008-02-01
23
<210> 31
<211> 507
<212> DNA
<213> hom*o sapiens
<400> 31
ggcgtggtcc agcctgggag gtccctgaga ctctcctgtg cagcgtctgg attcaccttc 60
agtagctatg gcatgcactg ggtccgccag gctccaggca aggggctgga gtgggtggca 120
gttatatggt atgatggaag taataaatac tatgcagact ccgtgaaggg ccgattcacc 180
atctccagag acaattccaa gaacacgctg tatctgcaaa tgaacagcct gagagccgag 240
gacacggctg tgtattactg tgcgagaggg gcccgtataa taaccccttg tatggacgtc 300
tggggccaag ggaccacggt caccgtctcc tcagcctcca ccaagggccc atcggtcttc 360
cccctggcgc cctgctccag gagcacctcc gagagcacag cggccctggg ctgcctggtc 420
aaggactact tccccgaacc ggtgacggtg tcgtggaact caggcgctct gaccagcggc 480
gtgcacacct tcccagctgt cctacag 507
<210> 32
<211> 501
<212> DNA
<213> hom*o sapiens
<400> 32
ggcgtggtcc agcctgggag gtccctgaga ctctcctgtg tagcgtctgg attcatcttc 60
agtagtcatg gcatccactg ggtccgccag gctccaggca aggggctgga gtgggtggca 120
gttatatggt atgatggaag aaataaagac tatgcagact ccgtgaaggg ccgattcacc 180
atctccagag acaattccaa gaacacgctg tatttgcaaa tgaacagcct gagagccgag 240
gacacggctg tgtattactg tgcgagagtg gccccactgg ggccacttga ctactggggc 300
cagggaaccc tggtcaccgt ctcctcagcc tccaccaagg gcccatcggt cttccccctg 360
gcgccctgct ccaggagcac ctccgagagc acagcggccc tgggctgcct ggtcaaggac 420
tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg ctctgaccag cggcgtgcac 480
accttcccag ctgtcctaca g 501
<210> 33
<211> 516
<212> DNA
<213> hom*o sapiens
<400> 33
tcgggcccag gactggtgaa gccttcacag atcctgtccc tcacctgcac tgtctctggt 60
ggctccatca gcagtggtgg tcactactgg agctggatcc gccagcaccc agggaagggc 120
ctggagtgga ttgggtacat ctattacatt gggaacacct actacaaccc gtccctcaag 180
agtcgagtta ccatatcagt agacacgtct aagaaccagt tctccctgaa gctgagctct 240
gtgactgccg cggacacggc cgtgtattat tgtgcgagag atagtgggga ctactacggt 300
atagacgtct ggggccaagg gaccacggtc accgtctcct cagcttccac caagggccca 360
tccgtcttcc ccctggcgcc ctgctccagg agcacctccg agagcacagc cgccctgggc 420
tgcctggtca aggactactt ccccgaaccg gtgacggtgt cgtggaactc aggcgccctg 480
accagcggcg tgcacacctt cccggctgtc ctacaa 516
<210> 34
<211> 459
<212> DNA
<213> hom*o sapiens
<400> 34
cctgggaggt ccctgagact ctcctgtgca gcgtctggat tcaccttcag tagtcatggc 60
atccactggg tccgccaggc tccaggcaag gggctggagt gggtggcagt tatatggtat 120
gatggaagaa ataaagacta tgcagactcc gtgaagggcc gattcaccat ctccagagac 180

CA 02356215 2008-02-01
24
aattccaaga acacgctgta tttgcaaatg aacagcctga gagccgagga cacggctgtg 240
tattactgtg cgagagtggc cccactgggg ccacttgact actggggcca gggaaccctg 300
gtcaccgtct cctcagcctc caccaagggc ccatcggtct tccccctggc gccctgctcc 360
aggagcacct ccgagagcac agcggccctg ggctgcctgg tcaaggacta cttccccgaa 420
ccggtgacgg tgtcgtggaa ctcaggcgct ctgaccagc 459
<210> 35
<211> 503
<212> DNA
<213> hom*o sapiens
<400> 35
ggcgtggtcc agcctgggag gtccctgaga ctctcctgtg cagcgtctgg attcaccttc 60
agtagctatg gcatgcactg ggtccgccag gctccaggca aggggctgga gtgggtggca 120
gttatatggt atgatggaag taataaatac tatgcagact ccgtgaaggg ccgattcacc 180
atctccagag acaattccaa gaacacgctg tatctgcaaa tgaacagcct gagagccgag 240
gacacggctg tgtattactg tgcgagagat ccgaggggag ctacccttta ctactactac 300
taccggtkgg acgtctgggg ccaagggacc acggtcaccg tctcctcagc ctccaccaag 360
ggcccatcgg tcttccccct ggcgccctgc tccaggagca cctccgagag cacagcggcc 420
ctgggctgcc tggtcaagga ctacttcccc gaaccggtga cggtgtcgtg gaactcaggc 480
gctctgacca gcggcgtgca cac 503
<210> 36
<211> 451
<212> DNA
<213> hom*o sapiens
<400> 36
ggcgtggtcc agcctgggag gtccctgaga ctctcctgtg cagcgtctgg attcaccttc 60
agtagctatg gcatgcactg ggtccgccag gctccaggca aggggctgga gtgggtggca 120
gttatatggt atgatggaag tcataaatac tatgcagact ccgtgaaggg ccgattcacc 180
atctccagag acaattccaa gaacacgctg tatctgcaaa tgaacagcct gagagccgag 240
gacacggctg tgtattactg tgcgagaggc gctgtagtag taccagctgc tatggacgtc 300
tggggccaag ggaccacggt caccgtctcc tcagcctcca ccaagggccc atcggtcttc 360
cccctggcgc cctgctccag gagcacctcc gagagcacag cggccctggg ctgcctggtc 420
aaggactact tccccgaacc ggtgacggtg t 451
<210> 37
<211> 438
<212> DNA
<213> hom*o sapiens
<220>
<221> modified base
<222> (64)
<223> a, c, t, g, other or unknown
<400> 37
gtggtccagc ctgggaggtc cctgagactc tcctgtgcag cgtctggatt caccttcagt 60
agcngtggca tgcactgggt ccgccaggct ccaggcaagg ggctggagtg ggtggcagtt 120
atatggtctg atggaagtca taaatactat gcagactccg tgaagggccg attcaccatc 180
tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac 240
acggctgtgt attactgtgc gagaggaact atgatagtag tgggtaccct tgactactgg 300
ggccagggaa ccctggtcac cgtctcctca gcctccacca agggcccatc ggtcttcccc 360
ctggcgccct gctccaggag cacctccgag agcacagcgg ccctgggctg cctggtcaag 420
gactacttcc ccgaaccg 438

CA 02356215 2008-02-01
<210> 38
<211> 562
<212> DNA
<213> hom*o sapiens
<400> 38
tcctgtgcag cgtctggatt caccttcagt tactatggcg tctgggggag gcgtggtcca 60
gcctgggagg tccctgagac tctcctgtgc agcgtctgga ttcaccttca gtagctatgg 120
cgtgcactgg gtccgccagg ctccaggcaa ggggctggag tgggtggcag ttatatggta 180
10 tgatggaagt aataaatact atgcagactc cgtgaagggc cgattcacca tctccagaga 240
caattccaag agcacgctgt atctgcaaat gaacagcctg agagccgagg acacggctgt 300
gtattattgt gcgagagact cgtattacga tttttggagt ggtcggggcg gtatggacgt 360
ctggggccaa gggaccacgg tcaccgtctc ctcagcctcc accaagggcc catcggtctt 420
ccccctggcg ccctgctcca ggagcacctc cgagagcaca gcggccctgg gctgcctggt 480
caaggactac ttccccgaac cggtgacggt gtcgtggaac tcaggcgctc tgaccagcgg 540
cgtgcacacc ttcccagctg tc 562
<210> 39
20 <211> 490
<212> DNA
<213> hom*o sapiens
<400> 39
gtccagcctg ggaggtccct gagactctcc tgtgcagcgt ctggattcac cttcagtaac 60
tatgccatgc actgggtccg ccaggctcca ggcaaggggc tggagtgggt ggtagttatt 120
tggcatgatg gaaataataa atactatgca gagtccgtga agggccgatt caccatctcc 180
agagacaatt ccaagaacac gctgtatctg caaatgaaca gcctgagagc cgaggacacg 240
gctgtatatt actgtgcgag agatcagggc actggctggt acggaggctt tgacttctgg 300
ggccagggaa ccctggtcac cgtctcctca gcctccacca agggcccatc ggtcttcccc 360
ctggcgccct gctccaggag cacctccgag agcacagcgg ccctgggctg cctggtcaag 420
gactacttcc ccgaaccggt gacggtgtcg tggaactcag gcgctctgac cagcggcgtg 480
cacaccttcc 490
<210> 40
<211> 708
<212> DNA
<213> hom*o sapiens
<400> 40
atggaaaccc cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccgga 60
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 120
ctctcctgca gggccagtca gagtattagc agcagcttct tagcctggta ccagcagaga 180
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 240
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag 300
cctgaagatt ttgcagtgta ttactgtcag cagtatggta cctcaccctg gacgttcggc 360
caagggacca aggtggaaat caaacgaact gtggctgcac catctgtctt catcttcccg 420
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 540
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 600
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 660
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttag 708
<210> 41
<211> 702
<212> DNA
<213> hom*o sapiens

017Z 40Pe3b4444 PbPPb4op4p 04404bPOPP 04e00E0404 OP0444PPED ebbb4pqobb 09
081 4bpob54600 q455p800rpo op4bbb54bp PPobq444Po oqpoP4obqo go4Pb43oqq.
OZT oe24pooDbu Pubbbpoppp ebpabpo4p4 bb444ppg44 p4opPoPPg4 pobpbeDqbe
09 Pobbboobqq opoqpoopog bpbpopbpbb P4b4oTeob4 oqb4poo4op qPoo.4345po
1717 <0017>
suaTdps owoH <ETZ>
VNG <ZTZ>
eSt <FEZ>
Pf7 <OTZ>
OS
SOL
bp4.4b 45Pbpbbbbp oppoggobpb PPeopo4boo obo43bebqo
099 ob6bpo4pop opogbPsBob gooboP4oqb PPUDPOPPEt ebopqopbeo bPPpobpbqo
009 boubgoopPo bpobeogoob popqoopobp oebbeppbeo pbbppbubpo poqbgbPbeb
of,s
5Popp4oppq bbbo4ppooq oopbopeqpb 54bbPpbb4b PDP4bPPPOO bbpbebpoop
0817 qe404;Deeq Pe5qob4pob qb4b4q5q04 pobqoPebb4 oqppebqq.bs obe54pb4o4
pooboopqqo gpoq4o45qo 4pDopob4ob b454opp6os peo4pqebbo, beppopebbb
09E q3o3bbo4q4 0Poq4eoppo goqeqbbqp4 beobeoqbqo eqqp4bqbe3 b444gebeeb
00E qopbpbbqop 5pobPo4poo pD4oqopo4q Debpoeb5b4 oqbbbqbpob bqbpo4.4bbp
017Z 0Pbupoo4Po bbqoPpobbb po5pooqP4b q5bqPqp4Po 4oppobbPoo oqobbPoobb 13
081 40OPPP5232 popp4bb433 5p4qoPqobe 3begmb4bPp po4beopb5b eqb4po4pqo
OZT opPoobpbpp ebbbbpooqo qbqqqp4bqo oppobbpopq oqbeoboeb4 qb4b44Pee5
og pbbooppopq ebPoopqabb go4oegob4o oqopqqp4pq qobpobobpo DoopPPbbqp
EP <0017>
suaTdps owoH <ET>
VNQ <ZTZ>
SOL <TTZ>
E17 <OTZ>
OE
LT17
bPopqbP ppoobbpbeb popoqeqogq oppqppb4ob goob45qbqq. bgogoobqop
ogE ebbqo4pppb gq.bPobpbqp bgo4poobo3 o4goqp044o qb4o4poopo b4obbgbqop
00E pbobsso4eq pbbqbeppoo pbbbqpoobb o44qopo4Te oppoqbbeqb bqpqbpobpa
q6qop4qpqb qbeob.444qp 55pbqopbeb bqopbpobpo geoppoqoqo poqqopbpop
081 bbbqp4bbbq bpob54bpoq 455poebpoo o4pobbq3po obbbpobpoo gpobgbbqP;
OZT ogPo4op4oP bppoogobbp pobbgooppp bpobpoop4b b4005Pqqop qabeobpoql,
og qbpbpoqbPo obbbeob4= 4o400ppoob Pbpppbbbbp po4pqbqqqo qbqopopobb
<0017>
suaTdps owoH < gTZ>
VNQ <ZTZ>
LT17 <TTZ>
ZT7 <OTZ>
ZOL be
4gb4bpbp6b bbpoppoqqo bPbpppoPo4 b000boqobp
ogg bqoobbbpoq poopeogbpp bobqopbopq 045PP2OPDP Pa5PEOP4OP .5E0.6PPPOb?
009 bqobos,5goo oppbuablpoq opbepeqcoe obpDpbbp23 beopbbpobe 52peo4bqbp
017s bPbbpopoqo ppqbbboqep pogoopbopp qpbbqbbppb bqbpopqbpp poobbPbPbp OT
08f7 pooqpqp4qp .2.2.4e254Dbq cobqb35.445 qogoob4opp bbqp4-eup6-4 qbeobebqpb
OZf, 404PoobDo3 4434P03404 bqoquooPa5 qpb.64.6qopE, bobppoq252 bbqbb2pooP
ogE bbbpbbobbo q4qoPo4qoo oPoqoqpobb qpq5eobeo4 bqoP4-4p4D4 bPobqqqq_Pb
00E 2pbqopbebb qoPbeobpoq popeoqoqoe oqqopbpoe6 5640.46554E1 pobb4.6p34-4
ofqz bbpopb2opo qpobbqopoo fabpobpopq Pob4bbqPqo qPogooqobb popogobbPo
081 obbqoopppb ppbPoopqbb 4pobp.1.4opq qbeobeobp4 qbqbpopubb pob43ogo4o
ozi oppop5pbee pb66beoDqD qbqqqp.4543 op.eabbeop4 oq6pcboe5q. qb.454qeep5
og pbbooppopq pbeopogobb go43-243.64o oqop44oqoq qp5p3bob-23 opoppebbqp
TDµ <OOP>
;
9Z
1O-Z0-800Z STZ9SEZO VD

CA 02356215 2008-02-01
27
tactactgtc aacagagtta cagtacccca ttcactttcg gccctgggac caaagtggat 300 .
atcaaacgaa ctgtggctgc accatctgtc ttcatcttcc cgccatctga tgagcagttg 360-
aaatctggaa ctgcctctgt tgtgtgcctg ctgaataact tctatcccag agaggccaaa 420
gtacagtgga aggtggataa cgccctccaa tcgggtaa 458
<210> 45
<211> 426
<212> DNA
<213> hom*o sapiens
<400> 45
tctccaggca ccctgtcttt gtctccaggg gaaagagcca ccctctcctg cagggccagt 60
cagagtatta gcagcaattt cttagcctgg taccagcaga aacctggcca ggctcccagg 120
ctcctcatct atcgtccatc cagcagggcc actggcatcc cagacagttt cagtggcagt 180
gggtctggga cagacttcac tctcaccatc agcagactgg agcctgagga ttttgcatta 240
tattactgtc agcagtatgg tacgtcacca ttcactttcg gccctgggac caaagtggat 300
atcaagcgaa ctgtggctgc accatctgtc ttcatcttcc cgccatctga tgagcagttg 360
aaatctggaa ctgcctctgt tgtgtgcctg ctgaataact tctatcccag agaggccaaa 420
gtacag 426
<210> 46
<211> 465
<212> DNA
<213> hom*o sapiens
<400> 46
tctccagact ttcagtctgt gactccaaag gagaaagtca ccatcacctg ccgggccagt 60
cagagcattg gtagtagctt acattggtat cagcagaaac cagatcagtc tccaaagctc 120
ctcatcaagt atgcttccca gtccttctct ggggtcccct cgaggttcag tggcagtgga 180
tctgggacag atttcaccct caccatcaat agcctggaag ctgaagatgc tgcaacgtat 240
tactgtcatc agagtagtag tttaccgctc actttcggcg gagggaccaa ggtggagatc 300
aaacgaactg tggctgcacc atctgtcttc atcttcccgc catctgatga gcagttgaaa 360
tctggaactg cctctgttgt gtgcctgctg aataacttct atcccagaga ggccaaagta 420
cagtggaagg tggataacgc cctccaatcg ggtaactccc aggag 465
<210> 47
<211> 440
<212> DNA
<213> hom*o sapiens
<400> 47
cagtctccag gcaccctgtc tttgtctcca ggggaaagag ccaccctctc ctgcagggcc 60
agtcagagtg tcagcagcta cttagcctgg taccagcaga aacctggcca ggctcccagg 120
ctcctcatct atggtgcatc cagcagggcc actggcatcc cagacaggtt cagtggcagt 180
gggtctggga cagacttcac tctcaccatc agcagactgg agcctgagga ttttgcagtg 240
tattactgtc aacagtatgg taggtcacca ttcactttcg gccctgggac caaagtagat 300
atcaagcgaa ctgtggctgc accatctgtc ttcatcttcc cgccatctga tgagcagttg 360
aaatctggaa ctgcctctgt tgtgtgcctg ctgaataact tctatcccag agaggccaaa 420
gtacagtgga aaggtggata 440
<210> 48
<211> 417
<212> DNA
<213> hom*o sapiens

CA 02356215 2008-02-01
28
<400> 48
ccatcctccc tgtctgcatc tgtaggagac agagtcacca tcacttgccg ggcaagtcag 60
agcattaaca gctatttaga ttggtatcag cagaaaccag ggaaagcccc taaactcctg 120
atctatgctg catccagttt gcaaagtggg gtcccatcaa ggttcagtgg cagtggatct 180
gggacagatt tcactctcac catcagcagt ctgcaacctg aagattttgc aacttactac 240
tgtcaacagt attacagtac tccattcact ttcggccctg ggaccaaagt ggaaatcaaa 300
cgaactgtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct 360
ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagta 417
<210> 49
<211> 402
<212> DNA
<213> hom*o sapiens
<220>
<221> modified base
<222> (207)
<223> a, c, t, g, other or unknown
<400> 49
acccagtctc catcctccct gtctgcatct gtaggagaca gagtcaccat cacttgccgg 60
gcaagtcaga acattagcag gtatttaaat tggtatcaac agaaaccagg gaaagcccct 120
aagttcctga tctatgttgc atctattttg caaagtgggg tcccatcagg gttcagtgcc 180
agtggatctg ggccagattt cactctnacc atcagcagtc tgcaacctga agattttgca 240
acttactact gtcaacagag ttacagtacc ccattcactt tcggccctgg gaccaaagtg 300
gatatcaaac gaactgtggc tgcaccatct gtcttcatct tcccgccatc tgatgagcag 360
ttgaaatctg gaactgcctc tgttgtgtgc ctgctgaata an 402
<210> 50
<211> 451
<212> DNA
<213> hom*o sapiens
<400> 50
acccagtctc catcctccct gtctgcatct gtaggagaca gagtcaccat cacttgccgg 60
gcaagtcaga gcatttgcaa ctatttaaat tggtatcagc agaaaccagg aaaagcccct 120
agggtcctga tctatgctgc atccagtttg caaggtgggg tcccgtcaag gttcagtggc 180
agtggatctg ggacagattg cactctcacc atcagcagtc tgcaacctga agattttgca 240
acttactact gtcaacagag ttacactacc ccattcactt tcggccctgg gaccagagtg 300
gatatcgaac gaactgtggc tgcaccatct gtcttcatct tcccgccatc tgatgagcag 360
ttgaaatctg gaactgcctc tgttgtgtgc ctgctgaata acttctatcc cagagaggcc 420
aaagtacagt ggaaggtgga taacgcctat t 451
<210> 51
<211> 419
<212> DNA
<213> hom*o sapiens
<400> 51
ccactctccc tgcccgtcac ccttggacag ccggcctcca tctcctgcag gtctagtcaa 60
agcctcgtat acagtgatgg aaacacctac ttgaattggt ttcagcagag gccaggccaa 120
tctccaaggc gcctaattta taaggtttct aactgggact ctggggtccc agacagattc 180
agcggcagtg ggtcaggcac tgatttcaca ctgaaaatca gcagggtgga ggctgaggat 240
gttggggttt attactgcat gcaaggttca cactggcctc cgacgttCgg ccaagggacc 300
aaggtggaaa tcaaacgaac tgtggctgca ccatctgtct tcatcttccc gccatctgat 360
gagcagttga aatctggaac tgcctctgtt gtgtgcctgc tgaataactt ctatcccac 419

Doeobe4obe 040340450o eo45.64Dooe 2E55E00656 64oe4oeb44, 44DD4b5o44 09
09E Deogbbebbe 5E5054540E 4-4E4545405 boeoubbebo 3bebeb400b POPPb4PPPO
00E 540444b405 DEDEE5EE00 44EEDe5e5e Do4o4EDDED 44eboobbbe Eb4bDoqoeb
017z eob4u4o24E 2.24Eeebeeb b4e54e4b54 e4e44beob5 4bbbq5ebb4 obbbbeeobb
081 eDo4obbeD3 50D45bb4De ob4eobb4eo 3be4beD44o oeD44Eb54o 4bobe4b4b4
OZT =4 40E5E5 400D455e5b bgpabeoD4B b4bobbebbb bb4o4bEbb4 bb4obeob4b
09 beD4b4bepo 45485E5-2E4 444D4D544b D4=444.455 b4obeb4ob5 64445ebb4e
17S <0017>
suaTcles owoH <61>
VNO <ZTZ> OS
6661 <TTZ>
f7S <OTZ>
Z6E1 eb
4eee4bbboo
08E1 40454DoD4o 4Dobebeube oboeoegoED DEEDeob4o4 obbub4ED54 eb4boo4D54
HET ED-4344 45o eebbbbeobe obb4bbeDbe beeoebb4bo Deo4obeeob 2324D4Do44
09Z1 044DD4Dbbo eboo4oeBB4 ob4Epoo400 eopooebEED EgDeepee52 bboobEobbb
0OZT 4PED5Ebeb5 b4bebb4BoD bo4EDEbobE DoDoe4o440 bbeeeo4b54 Do54DoE54o
Of7TT obe34bbeoo upbEe3D-264 Ebebbe556o oD4EDDDDD5 4 33E0E454 bbeoeopeEb
0801 eb000DbEob bbPPPOOPPP '200404'20OP EPPbPbOTED 0000bP0004 DOMPPPOPP
ONT Do4o4a6eeo b4bueoe4bE bbEeD55Dee 54D5b4DEb5 eDoeob4b4-4 boDeogoogb
096 DbeD4b5454 boo445DEob EDeED44beo bebbebbboe 30BPPPDEbP P0054PP4P0
006 54b6ebb4bo bboebb4boe 4b54DeeD44 bEDD4bbe6o ooDebEuboe Dobeb4boE5
0f78 54654554bo 5gboe3455-2 b4oDooEbbo Do4o4eb4ED 4Dopeoebbe POOOPPPPOO
08L opoo44oqoo -44o4beo45o DEbbuobb4b 4opEopeobe 000b4boDED Dob46ebo4b
4.64453,2-2ED bo6e644Beo ebEEDEbb4b 6PPODPOPPO beDoobeeoe oTebe46oee
099 D.54DDEDe4o 3P6P000Pab b04402POEIP oo4Doobq5D Deb4b545D5 eabeo40004
009 DE4D4Deb6e o4Do4beDe4 Do454obeDD 044DoeDeob 45obbobeDo eb4o4obobb
017g ED4oee6b45 D4b4bboub4 bboopeb000 044De4oebb EED4bb400b 4obbb4Doob 0E
08D, bobEDEobEb eboo4opeob Ebbeop4obq opobobb4Do 3=443455D TEDDobbbee
DoeDD400be o4Dogo4boo e0455400DE EbbbeDobbb 54DE4Deb.44 44Do4bbD44
096 0e04b6ebbE bebob4b4oe 4424b4bgob boeoebbebo Dbebeb400b EDEEbTeeeo
006 b4o444b4ob OPOPPbPPOO 44PP0252b2 03434PDOPD 44Eboo66bE Eb4boo4Deb
of7z EDb4e4oE4E PE422PE,PP5 b4Pb4P4bb4 e4e44bEabb 455645E5b4 obbbbeeobb
081 eoo4obbEDD boo4b554DE ob4eobb4eo obe4bED44D Deo44E554D 4536245454
OZT Do4o4oe5E5 4=45bebb bi.00bEDD4b 64bobbebbb bb4o4be554 554obED545
09 beo4b4bEDD 4b465e6ee4 444D4Db44b o4Do4444bb 5406-Eb4obb b44462554E
ES <0017>
suaTdes owoH <EU>
VNO
Z6E1 <TTZ>
ES <OTZ>
61D. 4EDD44-23-2 45EEE00bbe lebuoDo4e4 044DEE4Eeb 4ob400b4b4 b4-454o4Dob
0964opebb4D4e eeb445ED5E 54e54o4EDD boo -44o4b4o4ED DED54obb4b
006 40ee5Deeeo 4ebe554.55e 200e6b5256 D55D4m4Deo 4o4Do4DEEE De4D4obEeD
N'z 64E3540E44 e444555b44 54-255254ob bebb4bEbED beo4DEEE54 Deo-24444E5 0T
081 epeobbED4E 5b4beobbqb eD4455eopb 4Doo4bbbbo D4Dobbbo4E E4D44b554-4
4E4D4-2b4Do 4obeDeop4o qbeDebbeoD beebeob400 245544ebb4 44E40e-2o-24
09 EbbTee4be4 23.540343ot) ebeo4bE4o4 bbED544D4o 4EDD44Db5o Dbebebb400
ZS <0017>
sue-Tdes owoH <61>
VNG <7T7>
6TV <TTZ>
<OTZ>
;
1O-Z0-800Z STZ9SEZO VD

09
Z6ET Pb ;Pep-
4555pp
08ET 4o454=o4o 4pobpbeebp OBOPOP4OPO OPPDP05404 055P64P0b4 pb4boo4o54
OZET po4o44p4bo PPbbbbeobp obb4bbppbp 5ppopbb4bo oPo4obppob pop4o4=44
09z1 P-44=4obbo eboo4opbb4 ob4p3pp400 POPOOPE,PPO P4OPPOPPbP bboobpobbb
00ZT 4ePobPbebb .54bpbb4boo 504-pop5o5p poopp4o44p bbeepp4bb4 Pob4poP540
OvET obeo45.5poo ppfrepooe54 ebp66p555o oo4P000=5 4000Poe4b4 bb-poepoesb
0801 pboopobpob berePpooePe P00404POOP eppbpbo4pp P000bPoop4 opbbeppope
OZOT oo434b6eeo b4beepe4be bbepobbope b4obb4pebb Poopob4b44 boopo4=45
096 obPo4b6464 boo44boppb pepop445po bubbpbbbp-e 00bPPPOPbP poo.54-e-e4Po
006 5455-25545o 55 555
4554oppo44 5poo455p5o opopEppbop oobpb4Boeb os
0{78 64E645545o 5450pp-465p 54opoop5bo po4o4p.b4po gooppopbbp p000Peeepo
08L Poop4404= 44o4beo4bp opbbeo5545 4popoppo5e opob4boo-eo Po54bPbo45
OZL 4b44b4Pppo bobpb44bPo pb-ep3e6545 bppopeoppo beopo5PPop p4pb-e4bope
099 obqoopopqo opbppoopob boqqoppobe ppqopobqbp op545b4bob Pobpo4=o4
009 oP4o4opbbP 34=4bpoP4 po454o5poo 044oppopob 45obbobpoo P54o4obob5
0D,s Po4opp5545 045455op54 bbooppb000 o-4-4op4op55 peo4554op5 4obbb4opo5
0817 bobpopobpb pboo4oppob pbbpoo4o.b4 oppbobb4= opp44345bo 4p3oobbbee
On?. 33P3p4p3bp o4=4o4boo po4.554poop pbbbpoobbb b4op4oPb44 44=4bbo44
096 55D55
bp5o54.64op 44-e45454o5 bopopbbpbo o5p5P54005 eoppb4-epso
00E 54044454Pb opoepbppoo 44ppopbebP op4o4poopo 44pboo555p 254boo4oeb of/
017z pob4p4op42 2P4P2a6225 542E4-24554 p4p44beobb 4.5554bubb4 obbbbpPobb
081 pop4ob5po3 boo4b5b4op ob4pobb4po obp4beo44o opp44p554o 4b3bp4b4b4
OZT oo434oe5u5 4pooqbbe55 543o5eop45 5gbo55ebbb 5.54og5e664 55-4obuo545
09 5P34545pp3 4545bpbpp4 444p4o5445 o4=4444bb b4o5Pb4o55 5444b2b54P
SS <00f7>
suaTdps owoH
VNU <ZTZ>
Z661 <TTZ>
SS <OTZ> OE
6661
pb4Ppp4bb 5oo4o4b4=
0861 o4o4pob2bP E'bP0b0POP4 OPOOPPOPOB 4o4o55pbqp o54p545=4 054pp-4044o
0Z61 45opp.55bbp o5pobb4b5p obe5pp3p55 45popo4p5P Po5pop4p4o o44344=40
0981 .6.6op5poqop bb4obqpoop 4DOPOPODP5 peop4pepop a5p55ppbpo bbb4PPo5eb
0081 pbbb4bPb54 boobompopb obep000p4o 44ob5pp2o4 b54=54opp 54po5Po455
012.L1 PODPP5PPOO eb4pbpbbe5 5b0004p000 03b4000PDP 45455EOPOO pebpb0000b
0891 23565pp-eg3 op454o4pop poob4b4pb3 opb45p6bb4 opob4p4opo popobbo4p5
0Z91 boo55p5pop 554Popoob5 5pb4p4bbbb ob3opp5bb4 bbppPoopPe pop4o4poop
09S1 ppp5p534Po opoobppoo4 DObbPPEOPP op4o455ppo 545ppop4bp bbepobbopp
00S1 54o554opbb poppo54b44 5oopogoo45 o5po455454 boo445opo5 popeo445po
01 bebbebbbop Pobppeopbe eopb4pp4po b4bbebb4bo 55oe5b4bop 4554oppo44
08E1 bp=45bpbo poopbppbop pobp545op5 54.5b4.5b4bo b45opo4bbe 54poopP55o
OZET oo4o4p54-po 4000P0P56P PODOPPP?00 0000 D00 443452345o oebbpobb4b
09z1 400p00p05p 04=4-40404 .2=4=-2=4 boPoe54ob4 5554obPoop o5bpopb562
Hz' po4pob4005 e45p5p4poo 5456Pop555 055peo4o5p op4opobp4o pbbpopobpo
017TT obpp4.55ppo 354533p000 545e504545 4454ppe0b0 bebeob4p4o 404404PPOO
0801 o4opp45pbo p4p5ppooqo 0404044=P oPbbp4obpo q00043Po04 54opppoo55
0z01 PPP0000E50 obpP400pb4 opoob4poos b.bpbbbop4p 4.2006PPPPO ob4oppbpo4 oT
096 ob544p54bb pobbbbpopo poPo44opo5 beopoop4= op545554o5 beopobbpob
006 bPop40bb-po opoo44444o E.b4p443455 bpbpbbbeo4 ob4pp4opoo pobopob4o4
08 opb5pbbo00 p34=404b4 o4p000pb5p obb-epobpob 55 boo
pobpob4540
08L bbopooPobo p554=540p goopbeo4o5 5uoo5pp5b4 ob4p4b4bbb ebbbpbbbpo
OZL 40bPo05bp5 pb45b445Po p5ppop5545 bPEDOPOPPD bP000.5PPOP o4pbe45opp
099 0b400pop4o oebeopoppb bp44oPpobp op4opob4bo opb4hb4bob Pab204D004
009 op4o4opbbe p4po4bpop4 o045406Poo 34430ppeob 4bob5obeop p5qp4obob5
0D.g poqoppbb4b p454bbopb4 bbooeeb000 344op4op5b Peo415b4005 435554=05
08P bobpopobeb pboogoopob ebbPoo4054 oppbo554= opp44p4bbo 4popobbbpp
OE
1O-Z0-800Z STZ9SEZO VD

ozT opPoobebPu ub.5.6.6uooqo 464qqoqbqo opeobbpoog o46-eobo-ebq .46.4.5.4-4PP-
eb 09
09 ebboDupouq PEceopoorobb qoqop4ob43 34poqq.D4oq. qobPobobuo oppeePbbTe
80 <0017>
suaTdes owoH <ETZ>
Val <ZTZ>
ZOL <FEZ>
80 <OTZ>
06E1 ebgee
pqbbboD4o4 og
HET b4pooqp-433 bebppbpobo eppgpepoep opobqoqDbb -2542o54254 boo4o6Tpoq
ozET oqi.o4boppb bbbpoBeobb 456pobebee opbbgboopo qobppobeop gogooggogg
ogzi oD4obboubo 040Pbbq0b4 P0004002DP 3DPbee0:240 PPOPPbeb50 ObPObbb4PE
oozi obp.bebbfq.b pbfq.booboq. popbobeopo opgoggobbp ppoqbbgoob goopbgpobe
ovri oqbbpopuub epoopbqebe bbebbb000q p000pobqop o2o2q5q.bbe apooeebebo
0801 opobeobbbp PPOOPPPPOO qoqeooeeee bpboqepooD obpopoqopb Ecepupeeooi.
OZOT oqbbpeobqb 22opqbebbe 2obboeebqo bbqoebbeop Pobqbqqboo Pogooqbobe
096 o4bb4.54boo ;m63'235-23E, poqqbeobpb fiebbboppob PPP325PPOO 54-e-eqeob4b
006 bubbqbobbo Pabgboegbb qopeoqqbpo oq65e5opoo pEcepboppob ubqboebbqb
0f78 64E6450646 opoqbbebqo opopbEcoDq ogebTpoqop opopbbpuop DEPPED0000 017
08L oqqoqooggo gbeogbooeb beobbqbqoo POOP062030 bgbooppoob gbpboqbg64
on, qbgeePobob Pbqqbeoebe epebbqbbep 00:202P0bP0 opbppopoqe begboepobq
099 opupuqopeb PopoeobLoq qoppobeopq opobgbooeb 4.6.6q.bobpo.6 poqopogoeq
009 ogopbbeogo ogbuopqopq bgobpopogq oppopobgbp bbobpopubq o4obobbpo4
0D's oppbbgbogb 4bbopbgbbo opp6oppogq opqoubbueo 456qop.6qp6 6.64poobbob
0817 uopobebPbc ogooPobpbb pooqobgoop bobbqop000 44346634e poBbbppope
ozi7 opqopbpDgo ogogbopPoq bbgpooue65 bepobbbbqo e4oebqq.goe gooqbEbbqo
09E ubebpbubbp bebobqbgoe qq.eq.5q6.43.6 boupebbpbo obebebqopb POPP64PPEO
opE bgoTegbgob OPOPPBPPOO 44PPOP.645P pogogeoppo qqeboobbbp pbgboogoeb
opz 2bbquqouou puquE4buub b4pfq.e.4554 pq.eqqbpobb gabbqbebbq obbbbepobb
081 Pop4ob6eo3 booqbbbqoe ob4eobb424 pueqbpoggo oPoqqebbqo qbobppegbq
OZT oogoqoe6P.E1 qopogbbEbb bqopbepogb bgbobbubbb bbqoqbebbq bbqpbeobgb
09 bpogbqBeop qbgbbpbepg -4443qobqqb p4opq-444bb bqobebqobb bqq4bebb4e.
LS <0017>
suaTdes owoH <ETZ>
VNO <ZTZ>
0601 <TTZ>
LS <OTZ>
()
80L bpqqbqbe
b2.6.555poep oggobpbeee opoqbpoobo gobpbqopbb
099 beoqepoo2o 4.6eubobi.co bDP404.6PPP oupeue6e6o eqoebpabpu po6eb4oboe
009 bqooppobpo buoqopbpop qoppobeopb bepoBeo2bb pobebuoppq bqbe52552o
of/s poqoepqbbb oquepoqopo boepqebbqb beebbqbeop 46peepobbp bebepopq2q
08p oqqoppTeub qobqopfq..Eq. 64gbqoqopb qopebbqoqu upbqq.bpobp bqpbqoqpoD
ozt7 b000g4o4po ggogb4o4Po peobqob64.5 40PrebOPPPO qpppbbgbbce poopbbbpeo
ogE ob6044Bop.6 bqoppeoqop 2.4664245e buo.4.6qop44 ugbgbpob.44 gq.p.6-2-
2.6goo
00E bebbqoebeo bpo4eoppoq. oqp-epqqopE, popbbbgogb bfq.bpobbqb poqq.b.buopb
017z epooqeobbq oppobbbeo6 pooqpobqbb Teqoqeo4Do qobtceopogo bbepobbqoo 01
081 2bpbpDbpoo e4.664pobpq goggobeobu obEggegbeb eogbpoobbb pob4pogogo
ozT poppobp.bpp ebbbbppoqo 4b4qq.ogbqo poeobbpopq oqbpoboubq qbqbqq.p2pb
09 ebboDpoopq ebeoppqabb 43q3e4o543 oqooqqoqoq qobpobobeo oppeeebbqe
9; <00f7>
suaTdps owoH <E-t>
VNU <ZTZ>
80L <TTZ>
90 <OTZ>
;
1O-Z0-800Z STZ9SEZO VD

009 boeb4op3eo bpobeoqopb eopqoppobe oebbepobeo ebbeobebeo eogbqbebe6 09
c÷,g beoop4oeeq 6.66ogeeopq 000boepqp5 6466pebbqb eos4beeeop 68e6e6epoo
08D, Tegoqqoeeq p.264054006 4bT64q64o4 Dobqopebbq ogppeb4qbp obebqebqpq
0z17 upoboopqqo qeo4go.4640 qpoopo64o.6 bmbqopebou ppoqeqeb8; 5ppeope585
09E 4o33bbo444 0e04qe3opo 4o4eq164p4 beobp34bqo p44e4bqbp3 644qqubepb
00E 400be664oe beo6poqeoo eoqoqopo44 oebeoebbbq o4bbbqbe3b Eqbeoqq6bp
Of7Z Debecooqeo 66qopoobbb eobepoqpqb qbbqegogeo qopoobbeoo o4obbpoob5
081 qoopppBeoe pooeq6b400 bpqqoeqa6p obeqqb4bee eo4bpoobbb egbqooqogo
OZT opeoo6pbee eb66bepoqo 464443q6qo 30P f233 o46poboeb4 qbqbqquppb
09 ebboopoopq pbpo334obb 4ogoe4ob4o oqoo44oqpq qobpobobeo poopeebb4p
09 <00f7> OS
suaTdes owoH <ETZ>
YNG <ZTZ>
GOL <TTZ>
09 <OTZ>
Z6E1 ub
4ppeqbbboo
HET qoq64opoqo qoo6pbeubp oboeoeqopo D2E0'205404 ObbPb4P054 p5i.booqob4
ozsT pogogqoqlo ep565beobe obbm66eo6e beeopb6qbo opoqobepob poe4oqoo4q. of7
09Z1 3gg3043b6o ebo3q3e6b4 ob4epoo400 eopooebeeo p4oeeopebe bboobeobbb
0OZT 4Peo6pbeb5 bqbebbT6op boqeoebobp opoop4oqqo bbppeogbbq oobq3op64o
N,TT abeoq.65epo eebeepoubq pbebbe6.66o op4epoopob q3poppeq64 66eoeopep6
0801 eboopobeob 66eppopeee P00404e0OS P5E504E0 oppobepooq oobbeeepee
OZOT oo4o4bbeeo 6gbepoeqbe bbeeobbopp b4ob6qopbb eoppobqbqg boopo400qb
096 obeo456gbq boo4gbopo6 eopeoq4beo bebbpb6b3u opbeppoebe poobqee4eo
006 bqbbpb6qbo b6Dpbbqbop 4bbqoupp44 bepo4bbe6o oppebeeboe pobebgboeb
0,9 6466455-45o 5gbpeo46.6p 5qopoop660 ooqo4pb4eo qoppeopbbe popopeuppo
08L 030044o-43o q4o45eoq6o debbeD6546 goopoopobe poo.64boopo pobqbebo4b
OZL 4b4454eepo bobpbqqbeo pbep3e66q6 bPPOOPOPPO beopobeeoe oqebeqbopp 0E
099 obqoopoeqo oebp000pob bo4qopeobe ooqopobqbo op646bqb3b pobeoqopo4
009 op4o4oebbe ogoo4bepeg ooq5.435poo oqgooppeob q6obbobeo3 25434obobb
of7g eoqoppbbqb o464bEopb4 bboopp5poo oq4opqoe66 eepq6bqoob gobbbqoop5
08fi ba6popobeb pbooqDoeob ebbepo4o54 poobobbqoo opo44oVibp qe000bbbep
0z17 oopoo400be o400qoqboo poqbbqopop ebbbpoobbb bqop4opb44 goeqqb664o
09E. Bqoebboobe bp6o6qbqop q4eq6q64o6 boppe65e6o o6p5p6qoob popebqeeep
000 bqoqeqb4ob oepeebeeop qqepoe6pbe oo4oqeoppo qqpboobbbe pboboo4oe5
eob4eqoeoe peqppobeeb bgebqpqbb4 egeqqbeobb 46bbgbebb4 obbbbeeobb
081 e334o66poo boogbbbqoe ob4pob64p4 4.6e4bpoq4o osoq4ubbqo 4b3be3e4b4
ozT oo434opbeb 40334E6-e55 64pobe6o45 bqbobbebbb 6b4346e6bq 66qobuob4b
09 beo464beoo 46q.66ebeeq qq4oqo5;45 oqoo.4444.66 6qp6ebqobb 6.4qqbe.6.54e
60 <00f7>
suaTdes owoH <ETZ>
EiNO <ZTZ>
Z6E1 <TTZ>
60 <OTZ>
ZOL bp
.446qbebubb bbeoppoqqo bpbepeopo4 B000boqobe 01
099 b4D0655PD4 P000-234bPP bobqooboeq 04bPPPOPOP PP.5.250P40e 6upbepeobp
009 bqoboefq.00 peobeobeo4 oobeoeqoop obeopbbeeo beopbbpobe 6popo464be
017g bebbeopoqo ep4bbboqee poqopobopp gebb4bbeeb 6T6poeqbee poob6e6ebe
08D, 3oo4e43q4o epqpubqobq co.64.64.5qq5 gogoo5goee 5.54o4peebq qbeobeb4eb
On' 4Dgeoo6000 qqoquo4.40.4 bqoqeooeob qobb45.4pee bobeeoqebe bbgbbeepop
090 bbbeBbobbo 444oeo4400 opo4o4pobb 4e4beobeoq b4op44e4o4 beob4q4qp6
00E eebgoobabb 4oe6eobpoq eopeoqoqoe oqqopbeoub b54o4bbbqb pobbq6eo44
ofgz bbeop5eopo 4E365-40-Boo 5bbeobpoog eof,q55ge4o qpogooqobb p0004obbpo
081 obbqooPeeb ec6pooeqb5 qpobeqqopq qbeobeobeq 46q6eopebb pa6gooqoqo
1O-Z0-800Z STZ9SEZO VD

suGTdes owoH <ETz> 09
JHd <ZTZ>
E917 <TTZ>
E9 <OTZ>
f71L ebb
P44b46ebeb bbbuoeeo.44 06PEcePPDPD 4fil000bo4ob eb400bbbPo
099 4P3opeDgbp pbobqooboe qoqbeeepeo eePbaboPqo PbPobueepb eb4oboeb4o
009 oopobpabpo goobeopqop eobeoebbpp obpopbbpob pbpDpo4b4b ebebbPoopq
Of7S oeugb56o4E. Poo4opoboe eqabbqbbpp bb4bpopqbp ppoobbpbeb epooT2-4044
08D' oupqppbqob 4 00404544 .54o4o3b4oe ebb4oTeeeb qqb-eDbpb4u b4o4pooboo os
On' 04404P044o 4b4o4poopo .64abb4b4OP ebopppo4ep pbb46ppeoo pbbb4000bb
09E D4440P044e oo4ougbpop 4;p4bpoueo 4b4ougou4g ouuabqqq4E. 6eeb4opeeo
00E b404buobE0 4eopeo4oqo poqq4ebeop bbb4o4pbb4 bpobb4bpo4 qbbpeo4poo
017Z 34b6bb4bup eobqq45eoo 4pobqobqpq oqpbqopqop ppqopoobpp pbbbuooppu
oeT 6Pa6Po4e4b b44ebp444p 4obpopp44e obpbuoqbee obbboobqqo po4poo2o4b
HT ebuoubpbbp 4b;o4pobqo qbqopogoo4 poo4oq6eoo oebTebe3o4 poeb4bqpbp
09 03546bpboo 4obbqo4o24 ob4004obbb b4004obeo4 ob00004bbb ebqeoebb4e
Z9 <00>
suaTdes owoH <ETZ> Qrv
VNO <ZTZ>
PIL <TTZ>
Z9 <OW>
E1T71 pbq
peeqbbbooq o4bqopogoi. pobebeabeo
08E1 boeoP4opoo pupeo64o4o bbeb4pob4p b4boo4o6qP o4o44o4boe ubbbbuobeo
OZET bb4bbpobpb ppoebb4boo eo4obeeobp oe4o40044o 4.4004obboe boogoebbqo
09Z1 b4P00043DU DPOOPBEPOP 4peepeebpb 600beobb.64 eeobebebbb 4bEbb4boob
0HT oTeoubobuo oppe4o44ob bpeeo4bb4D ob400e6qoo beo4bbuopu ebeeopeb4p oE
OVIT bebbpbbbpo oTeoppop64 oopeoe4b4b bpoepopPbe b3330bPObb bPEPOOPEPP
0801 00404PooPP PPEcebo4poo opobeopp4o obbeePoPPD p4o4b5Puob qbeeoe4bet
OZOT bppobboPpb 4obb4oebbe poupbqb0 opeo4004bo beoqbbqb4b op4qbaeobe
096 peep446Pob pbbebbboeo obpppoubup oob4ee4eob 4bbebbqbpb bopbb4boe4
006 bbqoppo-44.5 poo46beboo poebppbopo obeb4bopbb 4654.6b46ob 4,5opo4bbpb
ove g0000pbboo o4o4e54-eog oopeopbbpp 000peue000 poo44o4Do4 4o4beo4boo
08L ebbeobbqbq oDeoopobpo oob4boopoo ob46e6o4.64 6'4454PP-236 obabqq.beoP
HL b2eoe6bqb6 eeooeopeob upoobepoPo 4Pbe4boPPo b400PoP400 pbuopouobb
ogg 044opuobeo o4000b4boo eb4bb4babe o6reo40004o e4o4o-ebb-eo 4op4bpoP4D
009 o4b4obuo3o 4qopepeob4 bobbobpoop b4o4obobbp oqoepbbqbo 46466opbqb ()
ovg booPPbopoo q4op4oebbe eogbbqopbq obbbqopobb obpouobubp boobp
08v bbuoo4o54o oobobb4000 oo44og6bo4 P000bbbeeo peop400b-eo 4Do4o4booe
Hv pqbboeope6 bbpepobbbb 4o4bopbElqu 4bbop4oe4o egoE,Dropq4q oppe4obpbb
ogE bbpboo4pbe bebob4b43-2 4424646qob bopopbbebo obpbeb4oDb popeb4e2eo
00E bqp4u4bgob oepepbppoo 44ppoubpbe oogogPopeo 44Pboobbbu pbgboo4opb
eob424oe4e eeqppqbpub 54pbTe4bb4 P4-244beobb 4bbb4bebb4 obbbbPeobb
081 epoprobbeop boo4b664op ob4pobbqe4 obuqbpoqqo opo44ebbqo 4bobuobqb4
HT oo4p4oebeb 4=46.6-266 64=6poo4.6 bgbobbpbbb bb4o4bebbq bbqpbpob4b
09 beo4b4bPoo 4b4bbpbppq 444p4ob445 o4004444.6.6 bqa6-2.64o66 6444bpbbqp
19 <0017> OT
suaTdes owoH <EU>
VNO <ZTZ>
ETT <ITZ>
19 <OTZ>
SOL bpqqb
4be5e55b5P oPPoqqabeb eeeoeo4boo obo4obabqo
099 obbbPoTeop peo4bepbot 430b0P404b PPPOPOPPEt pbopqopbeo bepeobp64o
EE
1O-Z0-800Z STZ9SEZO VD

CA 02356215 2008-02-01
34
<400> 63
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1 5 10 15
Val Gin Cys Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin
20 25 30
Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe
35 40 45
Ser Ser His Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
50 55 60
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn Lys Tyr Tyr Ala
65 70 75 80
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
85 90 95
Thr Leu Phe Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Gly Gly His Phe Gly Pro Phe Asp Tyr Trp Gly
115 120 125
Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130 135 140
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
145 150 155 160
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165 170 175
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
180 185 190
Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195 200 205
Pro Ser Ser Asn Phe Gly Thr Gin Thr Tyr Thr Cys Asn Val Asp His
210 215 220
Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
225 230 235 240
Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val
245 250 255
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
260 265 270
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
275 280 285
Val Gin Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
290 295 300
Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser Thr Phe Arg Val Val Ser
305 310 315 320

CA 02356215 2008-02-01
Val Leu Thr Val Val His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys
325 330 335
Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile
340 345 350
Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro
355 3.60 365
10 Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu
370 375 380
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
385 390 395 400
Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser
405 410 415
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
20 420 425 430
Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
435 440 445
His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys
450 455 460
<210> 64
30 <211> 463
<212> PRT
<213> hom*o sapiens
<400> 64
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1 5 10 15
Val Gin Cys Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin
20 25 30
Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe
35 40 45
Ser Ser His Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
55 60
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn Lys Tyr Tyr Ala
65 70 75 80
50 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
85 90 95
Thr Leu Phe Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Gly Gly His Phe Gly Pro Phe Asp Tyr Trp Gly
115 120 125
Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130 135 140

CA 02356215 2008-02-01
36
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
145 150 155 160
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165 170 175
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
180 185 190
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195 200 205
Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His
210 215 220
Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
225 230 235 240
Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val
245 250 255
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
260 265 270
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
275 280 285
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
290 295 300
Thr Lys Pro Arg Glu Glu Gln Phe Gln Ser Thr Phe Arg Val Val Ser
305 310 315 320
Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
325 330 335
Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile
340 345 350
Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
355 360 365
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
370 375 380
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
385 390 395 400
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser
405 410 415
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
420 425 430
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
435 440 445
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
450 455 460

CA 02356215 2008-02-01
37
<210> 65
<211> 235
<212> PRT
<213> hom*o sapiens
<400> 65
Met Glu Thr Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15
Asp Thr Thr Gly Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser
20 25 30
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
35 40 45
Ile Ser Ser Ser Phe Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gin Ala
50 55 60
Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro
65 70 75 80
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95
Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
100 105 110
Gly Thr Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
115 120 125
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
130 135 140
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
145 150 155 160
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
165 170 175
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
180 185 190
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
195 200 205
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
210 215 220
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235
<210> 66
<211> 464
<212> PRT
<213> hom*o sapiens
<400> 66
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1 5 10 15

CA 02356215 2008-02-01
38
Val Gin Cys Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin
20 25 30
Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe
35 40 45
Ser Asn Tyr Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
50 55 60
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys His Tyr Gly
65 70 75 80
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn
85 90 95
Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Gly Glu Arg Leu Gly Ser Tyr Phe Asp Tyr Trp
115 120 125
Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
130 135 140
Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr
145 150 155 160
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
165 170 175
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
180 185 190
Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
195 200 205
Val Pro Ser Ser Asn Phe Gly Thr Gin Thr Tyr Thr Cys Asn Val Asp
210 215 220
His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys
225 230 235 240
Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser
245 250 255
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
260 265 270
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
275 280 285
Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
290 295 300
Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser Thr Phe Arg Val Val
305 310 315 320
Ser Val Leu Thr Val Val His Gin Asp Trp Leu Asn Gly Lys Glu Tyr
325 330 335

CA 02356215 2008-02-01
39
Lys Cys Lys Val Ser:Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr
340 345 350
Ile Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu
355 360 365
Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys
370 375 380
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
385 390 395 400
Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp
405 410 415
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
420 425 430
Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
435 440 445
Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys
450 455 460
<210> 67
<211> 233
<212> PRT
<213> hom*o sapiens
<400> 67
Met Glu Thr Pro Ala Gin Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15
Asp Thr Thr Gly Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser
20 25 30
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Val Ser
35 40 45
Ser Ser Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg
55 60
Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg
65 70 75 80
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg
85 90 95
50 Leu Glu
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gin Gin Tyr Gly Ile
100 105 110
Ser Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr
115 120 125
Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu
130 135 140
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
145 150 155 160

CA 02356215 2008-02-01
Arg Glu Ala Lys: Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly
-165 170 175
Asn Ser Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr
180 185 190
Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
195 200 205
10 Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val
210 215 220
Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230
<210> 68
<211> 463
<212> PRT
20 <213> hom*o sapiens
<400> 68
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1 5 10 15
Val Gin Cys Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Glu
20 25 30
Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe
30 35 40 45
Ser Ser Tyr Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
55 60
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys His Tyr Ala
65 70 ' 75 80
Asp Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
85 90 95
Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Ala Gly Leu Leu Gly Tyr Phe Asp Tyr Trp Gly
115 120 125
Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130 135 140
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
145 150 155 160
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165 170 175
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
180 185 190
Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195 200 205

CA 02356215 2008-02-01
41
Pro Ser Set Asn Phe Gly Thr Gin Thr Tyr Thr Cys Asn Val Asp His
210 - 215 220
Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
225 230 235 240
Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val
245 250 255
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
260 265 270
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
275 280 285
Val Gin Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
290 295 300
Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser Thr Phe Arg Val Val Ser
305 310 315 320
Val Leu Thr Val Val His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys
325 330 335
Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile
340 345 350
Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro
355 360 365
Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu
370 375 380
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
385 390 395 400
Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser
405 410 415
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
420 425 430
Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
435 440 445
His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys
450 455 460
<210> 69
<211> 234
<212> PRT
<213> hom*o sapiens
<400> 69
Met Glu Thr Pro Ala Gin Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15
Asp Thr Thr Gly Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser
20 25 30

CA 02356215 2008-02-01
42
Leu Set Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
- 35 40 45
Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
50 55 60
Arg Pro Leu Ile Tyr Gly Val Ser Ser Arg Ala Thr Gly Ile Pro Asp
65 70 75 80
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95
Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly
100 105 110
Ile Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg
115 120 125
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
130 135 140
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
145 150 155 160
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
165 170 175
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
180 185 190
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
195 200 205
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
210 215 220
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230
<210> 70
<211> 451
<212> PRT
<213> hom*o sapiens
<400> 70
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

CA 02356215 2008-02-01
43
Le U Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Pro Arg Gly Ala Thr Leu Tyr Tyr Tyr Tyr Tyr Gly Met
100 105 110
Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr
115 120 125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser
130 135 140
Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175
Thr Phe Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190
Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gin Thr Tyr Thr Cys
195 200 205
Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu
210 215 220
Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser Thr Phe
290 295 300
Arg Val Val Ser Val Leu Thr Val Val His Gin Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr lie Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

CA 02356215 2008-02-01
44
: Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Lys
450
<210> 71
<211> 214
<212> PRT
<213> hom*o sapiens
<400> 71
Asp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Ser Ile Asn Ser Tyr
20 25 30
Leu Asp Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gin Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Tyr Tyr Ser Thr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly
115 120 125 =
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin
145 150 155 160
Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210

CA 02356215 2008-02-01
<210> 72
<211> 89
<212> PRT
<213> hom*o sapiens
<400> 72
Gly Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser
1 5 10 15
10 Gly Phe
Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gin Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn
35 40 45
Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
20 65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg
<210> 73
<211> 169
<212> PRT
<213> hom*o sapiens
<400> 73
Gly Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser
1 5 10 15
Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gin Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn
35 40 45
Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ala Arg Ile Ile Thr Pro
85 90 95
50 Cys Met
Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala
100 105 110
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser
115 120 125
Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
130 135 140
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
145 150 155 160

CA 02356215 2008-02-01
46
Val His Thr Phe Pro Ala Val Leu Gin
165
<210> 74
<211> 167
<212> PRT
<213> hom*o sapiens
<400> 74
Gly Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser
1 5 10 15
Gly Phe Thr Phe Her Ser His Gly Met His Trp Val Arg Gin Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn
35 40 45
Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
50 55 60
Asn Ser Lys Asn Thr Leu Phe Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly His Phe Gly Pro Phe
85 90 95
Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
100 105 110
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser
115 120 125
Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
130 135 140
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
145 150 155 160
Thr Phe Pro Ala Val Leu Gin
165
<210> 75
<211> 166
<212> PRT
<213> hom*o sapiens
<400> 75
Gly Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser
1 5 10 15
Gly Phe Thr Phe Ser Asn Tyr Gly Met His Trp Val Arg Gin Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn
35 40 45

CA 02356215 2008-02-01
47
Lys His Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp
50 55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu Arg Leu Gly Ser Tyr
85 90 95
Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser
100 105 110
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr
115 120 125
Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
130 135 140
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
145 150 155 160
His Thr Phe Pro Ala Val
165
<210> 76
<211> 167
<212> PRT
<213> hom*o sapiens
<400> 76
Gly Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser
1 5 10 15
Gly Phe Ile Phe Ser Ser His Gly Ile His Trp Val Arg Gin Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn
35 40 45
Lys Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Ala Pro Leu Gly Pro Leu
85 90 95
50 Asp Tyr
Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
100 105 110
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser
115 120 125
Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
130 135 140
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
145 150 155 160

CA 02356215 2008-02-01
48
Thr Phe Pro Ala Val Leu Gin
165
<210> 77
<211> 153
<212> PRT
<213> hom*o sapiens
<400> 77
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
1 5 10 15
Ser Ser His Gly Ile His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
20 25 30
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn Lys Asp Tyr Ala
35 40 45
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
50 55 60
Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
65 70 75 80
Tyr Tyr Cys Ala Arg Val Ala Pro Leu Gly Pro Leu Asp Tyr Trp Gly
85 90 95
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
100 105 110
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
115 120 125
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
130 135 140
Ser Trp Asn Ser Gly Ala Leu Thr Ser
145 150
<210> 78
<211> 163
<212> PRT
<213> hom*o sapiens
<400> 78
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
1 5 10 15
Ser Ser His Gly Ile His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu
20 25 30
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn Lys Asp Tyr Ala
35 40 45
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys
50 55 60

CA 02356215 2008-02-01
49
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
65 70 75 80
Tyr Tyr Cys Ala Arg Val Ala Pro Leu Gly Pro Leu Asp Tyr Trp Gly
85 90 95
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
100 105 110
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
115 120 125
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
130 135 140
'Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
145 150 155 160
=
Val Leu Gln
<210> 79
<211> 138
<212> PRT
<213> hom*o sapiens
<400> 79
Gly Gly Val Val Glu Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala
1 5 10 15
Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala
20 25 30
Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser
35 40 45
Asn Lys His Tyr Ala Asp Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg
50 55 60
Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala
65 70 75 80
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Leu Leu Gly Tyr
85 90 95
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
100 105 110
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr
115 120 125
Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
130 135
<210> 80
<211> 167
<212> PRT =
<213> hom*o sapiens

CA 02356215 2008-02-01
<400> 80
Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser
1 5 10 15
Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn
35 40 45
Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
50 55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Arg Gly Ala Thr Leu
85 90 95
Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val
100 105 110
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
115 120 125
Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
130 135 140
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
3,0 145 150 155 160
Ala Leu Thr Ser Gly Val His
165
<210> 81
<211> 150
<212> PRT
<213> hom*o sapiens
<400> 81
Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser
1 5 10 15
Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro
20 25 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser His
35 40 45
Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
50 55 60
Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ala Val Val Val Pro Ala
85 90 95

CA 02356215 2008-02-01
51
Ala Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala
100 105 110
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser
115 120 125
Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
130 135 140
Pro Glu Pro Val Thr Val
145 150
<210> 82
<211> 146
<212> PRT
<213> hom*o sapiens
<400> 82
Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
1 5 10 15
Phe Thr Phe Ser Ser Cys Gly Met His Trp Val Arg Gin Ala Pro Gly
20 25 30
Lys Gly Leu Glu Trp Val Ala Val Ile Trp Ser Asp Gly Ser His Lys
35 =40 45
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
50 55 60
Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp
65 70 75 80
Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Met Ile Val Val Gly Thr
85 90 95
Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser
100 105 110
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr
115 120 125
Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
130 135 140
Glu Pro
145
<210> 83
<211> 171
<212> PRT
<213> hom*o sapiens
<400> 83
Gly Val Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser
1 5 10 15

CA 02356215 2008-02-01
52
Gly Phe Thr Phe Ser Ser Tyr Gly Val His Trp Val Arg Gin Ala Pro
20 25 . 30
Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn
35 40 45
Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
50 55 60
Asn Ser Lys Ser Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu
65 70 75 80
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Tyr Tyr Asp Phe Trp
85 90 95
Ser Gly Arg Gly Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr
100 105 110
Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
115 120 125
Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val
130 135 140
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
145 150 155 160
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170
<210> 84
<211> 163
<212> PRT
<213> hom*o sapiens
<400> 84
Val Gin Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
1 5 10 15
Thr Phe Ser Asn Tyr Ala Met His Trp Val Arg Gin Ala Pro Gly Lys
20 25 30
Gly Leu Glu Trp Val Val Val Ile Trp His Asp Gly Asn Asn Lys Tyr
35 40 45
Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
55 60
50 Lys Asn
Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr
65 70 75 80
Ala Val Tyr Tyr Cys Ala Arg Asp Gin Giy Thr Gly Trp Tyr Gly Gly
85 90 95
Phe Asp Phe Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser
100 105 110
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr
115 120 125

CA 02356215 2008-02-01
53
Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
130 135 140
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
145 150 155 160
His Thr Phe
<210> 85
<211> 76
<212> PRT
<213> hom*o sapiens
<400> 85
Val Ser Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile
1 5 10 15
Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
20 25 30
Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
35 40 45
Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
50 55 60
Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
65 70 75
<210> 86
<211> 172
<212> PRT
<213> hom*o sapiens
<400> 86
Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Ile Leu Ser Leu Thr Cys
1 5 10 15
Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Gly His Tyr Trp Ser Trp
20 25 30
Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr
35 40 45
Tyr Ile Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr
55 60
50 Ile Ser Val
Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser
65 70 75 80
Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly
85 90 95
Asp Tyr Tyr Gly Ile Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val
100 105 110
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys
115 120 125

CA 02356215 2008-02-01
54
Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys
130 135 140
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
145 150 155 160
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
165 170
<210> 87
<211> 96
<212> PRT
<213> hom*o sapiens
<400> 87
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
<210> 88
<211> 141
<212> PRT
<213> hom*o sapiens
<400> 88
Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu
1 5 10 15
Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Phe Leu Ala Trp Tyr
20 25 30
Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser
35 40 45
Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly
50 55 60
Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala
65 70 75 80
Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro Trp Thr Phe Gly Gin
85 90 95
60-

CA 02356215 2008-02-01
=
Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
100 105 110
Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val
115 120 125
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140
<210> 89
<211> 141
<212> PRT
<213> hom*o sapiens
<400> 89
Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu
1 5 10 15
Ser Cys Arg Thr Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gin Gin
20 25 30
Lys Pro Gly Gin Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg
35 40 .45
Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
50 55 60
Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr
65 70 75 80
Tyr Cys Gin Gin Tyr Gly Ile Ser Pro Phe Thr Phe Gly Gly Gly Thr
85 90 95
Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
100 105 110
Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys
115 120 125
Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin
130 135 140
<210> 90
<211> 139
<212> PRT
<213> hom*o sapiens
<400> 90
Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg
1 5 10 15
Ala Ser Gin Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gin Gin Lys Pro
20 25 30
Gly Gin Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr
35 40 45

CA 02356215 2008-02-01
56
Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
50 55 60
Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys
65 70 75 80
Gin Gin Tyr Gly Arg Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val
85 90 95
Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
100 105 110
Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
115 120 125'
Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin
130 135
<210> 91
<211> 142
<212> PRT
<213> hom*o sapiens
<400> 91
Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu
1 5 10 15
Ser Cys Arg Ala Ser Gin Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gin
20 25 30
Gin Lys Pro Gly Gin Ala Pro Arg Pro Leu Ile Tyr Gly Val Ser Ser
35 40 45
Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
50 55 60
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val
65 ' 70 75 80
Tyr Tyr Cys Gin Gin Tyr Gly Ile Ser Pro Phe Thr Phe Gly Pro Gly
85 90 95
Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
100 105 110
Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val
115 120 125
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin
130 135 140
<210> 92
<211> 142
<212> PRT
<213> hom*o sapiens

CA 02356215 2008-02-01
57
<400> 92
Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
1 5 10 15
Cys Arg Ala Ser Gln Ser Ile Ser Ser Asn Phe Leu Ala Trp Tyr Gln
20 25 30
Gln Lys Pro Gly Gln Ala Pro Arg Lou Leu Ile Tyr Arg Pro Ser Ser
35 40 45
Arg Ala Thr Gly Ile Pro Asp Ser Phe Ser Gly Ser Gly Ser Gly Thr
50 55 60
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Leu
65 70 75 80
Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro Phe Thr Phe Gly Pro Gly
85 90 95
Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
100 105 110
Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
115 120 125
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln
130 135 140
<210> 93
<211> 146
<212> PRT
<213> hom*o sapiens
<400> 93
Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu
1 5 10 15
Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln
20 25 30
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser
35 40 45
Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
55 60
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val
50 65 70 75 80
Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Phe Thr Phe Gly Pro Gly
85 90 95
Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
100 105 110
Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
115 120 125

CA 02356215 2008-02-01
58
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys
130 135 140
Gly Gly
145
<210> 94
<211> 95
<212> PRT
<213> hom*o sapiens
<400> 94
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro
85 90 95
<210> 95
<211> 152
<212> PRT
<213> hom*o sapiens
<400> 95
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile
1 5 10 15
Thr Cys Arg Ala Ser Gln Ser Ile Asn Thr Tyr Leu Ile Trp Tyr Gln
20 25 30
Gln Lys Pro Gly Lys Ala Pro Asn Phe Leu Ile Ser Ala Thr Ser Ile
35 40 45
Leu Gln Ser Gly Val Pro Ser Arg Phe Arg Gly Ser Gly Ser Gly Thr
55 60
Asn Phe Thr Leu Thr Ile Asn Ser Leu His Pro Glu Asp Phe Ala Thr
65 70 75 80
Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly
85 90 95
Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
100 105 110

CA 02356215 2008-02-01
59
Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Set Val Val
115 120 125 -
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys
130 135 140
Val Asp Asn Ala Leu Gin Ser Gly
145 150
<210> 96
<211> 139
<212> PRT
<213> hom*o sapiens
<400> 96
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys
1 5 10 15
Arg Ala Ser Gin Ser Ile Asn Ser Tyr Leu Asp Trp Tyr Gin Gin Lys
20 25 30
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gin
35 40 45
Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
50 55 60
Thr Leu Thr Ile Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr
65 70 75 80
Cys Gin Gin Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys
85 90 95
Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
100 105 110
Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu
115 120 125
Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val
130 135
<210> 97
<211> 134
<212> PRT
<213> hom*o sapiens
<400> 97
Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
1 5 10 15
Ile Thr Cys Arg Ala Ser Gin Asn Ile Ser Arg Tyr Leu Asn Trp Tyr
20 25 30
Gin Gin Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Val Ala Ser
35 40 45

CA 02356215 2008-02-01
Ile Leu Gin Ser Gly Val Pro Ser Gly Phe Ser Ala Se -r Gly Ser Gly
50 55 60
Pro Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro Glu Asp Phe Ala
70 75 80
Thr Tyr Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Phe Thr Phe Gly Pro
85 90 95
10 Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
100 105 110
Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val
115 120 125
Val Cys Leu Leu Asn Asn
130
20 <210> 98
<211> 150
<212> PRT
<213> hom*o sapiens
<400> 98
Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
1 5 10 15
Ile Thr Cys Arg Ala Ser Gin Ser Ile Cys Asn Tyr Leu Asn Trp Tyr
30 20 25 30
Gin Gin Lys Pro Gly Lys Ala Pro Arg Val Leu Ile Tyr Ala Ala Ser
35 40 45
Ser Leu Gin Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
50 55 60
Ile Asp Cys Thr Leu Thr Ile Ser Ser Leu Gin Pro Glu Asp Phe Ala
65 70 75 80
Thr Tyr Tyr Cys Gin Gin Ser Tyr Ile Thr Pro Phe Thr Phe Gly Pro
85 90 95
Gly Thr Arg Val Asp Ile Glu Arg Thr Val Ala Ala Pro Ser Vol Phe
100 105 110
Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val
115 120 125
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp
130 135 140
Lys Val Asp Asn Ala Tyr
145 150
<210> 99
<211> 96
<212> PRT
<213> hom*o sapiens

CA 02356215 2008-02-01
61
<400> 99
Glu Ile Val Leu Thr Gin Ser Pro Asp Phe Gin Ser Val Thr Pro Lys
1 5 10 15
Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gin Ser Ile Gly Ser Ser
20 25 30
Leu His Trp Tyr Gin Gin Lys Pro Asp Gin Ser Pro Lys Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Gin Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
65 70 75 80
Glu Asp Ala Ala Thr Tyr Tyr Cys His Gin Ser Ser Ser Leu Pro Gin
85 90 95
<210> 100
<211> 364
<212> PRT
=
<213> hom*o sapiens
<400> 100
Met Gly Val Leu Leu Thr Gin Arg Thr Leu Leu Ser Leu Val Leu Ala
1 5 10 15
Leu Leu Phe Pro Ser Met Ala Ser Met Ala Met His Val Ala Gin Pro
20 25 30
Ala Val Val Leu Ala Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu
35 40 45
Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg
50 55 60
Gin Ala Asp Ser Gin Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met
65 70 75 80
Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser
85 90 95
Ser Gly Asn Gin Val Asn Leu Thr Ile Gin Gly Leu Arg Ala Met Asp
100 105 110
Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr
115 120 125
Tyr Leu Gly Ile Gly Asn Gly Thr Gin Ile Tyr Val Ile Asp Pro Glu
130 135 140
Pro Cys Pro Asp Ser Asp Leu Glu Gly Ala Pro Ser Val Phe Leu Phe
145 150 155 160
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
165 170 175

CA 02356215 2008-02-01
62
Thr Cys Val Val Val Asp Val Ser His Glu ASp Pro Glu Val Lys Phe
180 185 190
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
195 200 205
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
210 215 220
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
225 230 235 240
Ser Asn Lys Ala Leu Pro Thr Pro Ile Glu Lys Thr Ile Ser Lys Ala
245 250 255
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
260 265 270
Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
275 280 285
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
290 295 300
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
305 310 315 320
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gln
325 330 335
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
340 345 350
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 101
<211> 12
<212> PRT
<213> hom*o sapiens
<400> 101
Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser
1 5 10
<210> 102
<211> 120
<212> PRT
<213> hom*o sapiens
<400> 102
Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile
1 5 10 15
Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val
20 25 30

CA 02356215 2008-02-01
63
Arg Val Thr Val Leu Arg Gin Ala Asp Ser Gin Val Thr Glu Val Cys
35 40
Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser
55 60
Ile Cys Thr Gly Thr Ser Ser Gly Asn Gin Val Asn Leu Thr Ile Gin
65 70 75 80
10 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu
85 90 95
Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gin Ile
100 105 110
Tyr Val Ile Asp Pro Glu Pro Cys
115 120
20 <210> 103
<211> 11
<212> PRT
<213> hom*o sapiens
<400> 103
Met His Val Ala Gin Pro Ala Val Val Leu Ala
1 5 10
30 <210> 104
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer
<220>
<221> modified_base
40 <222> (21)
<223> i
<400> 104
caggtgcagc tggagcagtc ngg 23
<210> 105
<211> 24
<212> DNA
50 <213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer
<400> 105
gctgagggag tagagtcctg agga 24
<210> 106
<211> 49

CA 02356215 2008-02-01
64
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer
<400> 106
tatctaagct tctagactcg accgccacca tggagtttgg gctgagctg 49
<210> 107
<211> 46
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer
<400> 107
ttctctgatc agaattccta tcatttaccc ggagacaggg agagct 46
<210> 108
<211> 9
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Optimal Kozak sequence
<400> 108
accgccacc 9
<210> 109
<211> 45
<212> DNA
<213> hom*o sapiens
<400> 109
tcttcaagct tgcccgggcc cgccaccatg gaaaccccag cgcag 45
<210> 110
<211> 43
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Primer
<400> 110
ttctttgatc agaattctca ctaacactct cccctgttga agc 43
<210> 111
<211> 48
<212> DNA
<213> Artificial Sequence

CA 02356215 2008-02-01
<220>
<223> Description of Artificial Sequence: Primer
<400> 111
tcttcaagct tgcccgggcc cgccaccatg gacatgaggg tccccgct 48
<210> 112
<211> 155
10 <212> PRT
<213> hom*o sapiens =
<400> 112
Ser Pro Asp Phe Gin Ser Val Thr Pro Lys Glu Lys Val Thr Ile Thr
1 5 10 15
Cys Arg Ala Ser Gin Ser Ile Gly Ser Ser Leu His Trp Tyr Gin Gin
20 25 30
20 Lys Pro Asp Gin Ser Pro Lys Leu Leu Ile Lys Tyr Ala Ser Gin Ser
35 40 45
Phe Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
50 55 60
Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala Glu Asp Ala Ala Thr Tyr
65 70 75 80
Tyr Cys His Gin Ser Ser Ser Leu Pro Leu Thr Phe Gly Gly Gly Thr
30 85 90 95
Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
100 105 110
Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys
115 120 125
Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val
130 135 140
Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu
145 150 155
<210> 113
<211> 100
<212> PRT
<213> hom*o sapiens
<400> 113
Asp Val Val Met Thr Gin Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gin Pro Ala Ser Ile Ser Cys Arg Ser Ser Gin Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gin Gin Arg Pro Gly Gin Ser
35 40 45

CA 02356215 2008-02-01
66
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 -55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gin Gly
85 90 95
Thr His Trp Pro
100
<210> 114
<211> 139
<212> PRT
<213> hom*o sapiens
<400> 114
Pro Leu Ser Leu Pro Val Thr Leu Gly Gin Pro Ala Ser Ile Ser Cys
1 5 10 15
Arg Ser Ser Gin Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr Leu'Asn
20 25 30
Trp Phe Gin Gin Arg Pro Gly Gin Ser Pro Arg Arg Leu Ile Tyr Lys
35 40 45
Val Ser Asn Trp Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly
50 55 60
Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp
65 70 75 80
Val Gly Val Tyr Tyr Cys Met Gin Gly Ser His Trp Pro Pro Thr Phe
85 90 95
Gly Gin Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser
100 105 110
Val Phe Ile Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala
115 120 125
Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
130 135
<210> 115
<211> 100
<212> PRT
<213> hom*o sapiens
<400> 115
Asp Ile Val Met Thr Gin Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gin Ser Leu Leu His Ser
20 25 30

CA 02356215 2008-02-01
67
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gin Lys Pro Gly Gin Ser
35 _ 40 45
Pro Gin Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gin Ala
85 90 95
Leu Gin Thr Pro
100
<210> 116
<211> 133
<212> PRT
<213> hom*o sapiens
<400> 116
Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gin Ser Leu Leu
1 5 10 15
His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gin Lys Pro Gly
20 25 30
Gin Ser Pro Gin Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly
35 40 45
Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
50 55 60
Lys Leu Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met
65 70 75 80
Gin Ala Leu Gin Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu
85 90 95
Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser
100 105 110
Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn
115 120 125
Asn Phe Tyr Pro Arg
130
<210> 117
<211> 20
<212> PRT
<213> hom*o sapiens
<400> 117
Asp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

CA 02356215 2008-02-01
68
Asp Arg Val Thrl
<210> 118
<211> 20
<212> PRT
<213> hom*o sapiens
10 <400> 118
Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr
<210> 119
<211> 20
20 <212> PRT
<213> hom*o sapiens
<400> 119
Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr
30
<210> 120
<211> 20
<212> PRT
<213> hom*o sapiens
<400> 120
Asp Ile Gin Met Thr Gin Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15
40 Asp Arg Val Thr
=
<210> 121
<211> 20
<212> PRT
<213> hom*o sapiens
<400> 121
50 Thr Gly Glu Phe Val Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser
1 5 10 15
Pro Gly Glu Arg
<210> 122
<211> 20
<212> PRT
60 <213> hom*o sapiens

CA 02356215 2008-02-01
69
<400> 122 :
Glu Phe Val-Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr
<210> 123
10 <211> 20
<212> PRT
<213> hom*o sapiens
<400> 123
Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr
20
<210> 124
<211> 20
<212> PRT
<213> hom*o sapiens
<400> 124
Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr
<210> 125
<211> 20
<212> PRT
<213> hom*o sapiens
40 <400> 125
Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr
<210> 126
<211> 21
50 <212> PRT
<213> hom*o sapiens
<400> 126
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser
60

CA 02356215 2008-02-01
<210> 1-27
<211> 5
<212> PRT
<213> hom*o sapiens
<400> 127
Pro Glu Val Gin Phe
1 5
<210> 128
<211> 21
<212> PRT
<213> hom*o sapiens
<400> 128
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser
<210> 129
<211> 10
<212> PRT
<213> hom*o sapiens
<400> 129
Pro Glu Val Gin Phe Asn Trp Tyr Val Asp
1 5 10
<210> 130
<211> 18
<212> PRT
<213> hom*o sapiens
<400> 130
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
1 5 10 15
Ser Leu
<210> 131
<211> 8
<212> PRT
<213> hom*o sapiens
<400> 131
Pro Glu Val Gin Phe Asn Trp Tyr
1 5
<210> 132
<211> 20
<212> PRT
<213> hom*o sapiens

CA 02356215 2008-02-01
71
<400> 132
Glu Val Gin Leu Leu Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu
<210> 133
10 <211> 21
<212> PRT
<213> hom*o sapiens
<400> 133
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser
20
<210> 134
<211> 10
<212> PRT
<213> hom*o sapiens
<400> 134
Pro Glu Val Gin Phe Asn Trp Tyr Val Asp
1 5 10
<210> 135
<211> 21
<212> PRT
<213> hom*o sapiens
<400> 135
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser
<210> 136
<211> 9
<212> PRT
<213> hom*o sapiens
50 <400> 136
Pro Glu Val Gin Phe Asn Trp Tyr Val
1 5
<210> 137
<211> 21
<212> PRT
<213> hom*o sapiens

CA 02356215 2008-02-01
72
: <400> 137
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Gin Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser
<210> 138
10 <211> 6
<212> PRT
<213> hom*o sapiens
<400> 138
Pro Glu Val Gin She Asn
1 5
<210> 139
20 <211> 21
<212> PRT
<213> hom*o sapiens
<400> 139
Gin Val Gin Leu Val Glu Ser Gly Gly Gly Val Val Glu Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser
30
<210> 140
<211> 10
<212> PRT
<213> hom*o sapiens
<400> 140
Pro Glu Val Gin Phe Asn Trp Tyr Val Asp
1 5 10
<210> 141
<211> 8
<212> PRT
<213> hom*o sapiens
<400> 141
Asp Ile Gin Net Thr Gin Ser Pro
1 5
<210> 142
<211> 8
<212> PRT
<213> hom*o sapiens
<400> 142
Glu Ile Val Leu Thr Gin Ser Pro
1 5

CA 02356215 2008-02-01
73
<210> 143
<211> 8
<212> PRT
<213> hom*o sapiens
<400> 143
Glu Ile Val Leu Thr Gin Ser Pro
1 5
<210> 144
<211> 10
<212> PRT
<213> hom*o sapiens
<400> 144
Thr Gly Glu Phe Val Leu Thr Gin Ser Pro
1 5 10
<210> 145
<211> 8
<212> PRT
<213> hom*o sapiens
<400> 145
Glu Phe Val Leu Thr Gin Ser Pro
1 5
<210> 146
<211> 8
<212> PRT
<213> hom*o sapiens
<400> 146
Glu Ile Val Leu Thr Gin Ser Pro
1 5
<210> 147
<211> 8
<212> PRT
<213> hom*o sapiens
<400> 147
Glu Ile Val Leu Thr Gin Ser Pro
1 5